<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":3.711374,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpSAwwEEloAFx9SSkYMVgoHEkkZTAJXVlZXSwdWUFFIBlZWCQQJHQNACg4=","queueTime":0,"ttGuid":"bf2ea09faa4cc9fc"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full">
<meta property="description" name="description" content="Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutatio...">
<meta property="og:title" name="title" content="Frontiers | Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients">
<meta property="og:description" name="description" content="Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutatio...">
<meta name="keywords" content="breast cancer,genetic screening,BRCA1-Founder mutation,Next-generation sequencing,Novel mutation,Rad50">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="11">
<meta name="citation_journal_title" content="Frontiers in Genetics">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Genet.">
<meta name="citation_issn" content="1664-8021">
<meta name="citation_doi" content="10.3389/fgene.2020.552971">
<meta name="citation_firstpage" content="552971">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients">
<meta name="citation_keywords" content="breast cancer; genetic screening; BRCA1-Founder mutation; Next-generation sequencing; Novel mutation; Rad50">
<meta name="citation_abstract" content="Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutations not only helped in selecting high risk individuals that need appropriate prevention approaches but also led to the development of the PARP-inhibitors targeted therapy.This study aims to assess the prevalence of the most frequent BRCA1 mutation in Tunisia, c.211dupA, and provide evidence of its common origin as well as its clinicopathological characteristics. We also aimed to identify additional actionable variants using classical and next generation sequencing technologies (NGS) which would allow to implement cost-effective genetic testing in limited resource countries.Patients and Methods Using sanger sequencing, 112 breast cancer families have been screened for c.211dupA. A set of patients that do not carry this mutation have been investigated using NGS. Haplotype analysis was performed to assess the founder effect and to estimate the age of this mutation. Correlations between genetic and clinical data have been also performed.Results The c.211dupA mutation has been identified in 8 carriers and a novel private BRCA1 mutation, c.2418dupA, has been identified in one carrier. Both mutations are likely specific to North-Eastern Tunisia. Haplotype analysis confirmed the founder effect of c.211dupA and showed its recent origin. Phenotype-genotype correlation showed that both BRCA1 mutations seem to be associated with a severe phenotype. Whole Exome Sequencing (WES) analysis of a BRCA negative family revealed a Variant of Unknown Significance, c.3647C&gt;G on RAD50. Molecular modeling showed that this variant could be classified as deleterious as it is responsible for destabilizing the RAD50 protein structure. Variant prioritization and pathway analysis of the WES data showed additional interesting candidate genes including MITF and ANKS6. Conclusions We recommend the prioritization of BRCA1-c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia. We also highlighted the importance of NGS in detecting novel mutations, such as RAD50-c.3647C&gt;G. In addition, we strongly recommend using data from different ethnic groups to review the pathogenicity of this variant and reconsider its classification in ClinVar.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2020/10/16">
<meta name="citation_publication_date" content="2020/11/06">
<meta name="citation_author" content="Mighri, Najah ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Hamdi, Yosr ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boujemaa, Maroua ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Othman, Houcemeddine ">
<meta name="citation_author_institution" content="Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, South Africa">
<meta name="citation_author" content="Ben Nasr, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="El Benna, Houda ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia">
<meta name="citation_author" content="Mejri, Nesrine ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Labidi, Soumaya ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Ayari, Jihen ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Jaidene, Olfa ">
<meta name="citation_author_institution" content="Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia">
<meta name="citation_author" content="Bouaziz, Hanen ">
<meta name="citation_author_institution" content="Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia">
<meta name="citation_author" content="Ben Rekaya, Mariem ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Mrad, Ridha ">
<meta name="citation_author_institution" content="Service des Maladies Congnitales et Hrditaires, Hpital Charles Nicolle, Tunisia">
<meta name="citation_author" content="Haddaoui, Abderrazek ">
<meta name="citation_author_institution" content="The Military Hospital of Tunis, Department of Medical Oncology, Tunisia">
<meta name="citation_author" content="Rahal, Khaled ">
<meta name="citation_author_institution" content="Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia">
<meta name="citation_author" content="Boussen, Hamouda ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boubaker, Samir ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Abdelhak, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="dc.identifier" content="doi:10.3389/fgene.2020.552971">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients","author":[{"@type":"Person","name":"Najah Mighri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Yosr Hamdi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Maroua Boujemaa","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Houcemeddine Othman","affiliation":["Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, South Africa"]},{"@type":"Person","name":"Sonia Ben Nasr","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","The Military Hospital of Tunis, Department of Medical Oncology, Tunisia"]},{"@type":"Person","name":"Houda El Benna","affiliation":["Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia"]},{"@type":"Person","name":"Nesrine Mejri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia"]},{"@type":"Person","name":"Soumaya Labidi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia"]},{"@type":"Person","name":"Jihen Ayari","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","The Military Hospital of Tunis, Department of Medical Oncology, Tunisia"]},{"@type":"Person","name":"Olfa Jaidene","affiliation":["Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia"]},{"@type":"Person","name":"Hanen Bouaziz","affiliation":["Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia"]},{"@type":"Person","name":"Mariem Ben Rekaya","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Ridha Mrad","affiliation":["Service des Maladies Congnitales et Hrditaires, Hpital Charles Nicolle, Tunisia"]},{"@type":"Person","name":"Abderrazek Haddaoui","affiliation":["The Military Hospital of Tunis, Department of Medical Oncology, Tunisia"]},{"@type":"Person","name":"Khaled Rahal","affiliation":["Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia"]},{"@type":"Person","name":"Hamouda Boussen","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia"]},{"@type":"Person","name":"Samir Boubaker","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Sonia Abdelhak","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]}],"datePublished":"2020-11-06","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2020","isPartOf":{"@type":"PublicationVolume","volumeNumber":"11","isPartOf":{"@type":"Periodical","name":"Frontiers in Genetics"}}},"citation":["https://doi.org/10.3389/fgene.2020.552971"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/genetics" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Genet.</span><span>, 06 November 2020</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Genomic Medicine</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 11 - 2020 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fgene.2020.552971">https://doi.org/10.3389/fgene.2020.552971</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Identification of Novel <i>BRCA1</i> and <i>RAD50</i> Mutations Associated With Breast Cancer Predisposition in Tunisian Patients</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/958051" class="user-id-958051"><img class="pr5" src="https://loop.frontiersin.org/images/profile/958051/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Najah Mighri">Najah Mighri</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/954975" class="user-id-954975"><img class="pr5" src="https://loop.frontiersin.org/images/profile/954975/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Yosr Hamdi*">Yosr Hamdi</a><sup>1*</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/956852" class="user-id-956852"><img class="pr5" src="https://loop.frontiersin.org/images/profile/956852/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Maroua Boujemaa">Maroua Boujemaa</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1014413" class="user-id-1014413"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1014413/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Houcemeddine Othman">Houcemeddine Othman</a><sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957319" class="user-id-957319"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957319/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Sonia Ben Nasr,">Sonia Ben Nasr</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126178" class="user-id-1126178"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126178/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Houda El Benna">Houda El Benna</a><sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Nesrine Mejri," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Nesrine Mejri<sup>1,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Soumaya Labidi," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Soumaya Labidi<sup>1,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1125634" class="user-id-1125634"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1125634/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Jihen Ayari,">Jihen Ayari</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957930" class="user-id-957930"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957930/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Olfa Jaidene">Olfa Jaidene</a><sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Hanen Bouaziz" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Hanen Bouaziz<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Mariem Ben Rekaya" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Mariem Ben Rekaya<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/956101" class="user-id-956101"><img class="pr5" src="https://loop.frontiersin.org/images/profile/956101/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ridha M&#x;rad">Ridha M&#x2019;rad</a><sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Abderrazek Haddaoui" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Abderrazek Haddaoui<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Khaled Rahal" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Khaled Rahal<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Hamouda Boussen," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Hamouda Boussen<sup>1,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Samir Boubaker" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Samir Boubaker<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sonia Abdelhak" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sonia Abdelhak<sup>1</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia</li>
<li><span><sup>2</sup></span>Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, Johannesburg, South Africa</li>
<li><span><sup>3</sup></span>The Military Hospital of Tunis, Department of Medical Oncology, Tunis, Tunisia</li>
<li><span><sup>4</sup></span>Department of Medical Oncology, Abderrahmane Mami Hospital, Ariana, Tunisia</li>
<li><span><sup>5</sup></span>Department of Carcinological Surgery, Salah Azaiez Institute, Tunis, Tunisia</li>
<li><span><sup>6</sup></span>Service des Maladies Cong&#x00E9;nitales et H&#x00E9;r&#x00E9;ditaires, H&#x00F4;pital Charles Nicolle, Tunis, Tunisia</li>
</ul>
<p class="mb0"><b>Background:</b> Deleterious mutations on <i>BRCA1/2</i> genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutations not only helped in selecting high risk individuals that need appropriate prevention approaches but also led to the development of the PARP-inhibitors targeted therapy. This study aims to assess the prevalence of the most frequent <i>BRCA1</i> mutation in Tunisia, c.211dupA, and provide evidence of its common origin as well as its clinicopathological characteristics. We also aimed to identify additional actionable variants using classical and next generation sequencing technologies (NGS) which would allow to implement cost-effective genetic testing in limited resource countries.</p>
<p class="mb0"><b>Patients and Methods:</b> Using sanger sequencing, 112 breast cancer families were screened for c.211dupA. A set of patients that do not carry this mutation were investigated using NGS. Haplotype analysis was performed to assess the founder effect and to estimate the age of this mutation. Correlations between genetic and clinical data were also performed.</p>
<p class="mb0"><b>Results:</b> The c.211dupA mutation was identified in 8 carriers and a novel private <i>BRCA1</i> mutation, c.2418dupA, was identified in one carrier. Both mutations are likely specific to North-Eastern Tunisia. Haplotype analysis supported the founder effect of c.211dupA and showed its recent origin. Phenotype-genotype correlation showed that both <i>BRCA1</i> mutations seem to be associated with a severe phenotype. Whole Exome Sequencing (WES) analysis of a <i>BRCA</i> negative family revealed a Variant of Unknown Significance, c.3647C &#x003E; G on <i>RAD50</i>. Molecular modeling showed that this variant could be classified as deleterious as it is responsible for destabilizing the RAD50 protein structure. Variant prioritization and pathway analysis of the WES data showed additional interesting candidate genes including <i>MITF</i> and <i>ANKS6.</i></p>
<p class="mb0"><b>Conclusion:</b> We recommend the prioritization of <i>BRCA1</i>-c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia. We also highlighted the importance of NGS in detecting novel mutations, such as <i>RAD50-</i>c.3647C &#x003E; G. In addition, we strongly recommend using data from different ethnic groups to review the pathogenicity of this variant and reconsider its classification in ClinVar.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Breast cancer remains the most common cancer among women worldwide (<a href="#B11">Bray et al., 2018</a>). Each year, 2000 new breast cancer cases are diagnosed in Tunisia (<a href="#B11">Bray et al., 2018</a>) and the mean age at diagnosis is around 50 years old, a decade younger than Western countries (<a href="#B15">Chalabi et al., 2008</a>).</p>
<p class="mb15"><i>BRCA1</i> and <i>BRCA2</i> are the most studied breast cancer susceptibility genes that explain a significant proportion of hereditary breast and ovarian cancers (<a href="#B63">Miki et al., 1994</a>; <a href="#B97">Wooster et al., 1995</a>; <a href="#B27">Ford et al., 1998</a>). It has been reported that the average cumulative risks in <i>BRCA1</i>-mutation carriers by age of 70 were 65% and 39% for breast and ovarian cancers respectively and the corresponding estimates for <i>BRCA2</i> were 45% and 11% (<a href="#B3">Antoniou et al., 2003</a>). The frequency of germline mutations identified on the <i>BRCA</i> genes varies depending on the geographic and the ethnic distributions. Indeed, while most variations are shared between human populations, some of the <i>BRCA1/2</i> mutations are ethnic specific (<a href="#B26">Fackenthal and Olopade, 2007</a>).</p>
<p class="mb15">Since a good knowledge of population structure is essential for the development of efficient and individualized screening approaches, the identification of founder <i>BRCA</i> mutations is crucial to set up affordable and cost-effective breast cancer genetic testing. In North Africa, several <i>BRCA1/2</i> founder mutations were identified among which <i>BRCA1</i>-c.798_799delTT that was reported in 9.8% and 36.4% of familial and sporadic Algerian breast cancer cases, respectively (<a href="#B93">Uhrhammer et al., 2008</a>). This same mutation was reported in Tunisian population with a frequency of 18% (<a href="#B56">Mahfoudh et al., 2012</a>). Furthermore, <i>BRCA2-</i>c.1310_1313delAAGA is considered as a North African founder mutation since it has been identified in Algerian, Moroccan and Tunisian breast cancer cases (<a href="#B18">Cherbal et al., 2010</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B47">Laarabi et al., 2017</a>).</p>
<p class="mb15">In Tunisia, founder mutations explain around 42% of hereditary disorders (<a href="#B78">Romdhane et al., 2012</a>). This is mainly due to the high rates of consanguinity and endogamy. So far, few <i>BRCA1</i> deleterious mutations were identified in Tunisia and the most recurrent ones are c.211dupA and c.5266dupC (<a href="#B90">Troudi et al., 2008</a>; <a href="#B56">Mahfoudh et al., 2012</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B73">Riahi et al., 2015</a>). <i>BRCA1</i>-c.5266dupC was originally described as an Ashkenazi founder mutation. Then, it has been reported in several other populations such as Russian, Italian, Slovenian, Greek and Tunisian (<a href="#B40">Janavi&#x010D;ius, 2010</a>). However, the c.211dupA mutation seems to be specific to Tunisia since it has never been previously described in any other population (<a href="#B91">Troudi et al., 2007</a>).</p>
<p class="mb15">Besides <i>BRCA1</i> and <i>BRCA2</i>, more than 100 loci are known to be associated with breast cancer risk (<a href="#B33">Han et al., 2016</a>). For <i>BRCA</i> negative families, fine mapping of other high to moderate penetrant breast cancer genes is needed to explain the genetic predisposition to breast cancer. For this purpose, next generation sequencing technologies are widely used as a cost-effective approach for the detection of novel mutations (<a href="#B83">Shahi et al., 2019</a>). Indeed, target gene sequencing (TGS), whole exome sequencing (WES), and whole genome sequencing (WGS) are the main protocols currently used to identify either new mutations or new candidate genes associated with hereditary disorders (<a href="#B17">Chandler et al., 2016</a>; <a href="#B1">Akter et al., 2019</a>; <a href="#B8">Bewicke-Copley et al., 2019</a>; <a href="#B68">Posey, 2019</a>; <a href="#B83">Shahi et al., 2019</a>).</p>
<p class="mb0">In the present study, we used classical as well as next generation sequencing technologies to investigate the genetic predisposition to breast cancer in 112 Tunisian families. Targeted mutation screening followed by target gene and whole exome sequencing were performed. We have also studied the founder effect and the relative age of the most frequent <i>BRCA1</i> mutation in Tunisia (c.211dupA). In addition, genotypic data were correlated to drug response, clinicopathological and phenotypic features of all mutation carriers.</p>
<a id="h3" name="h3"></a><h2>Materials and Methods</h2>
<h3 class="pt0">Patients</h3>
<p class="mb15">A total of 122 individuals with strong familial history of breast cancer (111 patients and 11 healthy) were recruited from three principal medical oncology centers based in Tunis that provide care and services for Tunisian cancer patients from all over the country (Departments of Medical oncology of Abderrahmane Mami Hospital, of Military Hospital of Tunis and the surgical oncology Department of Institut Salah Azaiez). Prior to specimen collection, all participants signed written and informed consents and gave relevant information about their personal and familial cancer histories as well as their geographic origins. A patient was recruited if at least one of the following criteria is fulfilled: (1) Presence of at least two related first or second-degree breast cancer cases, (2) Breast cancer in young patients aged less than 36 years, (3) Presence of at least two cases of breast or ovarian cancer, regardless of age. The mean age at diagnosis of the whole studied cohort is 42.84 years. The geographic distribution of birth locations is as follows; the majority are originating from Northern Tunisia, however approximately 20% are from the Central region and 6% from the South region. Forty-three percent of patients have a strong family history of breast cancer where 2 or multiple family members were diagnosed with breast cancer. A family history of ovarian cancer was observed among approximately 10% of patients. Breast cancer patients selected for next generation sequencing are those with the strongest family history of breast cancer (having 2 or more cases) and/or with age at onset of less than 36 years.</p>
<p class="mb0">Clinico-pathological characteristics and follow-up data have been collected from medical records of patients.</p>
<h3>Sanger Sequencing</h3>
<p class="mb15">Total genomic DNA was isolated from peripheral blood using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x2019;s instructions. DNA purity and concentration were measured using a NanoDrop<sup>TM</sup> spectrophotometer.</p>
<p class="mb15">Polymerase chain reaction reactions were performed on genomic DNA, following standard protocols. Sanger sequencing was performed using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA, United States) and a cycle sequencing reaction kit (Bigdye Terminator v3.1 kit, Applied Biosystems). Data was analyzed using BioEdit software version 7.2.5.</p>
<p class="mb0">Sanger sequencing technique was first used to screen the c.211dupA mutation on exon 5 of <i>BRCA1</i> (NM_007294.3) among all 122 participants. It was also used to validate the identified variants resulting from the NGS assays. Non-carriers of c.211dupA mutation were tested for other recurrent <i>BRCA1/2</i> mutations in Tunisia namely <i>BRCA1-</i>c.798_799delTT, <i>BRCA1-</i>c.5266dupC, and <i>BRCA2-</i>c.1310_1313delAAGA (<a href="#B56">Mahfoudh et al., 2012</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B64">Msolly and Kassab, 2015</a>; <a href="#B73">Riahi et al., 2015</a>).</p>
<h3>Targeted <i>BRCA1/2</i> Genes Sequencing</h3>
<p class="mb0">Targeted <i>BRCA1/2</i> genes sequencing was performed for 9 patients. A DNA quantity of 40 ng measured by Qubit (Thermo Fisher Scientific, MA, United States) was used as a template to generate libraries for sequencing. Libraries were prepared using the QIAGEN Library Kit v2.0 and the GeneRead QIAact <i>BRCA1/2</i> panel (QIAGEN, Hilden, Germany), which comprises 253 pooled primer pairs custom designed to cover all coding regions of the <i>BRCA1</i> and <i>BRCA2</i> genes, including 20 bp flanking regions in adjacent introns. All steps of library preparation were performed according to the manufacturer&#x2019;s protocol. The libraries were then quantified using a Qubit dsDNA HS Assay Kit (Life Technologies, MA, United States) and QIAxcel (QIAGEN, Hilden, Germany). Nine individual libraries were pooled prior to emulsion PCR and bead enrichment steps that were carried out using an automated protocol on the GeneRead QIAcube (QIAGEN, Hilden, Germany) using the GeneRead Clonal Amp Q Kit (QIAGEN, Hilden, Germany), according to the manufacturer&#x2019;s protocol. Following bead enrichment, the pooled libraries were sequenced using the GeneReader platform (QIAGEN, Hilden, Germany).</p>
<h3>Whole Exome Sequencing (WES)</h3>
<p class="mb0">Whole exome sequencing was performed for 8 patients. Samples were prepared according to Agilent SureSelect Protocol Version 1.2 and enrichment was carried out according to Agilent SureSelect protocols. Sequencing was performed on Illumina HiSeq2000 platform using TruSeq v3 chemistry with paired-end (2 &#x00D7; 100 pb). Exome DNA sequences were mapped to their location based on the hg19/b37 human genome using the Burrows&#x2013;Wheeler Aligner (BWA) package (<a href="#B49">Li and Durbin, 2009</a>). Duplicate reads were removed using Picard (<a href="#B25">Ebbert et al., 2016</a>). The subsequent SAM files were converted to BAM files using Samtools (<a href="#B50">Li et al., 2009</a>). GATK was then used to recalibrate the base quality scores as well as for SNP and short INDEL calling (<a href="#B60">McKenna et al., 2010</a>).</p>
<h3>Functional Annotation and Variants Prioritization</h3>
<p class="mb15">Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) 2.10 software (<a href="#B23">Desvignes et al., 2018</a>). The annotated InDels and SNPs were filtered according to several criteria: (1) considering breast cancer as autosomal dominant disease, we removed variants that were found at homozygous state, (2) variants identified as intronic, intergenic and non-coding or synonymous were discarded, (3) assuming that causal variants are rare, we removed all variants with an allele frequency &#x003E; 1% either in 1000 Genomes or GnomAD_Exome databases, (4) benign or tolerated variants were discarded according to the following <i>in silico</i> prediction tools: Sorting Intolerant From Tolerant (SIFT), PolyPhen-2, Mutation Taster, LRT_pred and Combined Annotation Dependent Depletion CADD tool. We used SiPhy_log odds score calculated by ANNOVAR to keep deleterious variants with high scores and Gene Damage Index Prediction database (GDI) to exclude highly mutated genes.</p>
<p class="mb0">The Wikipathways (<a href="#B86">Slenter et al., 2017</a>) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (<a href="#B42">Kanehisa and Goto, 2000</a>) databases were used to assign genes to their pathways and the Network of Cancer Genes V 6.0 (<a href="#B72">Repana et al., 2019</a>) was used to identify genes associated with cancers.</p>
<h3>Molecular Modeling</h3>
<p class="mb15">We used the protein sequence of RAD50 annotated under the accession Q92878 in the Uniprot database (<a href="#B20">The Uniport Consortium, 2019</a>) as a reference sequence. To predict the 3D structure of the wild type RAD50 we used a comparative modeling approach with the satisfaction of spatial restraints using MODELLER version 9.22 (<a href="#B79">&#x0160;ali and Blundell, 1993</a>). Template identification consists of searching for homologous proteins to the RAD50 reference sequence in the Protein Data Bank (PDB) (<a href="#B7">Berman et al., 2000</a>) using BLAST (identity sequence cutoff &#x003E; 30%) (<a href="#B2">Altschul et al., 1990</a>).</p>
<p class="mb15">The search for a template identified the structure of &#x201C;DH domain-containing protein&#x201D; from <i>Chaetomium thermophilum</i> (PDB code 5DAC) (<a href="#B80">Seifert et al., 2016</a>) that shows a significant e-value of 4.2 e<sup>&#x2013;72</sup> and a sequence identity of 50% (locally aligned) compared to hRAD50. The alignment of hRAD50 with the template covers 32% of the reference sequence including the position of the mutation. We introduced a distance restraint of 10 &#x00C5; between the terminal residues of the coiled-coil segments belonging to the same monomer. Moreover, we built the model in the presence of ATP&#x03B3;S: Mg<sup>2+</sup> heteroatoms.</p>
<p class="mb0">The template and target sequences were then aligned using &#x2018;needle&#x2019; from the EMBOSS package (<a href="#B74">Rice et al., 2000</a>) and the alignment was then edited manually to correct for errors. We then built the model by generating 50 conformers with different seeds using a rapid refinement protocol. The final model was selected based on the calculation of the DOPE score (<a href="#B84">Shen and Sali, 2006</a>) and the quality assessment was checked by establishing the Ramachandran plot (<a href="#B53">Lovell et al., 2003</a>) and the local energy profile Verify3D (<a href="#B54">L&#x00FC;thy et al., 1992</a>). The structure of the mutant p.Ala1216Gly was then built using the 3D model of the wild type based on MODELLER script that mutates and refines the protein structure.</p>
<h3>Stability Analysis</h3>
<p class="mb0">We estimated the free energy of folding between the wild type and the mutant structure (&#x0394;&#x0394;G<sub>Wt</sub><sub>&#x2013;</sub><sub>Mut</sub>) using DynaMut (<a href="#B77">Rodrigues et al., 2018</a>). Moreover, we performed a simulation of protein flexibility with CABS-flex 2.0 (<a href="#B39">Jamroz et al., 2014</a>) for both the wild type and the mutant structures at a temperature of 1.6 (dimensionless value related to the physical temperature). For each protein, we performed four simulations with four different predefined seeds. The same set is used for the wild type and the mutant 3D structures. We run the simulation with a fully flexible backbone (protein-flexibility = 0), a number of Monte Carlo cycles of 100 (<i>y</i> = 100) and the protein restraints were reduced by a factor of 0.8. Root Mean Square Fluctuation (RMSF) value was analyzed by calculating the per residue one-tailed Welch&#x2019;s <i>t</i>-test under the null hypothesis that the RMSF at a given position in the sequence does not differ between the mutant and the wild type and an alternative hypothesis being that the RMSF value at given position of the sequence is greater for the mutant than the wild type structure. The analysis was performed using an in-house python script that employs the Scipy library for scientific computing.</p>
<h3>Copy Number Variations Analysis</h3>
<p class="mb0">Copy Number Variations (CNVs) calling was performed on WES data using the ExomeDepth R package (<a href="#B67">Plagnol et al., 2012</a>). All CNVs were annotated using AnnotSV software (<a href="#B30">Geoffroy et al., 2018</a>), a program designed for annotating and ranking Structural Variations (SV) from genomes. This tool compiles functionally, regulatory and clinically relevant information and aims to provide useful annotations to interpret SV potential pathogenicity. AnnotSV classifies CNVs into 5 classes (Class 1: benign, Class 2: likely benign, Class 3: VUS (Variant of Unknown Significance), Class 4: likely pathogenic, and Class 5: pathogenic). In order to identify the most relevant CNVs which may be associated with breast cancer risk, only CNVs classified as class 3, 4, and 5 were kept for further analysis. Biological pathways analysis has been performed using Wikipathways (<a href="#B86">Slenter et al., 2017</a>) and KEGG (<a href="#B42">Kanehisa and Goto, 2000</a>) datasets. Network of Cancer Genes V6.0 (<a href="#B72">Repana et al., 2019</a>) was used to identify genes associated with cancers.</p>
<h3>Genotyping and Haplotype Analysis of c.211dupA Mutation</h3>
<p class="mb0">Haplotype analysis was carried out for 39 individuals: six carriers of the c.211dupA mutation, 3 relatives, 15 breast cancer non-carriers, and 15 healthy age-matched Tunisian women from the general population. Four microsatellite markers (D17S800, D17S855 D17S902, and D17S806), spanning a 6.75 Mb region around the <i>BRCA1</i> gene were studied (<a href="#FS1">Supplementary Figure 1</a>). Primers&#x2019; sequences were obtained from the Probe NCBI database and PCR conditions are available on request. PCR product size was evaluated by capillary electrophoresis on an ABI prism 3500 DNA Genetic Analyzer using the GeneMapper V.5.0 software (Applied Biosystems, Foster City, CA, United States). For the D17S806 marker, results were inconclusive, and it was excluded from further analysis. Haplotypes were then reconstructed using PHASE v.2.1 software (<a href="#B87">Stephens et al., 2001</a>) that uses Bayesian methods to predict haplotype distribution.</p>
<h3>Estimation of c.211dupA Mutation Age</h3>
<p class="mb15">The DMLE + 2.3 program (<a href="#B71">Reeve and Rannala, 2002</a>) was used to estimate the age of the c.211dupA mutation. The DMLE input file included the full genotypes or haplotypes of probands and controls for the analyzed markers, chromosome map distances derived from the Marshfield sex-average genetic map, population growth rate per generation and an estimate of the proportion of disease chromosomes sampled. The other DMLE parameters were kept to their default values.</p>
<p class="mb0">For the population growth rate (r), we used data from the Tunisian Institute of Statistics (INS<sup id="footnotesuper1"><a id="footnote1a"></a><a class="footnoteanchor" href="#footnote1">1</a></sup>). This key parameter was estimated to be 1.348 per generation using the following formula: p<sub>1</sub> = p<sub>0</sub> &#x00D7; r<sup>g</sup>, where p<sub>1</sub> represents the Tunisian population size in 2014 (10.982.754), p<sub>0</sub> represents the Tunisian population in 1860 (1.1 million) (<a href="#B81">Seklani, 1974</a>), and g is the number of generations between these two-time points.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Investigating the State of <i>BRCA1</i>-c.211dupA, Founder Effect and Age</h3>
<p class="mb15">In the current study, 122 individuals from 112 Tunisian families with strong familial history of breast cancer were investigated using sanger and next generation sequencing. First, we looked for c.211dupA which is the most recurrent <i>BRCA1</i> mutation in the Tunisian population.</p>
<p class="mb15">A total of 8 carriers of c.211dupA belonging to 5 unrelated families were identified. All carriers originated from the North-Eastern region of Tunisia. The relative frequency of this mutation is 12.2% (5 out of 41) and 4.46% (5 out of 112) in this region and in the whole cohort, respectively. <i>BRCA1</i>-c.211dupA seems to be the most frequent <i>BRCA</i> mutation in Tunisia, accounting for approximately 41% of all identified <i>BRCA1</i> mutations, if we consider this report and previous Tunisian studies (<a href="#B91">Troudi et al., 2007</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B73">Riahi et al., 2015</a>). In addition, we have not been able to identify any of the other recurrent mutations (<i>BRCA1</i>-c.798_799delTT, <i>BRCA1</i>-c.5266dupC, and <i>BRCA2</i>-c.1310_1313delAAGA) in the other non-carrier patients of the c.211dupA mutation.</p>
<p class="mb15">To investigate the founder effect of c.211dupA, haplotype analysis was performed for 39 individuals. Results showed that 5 out of the 6 genotyped carriers shared an identical haplotype (170-145-147), corresponding to D17S800, D17S855, and D17S902 respectively and all carriers shared a common semi-haplotype (170-145) spanning a region of 2.15 Mb (1.08cM) on <i>BRCA1</i>. This haplotype was absent in non-carriers and was not found in control chromosomes. These results support the founder effect of the c.211dupA mutation in the North-East of Tunisia.</p>
<p class="mb0">Given that the prevalence of <i>BRCA1</i> and <i>BRCA2</i> carriers in the Tunisian general population is not well defined, for the mutation age estimation, three separate analyses were performed, each using a different estimate for the proportion of sampled population carrying the c.211dupA mutation: 0.005, 0.01, and 0.015. Thus, the age estimates for c.211dupA mutation were approximately 6.5 generations (95% CI [5.2&#x2013;8.8]), 6.3 generations (95% CI [4.7&#x2013;8.5]), and 6.00 generations (95% CI [4.4&#x2013;8.1]). Assuming a generation time of 20 years, the corresponding ages are 130 (95% CI [104&#x2013;176]), 126 (95% CI [94&#x2013;170]), and 120 (95% CI [88&#x2013;162]) years.</p>
<h3>Clinico-Pathological Features and Follow-up of c.211dupA Mutation Carriers</h3>
<p class="mb0">We further extended our analysis to the 9 additional carriers of c.211dupA mutation reported in previous Tunisian studies (<a href="#B91">Troudi et al., 2007</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B73">Riahi et al., 2015</a>). For a total of 15 c.211dupA carriers, the mean age at diagnosis was 39.41 years, ranging from 28 to 58 years (<a href="#T1">Table 1</a>). Family history of breast cancer was observed in 93.33% cases (14/15) among which 20% (3/15) presented a family history of ovarian cancer. Other malignancies such as leukemia, prostate, colon and cervical cancers were observed in family members. Infiltrating ductal carcinoma (IDC) was the predominant tumor subtype, high grade 3 and axillary node involvement were observed in about 50% of carriers. The mean tumor size was 30 mm and 50% of carriers displayed a triple negative breast cancer (TNBC) phenotype with two additional cases harboring negative hormone receptors with unknown human epidermal growth factor receptor 2 (HER2) status. Thus, this mutation is likely associated with a severe phenotype.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" name="table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a>
<p><strong>Table 1.</strong> Clinico-pathological features of <i>BRCA1</i> and <i>RAD50</i> carriers.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Assessment of disease evolution for c.211dupA carriers as well as their response to treatment were performed. Radical mastectomy was performed in 4 cases. Sequential adjuvant chemotherapy, 5-Fluorouracil-Epirubicin-Cyclophosphamide-Paclitaxel/Docetaxel (FEC-TXL/TXT) was administered to the majority of carriers and radiotherapy was performed in non-metastatic cases (<a href="#T1">Table 1</a>). Two carriers (BC-TN-F204 and BC-TN-F009) have developed ovarian cancer 13 and 15 years after their breast cancer diagnosis respectively. Contralateral recurrence was observed in two cases (BC-TN-F009 and BC-TN-F0049-1). One patient diagnosed with triple negative metastatic breast cancer (BC-TN-F199) has a refractory disease treatment and died within 12 months by disease progression. However, the median survival of non-metastatic carriers was 12 years. We therefore concluded that except for the metastatic breast cancer case, chemotherapy treatments were well tolerated, and carriers had a good survival despite the severity of their clinico-pathological phenotype.</p>
<h3>BRCA1 and BRCA2 Variants Identified by Next-Generation Sequencing</h3>
<p class="mb0">After studying the carriers of c.211dupA mutation in detail, we then selected 17 other breast cancer patients to be investigated by next generation sequencing. The selection was done on the basis of family history and disease onset. Targeted <i>BRCA1/2</i> sequencing and whole exome sequencing were performed on 9 and 8 breast cancer patients respectively. Familial pedigrees as well as phenotypic characteristics of all carriers are shown in <a href="#F1">Figure 1</a> and <a href="#T1">Table 1</a> respectively.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1.</strong> Familial Pedigrees of <i>BRCA1</i> and <i>RAD50</i> mutations carriers. Available age at diagnosis of breast cancer cases is indicated between brackets. For some cases, only age at death was available and is indicated in square brackets. BOC, Breast and ovarian cancers; CBC, Contralateral breast cancer; IBC, Inflammatory breast cancer; OC, ovarian cancer. Black boxes mean breast cancer and half black boxes mean other cancer types.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">The distribution of the identified <i>BRCA1/2</i> variations is illustrated in <a href="#F2">Figure 2</a>. Exonic coding variants represented 27 out of 67 variants and based on ClinVar database, the majority of the identified <i>BRCA1/2</i> variants were classified as benign (58), 4 were classified as likely benign and 4 variants were not reported in ClinVar.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2.</strong> Distribution of <i>BRCA1/2</i> variations identified in patients investigated by target gene and whole exome sequencing. <b>(A)</b> SNVs/InDels distribution, <b>(B)</b> Distribution of coding variations, <b>(C)</b> ClinVar classification of detected variations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Additionally, our results identified a novel <i>BRCA1</i> pathogenic mutation on exon 11 (c.2418dupA and rs886040036) in one patient. This mutation has not been reported in previous studies neither in Tunisia nor in other populations. Nevertheless, it is already listed and classified as pathogenic in ClinVar and predicted to result in the substitution of Alanine to Serine (p.Ala807Serfs) followed by a premature truncation of BRCA1 protein at amino acid position 809.</p>
<p class="mb15">Patient (BC-TN-F0093) harboring the c.2418dupA mutation is also originating from the North Eastern region of Tunisia. She was diagnosed with triple negative inflammatory breast cancer at 34 years old. Pathological examination of the tumor revealed invasive ductal carcinoma, Scarff-Bloom and Richardson (SBR) grade 2 with Ki-67 of 30%. No additional carriers of this mutation were found in the studied cohort.</p>
<p class="mb0">The remaining 16 patients did not carry any pathogenic mutation on the <i>BRCA</i> genes.</p>
<h3>Whole Exome Sequencing Data Analysis</h3>
<h4 class="pt0">Analysis of Known Breast Cancer Susceptibility Genes</h4>
<p class="mb15">In our current study, in addition to the sanger sequencing analysis, and after screening for pathogenic <i>BRCA1/2</i> mutations among 17 breast cancer patients by NGS. We then selected a unique patient investigated by WES, originating from the North-East of Tunisia for detailed analysis, in order to shed light on the genetic architecture of breast cancer in this specific region. First, we looked for variations on 29 genes known to be associated with breast cancer. At this step we have identified a VUS on <i>RAD50</i>. Therefore, for this same patient, we extended our analysis in order to select other relevant variants on candidate genes that could be associated with malignancies based on <i>in silico</i> analysis and several genomic and biological pathways databases. The proband (BC-TN-F0019) was diagnosed with a locally advanced breast cancer at age 49 with negative hormone receptors status and SBR grade 2. Using whole exome data, we first investigated a list of 29 genes known to be associated with hereditary breast and ovarian cancers. Coverage analysis for these 29 genes demonstrated that we reached a depth of &#x223C;50X and a percentage of coverage of 82% for the targeted regions (<a href="#S11">Supplementary Table 1</a>).</p>
<p class="mb15">A total of 31 exonic variants and one splicing SNP were identified on the 29 genes (<a href="#S11">Supplementary Table 2</a>). None of these variants was classified as pathogenic in ClinVar. However, a VUS, c.3647C &#x003E; G, p.Ala1216Gly, was identified on <i>RAD50</i>. In the same patient, another variant, rs28908468, described by ClinVar as associated with &#x201C;Drug response&#x201D; (PARP inhibitors), was identified on <i>RAD51B.</i></p>
<p class="mb15">We then made a detailed analysis of the mutation identified in the <i>RAD50</i> gene in order to investigate the possibility of revising its current classification in public databases such as ClinVar. Several <i>in silico</i> analysis, indeed, suggest the deleterious aspect of the RAD50 p.Ala1216Gly mutation.</p>
<p class="mb0">To assess the putative effect of this mutation on RAD50 function, we performed a protein modeling and simulation analysis. First, we verified the conservation of the residue <i>NP_005723.2: p.Ala1216</i> by establishing a multiple sequence alignment using homologous RAD50 proteins of model organisms (<a href="#F3">Figure 3A</a>). We observed that <i>Ala1216</i> is located in a highly conserved segment found in all orthologous sequences belonging to organisms emerging at different evolution periods.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3.</strong> Molecular modeling and stability analysis of RAD50_p.Ala1216Gly variation. <b>(A)</b> Multiple sequence alignment of hRAD50 with homologous proteins from model organisms, <i>Gorilla</i> (XP_004042521.1), <i>Mus musculus</i> (NP_033038.2), <i>Gallus</i> (XP_414645.3), <i>Xenopus laevis</i> (NP_001154855.1), <i>Danio rerio</i> (XP_005167995.1), <i>Anolis carolinensis</i> (XP_003217435.1) and <i>Drosophila melanogaster</i> (NP_001246461.1). <b>(B)</b> Predicted 3D structure of hRAD50 predicted with comparative modeling showing the mutation site and the different domains of the protein. DNA docking was generated by transferring the coordinates of the nucleic acid after a structural superposition of the symmetric chains. <b>(C)</b> Position of the mutation A1216G on the ATP&#x03B3;S:Mg ++ stabilizing &#x03B1;-helix extended over residues 1203-1221. <b>(D)</b> Comparative RMSF analysis between the reference protein (A1216, solid lines) and the mutated protein (G1216, dashed lines). The values of RMSF for the reference protein were shifted to +3 &#x00C5;. For the sake of visibility. The green dots represent the position where p-values are significant at a confidence level &#x03B1; = 0.05.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Next, we constructed a homology model of RAD50. The predicted 3D model of hRAD50 consists of the assembly into a homodimer (<a href="#F3">Figure 3B</a>). Each monomer covers segments 2-221 and 1098-1315 which include a relatively small coiled-coil region and the Walker A and Walker B globular domains. The assembly of the latter contains the Protein-DNA interface and the interaction surface with MRE11. The Stereochemical and the local energy quality were validated for the predicted model in comparison with the template structure (<a href="#FS2">Supplementary Figure 2</a>).</p>
<p class="mb15">The mutation site is situated in the core of hRAD50 as part of an &#x03B1; helix extended over residues 1203-1221 (<a href="#F3">Figures 3B,C</a>). Residue A1216 establishes a hydrophobic contact with I1146 situated on another &#x03B1;-helix with a C&#x03B1;-C&#x03B1; distance of 5.7 &#x00C5;. The mutation p.Ala1216Gly is able to preserve this hydrophobic contact. The N-terminal end of the &#x03B1;-helix stabilizes both the Mg<sup>2+</sup> and the ATP&#x03B3;S particularly, the thiotriphosphate moiety of the substrate. The calculation of &#x0394;&#x0394;G<sub>Wt</sub><sub>&#x2013;</sub><sub>Mut</sub> predicted a destabilizing effect for all five methods, DynaMut, ENCoM, mCSM, SDM and DUET with values of -0.037, -0.416, -1.4, -2.170, -1.643 kcal.mol<sup>&#x2013;1</sup> respectively. Moreover, ENCoM predicted a vibrational entropy energy of 0.52 kcal.mol<sup>&#x2013;1</sup>.K<sup>&#x2013;1</sup> suggesting an increase of the molecular flexibility.</p>
<p class="mb0">Because a substitution to glycine may affect the flexibility of other regions in the protein, the extent of this mutation was evaluated by simulating hRAD50 using CABS-flex approach (<a href="#F3">Figure 3D</a>). Our results suggest a significant increase in the RMSF values at a confidence level of 5% (Green dots of <a href="#F3">Figure 3D</a>) for 71 positions located on both monomers. Of these, residues P165, L166, S1210, I1213 seems to be the most critical as they belong to the helix harboring the mutation (S1210, I1213) or are in the proximity of ATP&#x03B3;S: Mg<sup>2+</sup> interaction site (P165, L166). Interestingly, the flexibility does also increase for several amino acids that belong to the surface patch involved in the interaction with MRE11 (<a href="#B80">Seifert et al., 2016</a>). These residues are: F28, L31, V89, N90, G91, K112, T113, L114, E115, G116, I119 of Walker A and D1272, D1295, Q1296, C1297, S1298, K1301, C1302, S1303, V1304 of Walker B.</p>
<h4>Identification of Novel Candidate Variants</h4>
<p class="mb15">In addition to the 29 genes known to be associated with breast cancer, we investigated all the other variants resulting from WES analysis. In order to identify the relevant variants that could be associated with malignancies, we used several <i>in silico</i> prediction tools, genomic databases, biological pathways databases and we performed a literature review. Eleven variants in 11 genes were identified of which 2 candidate variants have been submitted in the ClinVar database. The remaining variants were not reported in the ClinVar database and therefore, their pathogenicity is still not documented. For this, functional and association studies are needed to verify that.</p>
<p class="mb0">A total of 61,404 heterozygous variants were identified (<a href="#F4">Figure 4</a>). Among them, 6773 relevant variants (exonic, splicing, non-synonymous, frameshift Indels, stopgain and stoploss) were identified. Variants with MAF &#x003E; 1% in 1000 Genomes and gnomAD_Exome databases were excluded. Therefore, 677 rare variations were selected for further investigations. In order to select the most relevant SNPs, several <i>in silico</i> prediction tools and databases were used as described in the methods section. A list of 33 non-synonymous variants belonging to 33 genes were retained.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 4</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" name="figure4" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg" alt="www.frontiersin.org" id="F4" loading="lazy">
  </picture>
</a>
<p><strong>Figure 4.</strong> Variants prioritization. Total variations: represents the total number of the identified heterozygous variants and CNVs. Rare relevant variants: we kept (exonic, splicing, non-synonymous, frameshift Indels, stop gain, stop loss) variants. We excluded variants with a frequency &#x003E; 1% in 1000 genomes and gnomAD_Exome databases and CNVs with a frequency &#x003E; 1% in DGV. Functional prediction: using several prediction tools: SIFT (Deleterious), PolyPhen2 (Probably damaging), Mutation Taster (disease-causing), LRT_pred (Deleterious), CADD (score &#x2265; 15), SiPhy_29way_logOdds (score &#x003E; 16), GDI database (excluding highly mutated genes). Using AnnotSV only CNVs (VUS, likely pathogenic or pathogenic) are kept. Biological pathways investigation and selection of candidate variants and CNVs disrupting cancer genes: Using wikipathways, KEGG databases, network of cancer genes 6.0 database and literature review.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">These 33 genes were further filtered based on their implication in cancer etiology using Network of Cancer Genes V6.0. The list of genes was compared to those listed in Wikipathways and KEGG datasets as belonging to pathways relevant in cancers. In addition, we performed a literature review to identify genes more likely to be involved in malignancies development.</p>
<p class="mb0">Based on these analyses, 11 genes were selected, namely <i>MITF, COL7A1, FOXM1, TSHZ2, AMOTL2, ANKS6, ACACB, LIPE, SNRK, CACNA2D3</i>, and <i>SMG1</i> (<a href="#T2">Table 2</a>). Among all variants identified on these genes, two variants, namely <i>ANKS6</i>_rs199722684 and <i>MITF</i>_rs149617956 have been classified in ClinVar as a VUS and a variant with &#x201C;conflicting interpretations of pathogenicity,&#x201D; respectively.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" name="table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a>
<p><strong>Table 2.</strong> Candidate variations identified in whole exome sequenced breast cancer patient.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h4>Copy Number Variations Analysis</h4>
<p class="mb15">Copy number variations were also investigated in order to assess their possible contribution to disease susceptibility (<a href="#F4">Figure 4</a>). Fifty-one CNVs including 30 deletions and 21 duplications were identified with an average size of 24.2 kb (ranging from 64 bp to 123918 bp). Only rare (&#x003C; 1%) and relevant CNVs (of unknown significance, likely pathogenic or pathogenic and ranked as class 3, class 4, and class 5 respectively based on AnnotSV) were kept (<a href="#F4">Figure 4</a>).</p>
<p class="mb0">A total of 7 CNVs affecting 11 genes were identified. Biological pathways analysis has been also performed to select genes linked to breast cancer etiology. In addition, we searched published literature regarding genes affected by CNVs and breast cancer risk (<a href="#T3">Table 3</a>). Among the 11 genes, 5 had been previously identified as cancer genes or candidate cancer genes namely <i>TMTC3, BCL3, COL7A1, RNF5</i>, and <i>CEP290.</i></p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" name="table3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a>
<p><strong>Table 3.</strong> Candidate rare Copy Number Variations likely associated with cancers.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">Since their discovery in 1994 and 1995, a wide range of mutational spectrum have been described for <i>BRCA1</i> and <i>BRCA2</i> genes (<a href="#B48">Laraqui et al., 2015</a>). Several recurrent mutations have been reported in the Tunisian population. Some of these mutations are specific to Tunisians, others are shared with neighboring populations (<a href="#B90">Troudi et al., 2008</a>; <a href="#B56">Mahfoudh et al., 2012</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B64">Msolly and Kassab, 2015</a>; <a href="#B73">Riahi et al., 2015</a>). So far, <i>BRCA1</i>-c.211dupA mutation has been reported only in Tunisian families with breast cancer (<a href="#B91">Troudi et al., 2007</a>; <a href="#B28">Fourati et al., 2014</a>; <a href="#B73">Riahi et al., 2015</a>). In the present report, 8 carriers of c.211dupA were identified, all originating from the North-East of Tunisia, suggesting that this mutation is specific to this region. This finding is in agreement with the results of Riahi and colleagues where all carriers of the c.211dupA mutation were all originating from the North-Eastern region of Tunisia (<a href="#B73">Riahi et al., 2015</a>).</p>
<p class="mb15">In order to unravel the genetic specificities of this mutation and to trace its origin, a haplotype analysis was conducted and results support the founder effect of c.211dupA mutation in the North-East of Tunisia. We have also estimated the <i>BRCA1-</i>c.211dupA approximative age. Indeed, it seems that this mutation appeared 130 years ago in Tunisia, during the second half of the 19th century and after the French occupation that took place in 1881. All migratory waves that occurred at the colonial period may be at the origin of new mutations and had therefore a considerable impact on the genetic diversity of the Tunisian population.</p>
<p class="mb15">The recent origin and the limited geographical distribution of this mutation may also suggest that it could be a <i>de novo</i> mutation that occurred in the 19th century in an individual from the North East of Tunisia. Despite the high rates of <i>de novo</i> mutation that have been observed in several other genes, only 15 carriers of <i>de novo BRCA1/2</i> mutations have been reported to date (<a href="#B31">Golmard et al., 2016</a>).</p>
<p class="mb15">Furthermore, investigation of clinicopathological features of c.211dupA carriers showed that the majority exhibited high histological tumor grade and were diagnosed with TNBC. Our findings are in agreement with previous studies reporting that breast carcinomas in <i>BRCA1</i> mutation carriers are associated with aggressive tumor characteristics (<a href="#B4">Armes et al., 1998</a>). Additionally, the TNBC phenotype is the most observed molecular subtype in patients with <i>BRCA1</i> mutation and it is well documented that breast cancer patients with <i>BRCA1</i> mutation are significantly associated with worse overall survival than patients with a non-mutated <i>BRCA1</i> allele (pooled HR = 1.69 (95% CI 1.35 to 2.12, <i>p</i> &#x003C; 0.001; <i>I</i><sup>2</sup> = 59.1%) (<a href="#B98">Zhu et al., 2016</a>). Nevertheless, in the present study, median survival of non-metastatic carriers of c.211dupA mutation was 12 years.</p>
<p class="mb15">We have also investigated the treatment response and the clinical evolution of the disease among carriers. For c.211dupA mutation, two carriers have developed contralateral breast cancer. This observation is similar to those described in the literature where the risk of contralateral recurrence in women with <i>BRCA</i> mutation is approximately 40% at 10 years (<a href="#B61">Metcalfe et al., 2004</a>). Besides, two other carriers have developed ovarian cancer 15 and 13 years after their breast cancer. This observation is also in accordance with what has been reported in the literature on the cumulative risk of developing ovarian carcinoma after breast cancer in <i>BRCA1</i> mutation carriers that was estimated to almost 12.7% at 10 years (<i>p</i> = 0.03) (<a href="#B62">Metcalfe et al., 2005</a>). It is noteworthy that personal and/or familial ovarian cancer history was present in a high proportion of families (3/5) carrying the c.211dupA mutation.</p>
<p class="mb15">Based on the risk of contralateral recurrence and the risk of developing ovarian cancer several years after breast cancer, risk-reducing mastectomy (<a href="#B34">Hartmann et al., 1999</a>) and salpingo-oophorectomy (<a href="#B69">Rebbeck et al., 2002</a>) are recommended for <i>BRCA1</i>-c.211dupA carriers. Moreover, affected cases carrying this mutation could also benefit from personalized therapeutic options. Indeed, the identification of c.211dupA mutation in a metastatic breast cancer patient helped to reorient her therapeutic decision by using carboplatins, platinum-based agents, that are recommended for the treatment of metastatic <i>BRCA</i>-mutated breast cancer with an overall response rate of 80%, including 45% with complete response (<a href="#B13">Byrski et al., 2012</a>; <a href="#B92">Turner and Tutt, 2012</a>; <a href="#B19">Coates et al., 2015</a>).</p>
<p class="mb15">Therefore, the severe phenotype associated with this mutation (young age of onset, contralateral recurrence, aggressive disease form and ovarian cancer presentation), could be managed if the disease is diagnosed at an early age and if adequate therapeutic and preventive measures are taken.</p>
<p class="mb15">In the current study, beyond the recurrent founder c.211dupA mutation, a novel private <i>BRCA1</i> mutation, c.2418dupA, was identified in a breast cancer patient from the North-East of Tunisia, using targeted gene sequencing. This mutation has never been reported in previous published studies neither in Tunisia nor in other populations. Furthermore, it is not described in the gnomAD database. However, it is listed and classified in ClinVar as pathogenic. This frameshift mutation is located in <i>BRCA1</i> exon 11 that binds important homologous recombination proteins including RAD50 and RAD51. Recent studies showed that <i>BRCA1</i>-exon 11 constitutes an Ovarian Cancer Clustering Region (OCCR) since mutations located in this region are more associated with ovarian cancer risk than breast cancer (<a href="#B66">Orr and Savage, 2015</a>; <a href="#B70">Rebbeck et al., 2015</a>).</p>
<p class="mb15">Using whole exome sequencing, we also identified a rare exonic VUS on <i>RAD50</i> (c.3647C &#x003E; G, rs1314725075, MAF = 4.061 &#x00D7; 10<sup>&#x2013;06</sup>) in a breast cancer patient originating also from the North Eastern Tunisian region. Accumulating evidence indicates that <i>RAD50</i> is a breast cancer susceptibility gene associated with genomic instability (<a href="#B35">Heikkinen et al., 2003</a>, <a href="#B36">2006</a>; <a href="#B38">Hsu et al., 2007</a>; <a href="#B22">Damiola et al., 2014</a>; <a href="#B44">Kleibl and Kristensen, 2016</a>; <a href="#B43">Kim et al., 2017</a>; <a href="#B9">Bian et al., 2019</a>). Indeed, RAD50 is part of the MRE11/RAD50/NBN (MRN) complex that plays a key role in detecting DNA double-strand breaks, recruiting and activating Ataxia-Telangiectasia Mutated protein (ATM) and in processing the DNA repair pathway (<a href="#B9">Bian et al., 2019</a>; <a href="#B85">Situ et al., 2019</a>). Mutations in one or more genes forming this complex may lead to hypersensitivity to genotoxic agents and predisposition to malignancy (<a href="#B9">Bian et al., 2019</a>).</p>
<p class="mb15"><i>In silico</i> analysis at the sequence and structure levels of hRAD50 protein suggest a deleterious impact of the substitution p.Ala1216Gly. The fact that the amino acid Ala is highly conserved in different distantly related orthologous sequences indicates a high positive selective pressure at that position suggesting, therefore, its functional importance for hRAD50. In addition, A1216 is located in the protein core as part of an &#x03B1;-helix segment that stabilizes the binding sites of ATP. Alanine residue, in particular, is the most stabilizing amino acid for helical secondary structures (<a href="#B82">Serrano et al., 1992</a>; <a href="#B52">Lopez-Llano et al., 2006</a>). A mutation to glycine, however, would be highly destabilizing for the entire &#x03B1;-helix and consequently for the ATP binding site. Non-capping &#x03B1;-helical Glycine may introduce a significant conformational degree of freedom due to its simple side chain and therefore introduce more flexibility to its local environment. Indeed, Alanine to Glycine mutations were found to have a significant increase in the stabilizing energy of an &#x03B1; helix of 0.4-2 kcal mol<sup>&#x2013;1</sup> (<a href="#B82">Serrano et al., 1992</a>) and in the increase in its local flexibility. Interestingly, the simulation revealed a putative outcome on the interaction of hRAD50 with MRE11 since several residues of the protein-protein interface showed an increase in the local flexibility that need to be investigated further.</p>
<p class="mb15">Moreover, RAD50 is involved in DNA double-stranded break (DSB) repair by homologous recombination (HR). Recent evidence showed that ovarian cancer patients with a homologous recombination deficiency phenotype (HRD) caused by germline and/or somatic mutations on HR genes exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors (<a href="#B59">Mateo et al., 2019</a>). However, based on the latest guidelines released by the American Society of Clinical Oncology (ASCO), clinical decisions for ovarian cancer patients should not be based on VUSs identified on HRD genes (<a href="#B46">Konstantinopoulos et al., 2020</a>).</p>
<p class="mb15">Therefore, re-evaluating the clinical relevance of VUS identified on HR genes such as the <i>RAD50</i> variant characterized in this current study (c.3647C &#x003E; G) is of keen interest to improve the clinical interpretation of this category of variants and their potential use in precision oncology practice. Indeed, Bope et al., investigated the <i>in silico</i> mutation prediction of variants in African genomes and propose recommendations for re-evaluating the pathogenicity of actionable variants used in research and clinical practice (<a href="#B10">Bope et al., 2019</a>). In addition, Dorschener et al., analyzed actionable pathogenic variants in 500 European and 500 African descent using exome data (<a href="#B24">Dorschner et al., 2013</a>). The results showed major disparities in Africans with an estimated frequency of around 3.4% for those with European origin and 1.2% for those with African descent. <a href="#B58">Manrai et al. (2016)</a> reported a study on patients that were misdiagnosed with hypertrophic cardiomyopathy due to lack of access to non-European data. Indeed, patients from African or unspecified ancestry received positive reports with variants misclassified as pathogenic. Authors concluded that the inclusion of even a small number of African-Americans in control cohorts probably would have prevented this misclassification and misdiagnosis. Therefore, based on this evidence and on the results of our current study, we propose to update the classification of the <i>RAD50</i> c.3647C &#x003E; G mutation and maybe reclassifying it as &#x201C;likely pathogenic variant.&#x201D;</p>
<p class="mb15">For this same patient, a missense variant associated with PARP inhibitor response, rs28908468, has been identified on <i>RAD51B</i>, which is a paralog of <i>RAD51</i> that has an important role in DNA damage response. Indeed, it was demonstrated that RAD51 is a functional biomarker that enables the identification of PARP inhibitors-sensitive breast cancer cases (<a href="#B14">Castroviejo-Bermejo et al., 2018</a>; <a href="#B21">Cruz et al., 2018</a>). The <i>RAD51B</i> variant was clearly classified by an expert panel in ClinVar as a variant that affects only the drug response. However, for the <i>RAD50</i> variant, evidence of the pathogenicity was conflicting. Indeed, expert panel evaluation according to the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines for the interpretation of sequence variants, showed that this variant is of Uncertain Significance (VUS). Thus, we have made an extensive <i>in silico</i> analysis that suggested the need to revise its annotation status.</p>
<p class="mb15">After investigating known breast cancer genes, we extended our analysis to other genes not yet reported as associated with breast carcinoma. Eleven candidate genes were selected based on several filters, namely: <i>MITF, COL7A1, FOXM1, TSHZ2, AMOTL2, ANKS6, ACACB, LIPE, SNRK, CACNA2D3</i>, and <i>SMG1.</i> Only two variants identified on these genes were listed in ClinVar including one VUS found on <i>ANKS6</i> gene (rs199722684) and a variant of &#x201C;conflicting interpretations of pathogenicity&#x201D; identified on <i>MITF</i> gene (rs149617956).</p>
<p class="mb15">Mutations in <i>ANKS6</i> are known to cause a nephronophthisis-like phenotype (<a href="#B89">Taskiran et al., 2014</a>). Based on Cancer Genetic Markers of Susceptibility breast cancer study (CGEMS), 3 SNPs located between <i>ANKS6</i> and <i>GALNT12</i> were identified as significantly associated with breast cancer (<a href="#B37">Higginbotham et al., 2012</a>).</p>
<p class="mb15"><i>MITF</i> is associated with development, differentiation, survival and cell cycle regulation. Recent studies showed that the same mutation (rs149617956, E318K) identified on <i>MITF</i>, has been reported as associated with a high risk of melanoma, renal cell carcinoma and pancreatic cancer (<a href="#B32">Gromowski et al., 2014</a>; <a href="#B88">Sturm et al., 2014</a>). The potential association between E318K and the risk of developing other malignancies such as breast carcinoma has been evaluated by Gromowski et al. Authors concluded that E318K is very rare in breast cancer patients (<a href="#B32">Gromowski et al., 2014</a>).</p>
<p class="mb0">Here we also identified 4 candidate CNVs disrupting 5 genes associated with several carcinomas and involved in interesting biological pathways namely <i>BCL3, COL7A1, RNF5, CEP290</i> and <i>TMTC3.</i> The screening of these CNVs could be considered particularly in breast cancer patients&#x2019; non-carriers of pathogenic point mutations.</p>
<a id="h6" name="h6"></a><h2>Conclusion</h2>
<p class="mb0">The identification of founder and novel private mutations on <i>BRCA1/2</i> as well as functional variants on genes involved in the homologous recombination pathway has significant impact on genetic screening and clinical management of breast and ovarian cancer patients. Our findings also highlight the importance of the use of NGS technologies in detecting novel mutations involved in breast cancer susceptibility in under-investigated populations. <i>In silico</i> analyses that were performed in this study on <i>RAD50</i>-c.3647C &#x003E; G variant classified as VUS in ClinVar suggests a re-evaluation of the current classifications of several variants in public databases. Such a reconsideration would improve criteria of pathogenicity assessment by studying African populations, in particular, North Africans that are still poorly investigated.</p>
<a id="h7" name="h7"></a><h2>Data Availability Statement</h2>
<p class="mb0">The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.</p>
<a id="h8" name="h8"></a><h2>Ethics Statement</h2>
<p class="mb0">The study was conducted according to the declaration of Helsinki and with the approval of the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#x00F4;pital A-M). Written informed consent was obtained from the participants in this study for the publication of any potentially identifiable images or data included in this article.</p>
<a id="h9" name="h9"></a><h2>Author Contributions</h2>
<p class="mb0">NaM did the experiments, analysis, and data interpretation, and drafted the manuscript. YH and MB did analysis and data interpretation, and reviewed the manuscript. MBR contributed in data analysis. SBN, HE, NeM, SL, JA, OJ, HanB, RM, AH, and KR contributed to clinical investigation of patients. HO performed the <i>in silico</i> analyses and reviewed the manuscript. YH and SA contributed to study concept and design. YH, HamB, SB, and SA critically revised the manuscript. YH and SA supervised the study. All authors read and approved the final manuscript.</p>
<a id="fun1" name="fun1"></a><h2>Funding</h2>
<p class="mb0">This work was supported by the Tunisian Ministry of Higher Education and Scientific Research (LR16IPT05) and the Tunisian Ministry of Public Health (PEC-4-TUN). MB and MBR are recipient of a MOBIDOC fellowship funded by the EU through the EMORI and PASRI programs managed by the ANPR.</p>
<a id="conf1" name="conf1"></a><h2>Conflict of Interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="ack1" name="ack1"></a><h2>Acknowledgments</h2>
<p class="mb0">We are grateful to all participants and their family members for their participation in the study.</p>
<a id="S11" name="S11"></a><h2>Supplementary Material</h2>
<p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fgene.2020.552971/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2020.552971/full#supplementary-material</a></p>
<p class="mb15" id="FS1"><b>Supplementary Figure 1 &#x007C;</b> Diagram of the Short Tandem Repeats used for the haplotype analysis. This map is based on the information provided by UniSTS, UCSC. The location and order of the loci used in the present study, as well as their physical and genetic positions are shown. These data are extracted from the Marshfield genetic map (Marshfield Center for Medical Genetics).</p>
<p class="mb0" id="FS2"><b>Supplementary Figure 2 &#x007C;</b> Assessment of the stereochemical <b>(A)</b> and local <b>(B)</b> qualities of hRAD50 homology model in comparison with the template structure by establishing the Ramachandran Plot and the Verif3D profile respectively.</p>
<a id="abbr1" name="abbr1"></a><h2>Abbreviations</h2>
<p class="mb0">ACMG, American College of Medical Genetics and Genomics; ATM, ataxia-telangiectasia mutated protein; CNVs, copy number variations; DNA, deoxyribonucleic acid; DSB, double-stranded break; HER2, human epidermal growth factor receptor 2; HR, homologous recombination; HRD, homologous recombination deficiency phenotype; IDC, intraductal carcinoma; InDels, insertions and deletions; INS, Institute of Statistics; KEGG, kyoto encyclopedia of genes and genomes; MAF, minor allele frequency; MRN, MRE11/RAD50/NBN; NCG, network of cancer genes; NGS, next generation sequencing; OCCR, ovarian cancer clustering region; PARP, poly (ADP-ribose) polymerase; PCR, polymerase chain reaction; PDB, protein data bank; RMSF, root mean square fluctuation; SBR, Scarff-Bloom and Richardson; SNP, single nucleotide polymorphism; SV, structural variations; TGS, target gene sequencing; TNBC, triple negative breast cancer; VarAFT, variant annotation and filtering tool; VUS, variant of unknown significance; WES, whole exome sequencing.</p>
<a id="FNT1" name="FNT1"></a><h2>Footnotes</h2>
<ol>
<li id="footnote1"><strong><a style="color:gray;" class="footnotetextanchor" href="#footnote1a" title="">^</a></strong> <a style="color:gray;" href="http://www.ins.nat.tn">www.ins.nat.tn</a></li>
</ol>
<a id="refer1" name="refer1"></a><h2>References</h2>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B1" id="B1"></a>Akter, H., Sultana, N., Martuza, N., Siddiqua, A., Dity, N. J., Rahaman, M. A., et al. (2019). Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. <i>BMC Med. Genet.</i> 20:150.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Novel+mutations+in+actionable+breast+cancer+genes+by+targeted+sequencing+in+an+ethnically+homogenous+cohort%2E&#x0026;journal=BMC+Med%2E+Genet%2E&#x0026;author=Akter+H.&#x0026;author=Sultana+N.&#x0026;author=Martuza+N.&#x0026;author=Siddiqua+A.&#x0026;author=Dity+N.+J.&#x0026;author=Rahaman+M.+A.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=150" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B2" id="B2"></a>Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. <i>J. Mol. Biol.</i> 215, 403&#x2013;410.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Basic+local+alignment+search+tool%2E&#x0026;journal=J%2E+Mol%2E+Biol%2E&#x0026;author=Altschul+S.+F.&#x0026;author=Gish+W.&#x0026;author=Miller+W.&#x0026;author=Myers+E.+W.&#x0026;author=Lipman+D.+J.&#x0026;publication_year=1990&#x0026;volume=215&#x0026;pages=403&#x2013;410" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B3" id="B3"></a>Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. <i>Am. J. Hum. Genet.</i> 72, 1117&#x2013; 1130.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Average+risks+of+breast+and+ovarian+cancer+associated+with+BRCA1+or+BRCA2+mutations+detected+in+case+series+unselected+for+family+history%3A+a+combined+analysis+of+22+studies%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Antoniou+A.&#x0026;author=Pharoah+P.+D.&#x0026;author=Narod+S.&#x0026;author=Risch+H.+A.&#x0026;author=Eyfjord+J.+E.&#x0026;author=Hopper+J.+L.&#x0026;publication_year=2003&#x0026;volume=72&#x0026;pages=1117&#x2013; 1130" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B4" id="B4"></a>Armes, J. E., Egan, A. M., Southey, M. C., Dite, G. S., McCredie, M. R., Giles, G. G., et al. (1998). The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. <i>Cancer Interdiscip. Int. J. Am. Cancer Soc.</i> 83, 2335&#x2013;2345. doi: 10.1002/(sici)1097-0142(19981201)83:11&#x003C;2335::aid-cncr13&#x003E;3.0.co;2-n</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1002/(sici)1097-0142(19981201)83:11&#x003C;2335::aid-cncr13&#x003E;3.0.co;2-n" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+histologic+phenotypes+of+breast+carcinoma+occurring+before+age+40+years+in+women+with+and+without+BRCA1+or+BRCA2+germline+mutations%3A+a+population-based+study%2E&#x0026;journal=Cancer+Interdiscip%2E+Int%2E+J%2E+Am%2E+Cancer+Soc%2E&#x0026;author=Armes+J.+E.&#x0026;author=Egan+A.+M.&#x0026;author=Southey+M.+C.&#x0026;author=Dite+G.+S.&#x0026;author=McCredie+M.+R.&#x0026;author=Giles+G.+G.&#x0026;publication_year=1998&#x0026;volume=83&#x0026;pages=2335&#x2013;2345" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B5" id="B5"></a>Bai, J., Zhang, X., Kang, X., Jin, L., Wang, P., and Wang, Z. (2019). Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets. <i>Oncol. Lett.</i> 18, 5821&#x2013;5830.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Screening+of+core+genes+and+pathways+in+breast+cancer+development+via+comprehensive+analysis+of+multi+gene+expression+datasets%2E&#x0026;journal=Oncol%2E+Lett%2E&#x0026;author=Bai+J.&#x0026;author=Zhang+X.&#x0026;author=Kang+X.&#x0026;author=Jin+L.&#x0026;author=Wang+P.&#x0026;author=Wang+Z.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=5821&#x2013;5830" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B6" id="B6"></a>Bektas, N., Ten Haaf, A., Veeck, J., Wild, P. J., &#x00FC;scher-Firzlaff, J. L., Hartmann, A., et al. (2008). Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. <i>BMC Cancer</i> 8:42.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Tight+correlation+between+expression+of+the+Forkhead+transcription+factor+FOXM1+and+HER2+in+human+breast+cancer%2E&#x0026;journal=BMC+Cancer&#x0026;author=Bektas+N.&#x0026;author=Ten+Haaf+A.&#x0026;author=Veeck+J.&#x0026;author=Wild+P.+J.&#x0026;author=&#x00FC;scher-Firzlaff+J.+L.&#x0026;author=Hartmann+A.&#x0026;publication_year=2008&#x0026;volume=8&#x0026;issue=42" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B7" id="B7"></a>Berman, H., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T., Weissig, H., et al. (2000). RCSB protein data bank: structural biology views for basic and applied research. <i>Nucleic Acids Res.</i> 28, 235&#x2013;242.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=RCSB+protein+data+bank%3A+structural+biology+views+for+basic+and+applied+research%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Berman+H.&#x0026;author=Westbrook+J.&#x0026;author=Feng+Z.&#x0026;author=Gilliland+G.&#x0026;author=Bhat+T.&#x0026;author=Weissig+H.&#x0026;publication_year=2000&#x0026;volume=28&#x0026;pages=235&#x2013;242" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B8" id="B8"></a>Bewicke-Copley, F., Kumar, E. A., Palladino, G., Korfi, K., and Wang, J. (2019). Applications and analysis of targeted genomic sequencing in cancer studies. <i>Comput. Struct. Biotechnol. J.</i> 17, 1348&#x2013;1359. doi: 10.1016/j.csbj.2019.10.004</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31762958" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.csbj.2019.10.004" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Applications+and+analysis+of+targeted+genomic+sequencing+in+cancer+studies%2E&#x0026;journal=Comput%2E+Struct%2E+Biotechnol%2E+J%2E&#x0026;author=Bewicke-Copley+F.&#x0026;author=Kumar+E.+A.&#x0026;author=Palladino+G.&#x0026;author=Korfi+K.&#x0026;author=Wang+J.&#x0026;publication_year=2019&#x0026;volume=17&#x0026;pages=1348&#x2013;1359" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B9" id="B9"></a>Bian, L., Meng, Y., Zhang, M., and Li, D. (2019). MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. <i>Mol. Cancer</i> 18, 1&#x2013;14. doi: 10.1002/9783527678679.dg07931</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1002/9783527678679.dg07931" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=MRE11-RAD50-NBS1+complex+alterations+and+DNA+damage+response%3A+implications+for+cancer+treatment%2E&#x0026;journal=Mol%2E+Cancer&#x0026;author=Bian+L.&#x0026;author=Meng+Y.&#x0026;author=Zhang+M.&#x0026;author=Li+D.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=1&#x2013;14" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B10" id="B10"></a>Bope, C. D., Chimusa, E. R., Nembaware, V., Mazandu, G. K., de Vries, J., and Wonkam, A. (2019). Dissecting in silico mutation prediction of variants in african genomes: challenges and perspectives. <i>Front. Genet.</i> 10:601.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Dissecting+in+silico+mutation+prediction+of+variants+in+african+genomes%3A+challenges+and+perspectives%2E&#x0026;journal=Front%2E+Genet%2E&#x0026;author=Bope+C.+D.&#x0026;author=Chimusa+E.+R.&#x0026;author=Nembaware+V.&#x0026;author=Mazandu+G.+K.&#x0026;author=de+Vries+J.&#x0026;author=Wonkam+A.&#x0026;publication_year=2019&#x0026;volume=10&#x0026;issue=601" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B11" id="B11"></a>Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J. Clin.</i> 68, 394&#x2013;424. doi: 10.3322/caac.21492</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30207593" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21492" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries%2E&#x0026;journal=CA+Cancer+J%2E+Clin%2E&#x0026;author=Bray+F.&#x0026;author=Ferlay+J.&#x0026;author=Soerjomataram+I.&#x0026;author=Siegel+R.+L.&#x0026;author=Torre+L.+A.&#x0026;author=Jemal+A.&#x0026;publication_year=2018&#x0026;volume=68&#x0026;pages=394&#x2013;424" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B12" id="B12"></a>Bromberg, K. D., Kluger, H. M., Delaunay, A., Abbas, S., DiVito, K. A., Krajewski, S., et al. (2007). Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. <i>Cancer Res.</i> 67, 8172&#x2013;8179. doi: 10.1158/0008-5472.can-07-0045</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17804730" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/0008-5472.can-07-0045" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Increased+expression+of+the+E3+ubiquitin+ligase+RNF5+is+associated+with+decreased+survival+in+breast+cancer%2E&#x0026;journal=Cancer+Res%2E&#x0026;author=Bromberg+K.+D.&#x0026;author=Kluger+H.+M.&#x0026;author=Delaunay+A.&#x0026;author=Abbas+S.&#x0026;author=DiVito+K.+A.&#x0026;author=Krajewski+S.&#x0026;publication_year=2007&#x0026;volume=67&#x0026;pages=8172&#x2013;8179" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B13" id="B13"></a>Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., et al. (2012). Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. <i>Breast Cancer Res.</i> 14:R110.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Results+of+a+phase+II+open-label%2C+non-randomized+trial+of+cisplatin+chemotherapy+in+patients+with+BRCA1-positive+metastatic+breast+cancer%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Byrski+T.&#x0026;author=Dent+R.&#x0026;author=Blecharz+P.&#x0026;author=Foszczynska-Kloda+M.&#x0026;author=Gronwald+J.&#x0026;author=Huzarski+T.&#x0026;publication_year=2012&#x0026;volume=14&#x0026;issue=R110" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B14" id="B14"></a>Castroviejo-Bermejo, M., Cruz, C., Llop-Guevara, A., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Ducy, M., Ibrahim, Y. H., et al. (2018). A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Mol. Med.</i> 10:e9172.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+RAD+51+assay+feasible+in+routine+tumor+samples+calls+PARP+inhibitor+response+beyond+BRCA+mutation%2E&#x0026;journal=EMBO+Mol%2E+Med%2E&#x0026;author=Castroviejo-Bermejo+M.&#x0026;author=Cruz+C.&#x0026;author=Llop-Guevara+A.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Ducy+M.&#x0026;author=Ibrahim+Y.+H.&#x0026;publication_year=2018&#x0026;volume=10&#x0026;issue=e9172" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B15" id="B15"></a>Chalabi, N., Bernard-Gallon, D., Bignon, Y.-J., agier, M., Vidal, V., Laplace-Chabaud, V., et al. (2008). Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. <i>Cancer Genomics Proteomics</i> 5, 253&#x2013;261.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+clinical+and+transcriptomal+profiles+of+breast+cancer+between+French+and+South+Mediterranean+patients+show+minor+but+significative+biological+differences%2E&#x0026;journal=Cancer+Genomics+Proteomics&#x0026;author=Chalabi+N.&#x0026;author=Bernard-Gallon+D.&#x0026;author=Bignon+Y.-J.&#x0026;author=agier+M.&#x0026;author=Vidal+V.&#x0026;author=Laplace-Chabaud+V.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;pages=253&#x2013;261" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B16" id="B16"></a>Chan, T. A., Glockner, S., Yi, J. M., Chen, W., Van Neste, L., Cope, L., et al. (2008). Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. <i>PLoS Med.</i> 5:e114. doi: 10.1371/journal.pmed.0050114</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18507500" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pmed.0050114" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Convergence+of+mutation+and+epigenetic+alterations+identifies+common+genes+in+cancer+that+predict+for+poor+prognosis%2E&#x0026;journal=PLoS+Med%2E&#x0026;author=Chan+T.+A.&#x0026;author=Glockner+S.&#x0026;author=Yi+J.+M.&#x0026;author=Chen+W.&#x0026;author=Van+Neste+L.&#x0026;author=Cope+L.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;issue=e114" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B17" id="B17"></a>Chandler, M. R., Bilgili, E. P., and Merner, N. D. (2016). A review of whole-exome sequencing efforts toward hereditary breast cancer susceptibility gene discovery. <i>Hum. Mutat.</i> 37, 835&#x2013;846. doi: 10.1002/humu.23017</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27226120" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23017" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+review+of+whole-exome+sequencing+efforts+toward+hereditary+breast+cancer+susceptibility+gene+discovery%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Chandler+M.+R.&#x0026;author=Bilgili+E.+P.&#x0026;author=Merner+N.+D.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=835&#x2013;846" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B18" id="B18"></a>Cherbal, F., Bakour, R., Adane, S., Boualga, K., Benais-Pont, G., and Maillet, P. (2010). BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. <i>Dis. Mark.</i> 28, 377&#x2013;384.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+germline+mutations+screening+in+Algerian+breast%2Fovarian+cancer+families%2E&#x0026;journal=Dis%2E+Mark%2E&#x0026;author=Cherbal+F.&#x0026;author=Bakour+R.&#x0026;author=Adane+S.&#x0026;author=Boualga+K.&#x0026;author=Benais-Pont+G.&#x0026;author=Maillet+P.&#x0026;publication_year=2010&#x0026;volume=28&#x0026;pages=377&#x2013;384" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B19" id="B19"></a>Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., et al. (2015). Tailoring therapies&#x2014;improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. <i>Ann. Oncol.</i> 26, 1533&#x2013;1546.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Tailoring+therapies&#x2014;improving+the+management+of+early+breast+cancer%3A+St+Gallen+international+expert+consensus+on+the+primary+therapy+of+early+breast+cancer+2015%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Coates+A.+S.&#x0026;author=Winer+E.+P.&#x0026;author=Goldhirsch+A.&#x0026;author=Gelber+R.+D.&#x0026;author=Gnant+M.&#x0026;author=Piccart-Gebhart+M.&#x0026;publication_year=2015&#x0026;volume=26&#x0026;pages=1533&#x2013;1546" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B20" id="B20"></a>The Uniport Consortium (2019). UniProt: a worldwide hub of protein knowledge. <i>Nucleic Acids Res.</i> 47, D506&#x2013;D515.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=UniProt%3A+a+worldwide+hub+of+protein+knowledge%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;publication_year=2019&#x0026;volume=47&#x0026;pages=D506&#x2013;D515" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B21" id="B21"></a>Cruz, C., Castroviejo-Bermejo, M., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Llop-Guevara, A., Ibrahim, Y., Gris-Oliver, A., et al. (2018). RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Ann. Oncol.</i> 29, 1203&#x2013;1210. doi: 10.1093/annonc/mdy099</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29635390" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdy099" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=RAD51+foci+as+a+functional+biomarker+of+homologous+recombination+repair+and+PARP+inhibitor+resistance+in+germline+BRCA-mutated+breast+cancer%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Cruz+C.&#x0026;author=Castroviejo-Bermejo+M.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Llop-Guevara+A.&#x0026;author=Ibrahim+Y.&#x0026;author=Gris-Oliver+A.&#x0026;publication_year=2018&#x0026;volume=29&#x0026;pages=1203&#x2013;1210" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B22" id="B22"></a>Damiola, F., Pertesi, M., Oliver, J., Calvez-Kelm, F. Le, Voegele, C., Young, E. L., et al. (2014). Rare key functional domain missense substitutions in MRE11A, RAD50, and NBNcontribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. <i>Breast Cancer Res.</i> 16:R58.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Rare+key+functional+domain+missense+substitutions+in+MRE11A%2C+RAD50%2C+and+NBNcontribute+to+breast+cancer+susceptibility%3A+results+from+a+Breast+Cancer+Family+Registry+case-control+mutation-screening+study%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Damiola+F.&#x0026;author=Pertesi+M.&#x0026;author=Oliver+J.&#x0026;author=Calvez-Kelm+F.+Le+Voegele+C.&#x0026;author=Young+E.+L.&#x0026;publication_year=2014&#x0026;volume=16&#x0026;issue=R58" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B23" id="B23"></a>Desvignes, J.-P., Bartoli, M., Delague, V., Krahn, M., Miltgen, M., B&#x00E9;roud, C., et al. (2018). VarAFT: a variant annotation and filtration system for human next generation sequencing data. <i>Nucleic Acids Res.</i> 46, W545&#x2013;W553.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=VarAFT%3A+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Desvignes+J.-P.&#x0026;author=Bartoli+M.&#x0026;author=Delague+V.&#x0026;author=Krahn+M.&#x0026;author=Miltgen+M.&#x0026;author=B&#x00E9;roud+C.&#x0026;publication_year=2018&#x0026;volume=46&#x0026;pages=W545&#x2013;W553" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B24" id="B24"></a>Dorschner, M. O., Amendola, L. M., Turner, E. H., Robertson, P. D., Shirts, B. H., Gallego, C. J., et al. (2013). Actionable, pathogenic incidental findings in 1,000 participants&#x2019; exomes. <i>Am. J. Hum. Genet.</i> 93, 631&#x2013;640. doi: 10.1016/j.ajhg.2013.08.006</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24055113" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ajhg.2013.08.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Actionable%2C+pathogenic+incidental+findings+in+1%2C000+participants&#x2019;+exomes%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Dorschner+M.+O.&#x0026;author=Amendola+L.+M.&#x0026;author=Turner+E.+H.&#x0026;author=Robertson+P.+D.&#x0026;author=Shirts+B.+H.&#x0026;author=Gallego+C.+J.&#x0026;publication_year=2013&#x0026;volume=93&#x0026;pages=631&#x2013;640" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B25" id="B25"></a>Ebbert, M. T., Wadsworth, M. E., Staley, L. A., Hoyt, K. L., Pickett, B., Miller, J., et al. (2016). Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches. <i>BMC Bioinformatics</i> 17:239.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Evaluating+the+necessity+of+PCR+duplicate+removal+from+next-generation+sequencing+data+and+a+comparison+of+approaches%2E&#x0026;journal=BMC+Bioinformatics&#x0026;author=Ebbert+M.+T.&#x0026;author=Wadsworth+M.+E.&#x0026;author=Staley+L.+A.&#x0026;author=Hoyt+K.+L.&#x0026;author=Pickett+B.&#x0026;author=Miller+J.&#x0026;publication_year=2016&#x0026;volume=17&#x0026;issue=239" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B26" id="B26"></a>Fackenthal, J. D., and Olopade, O. I. (2007). Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. <i>Nat. Rev. Cancer</i> 7:937. doi: 10.1038/nrc2054</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18034184" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc2054" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+cancer+risk+associated+with+BRCA1+and+BRCA2+in+diverse+populations%2E&#x0026;journal=Nat%2E+Rev%2E+Cancer&#x0026;author=Fackenthal+J.+D.&#x0026;author=Olopade+O.+I.&#x0026;publication_year=2007&#x0026;volume=7&#x0026;issue=937" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B27" id="B27"></a>Ford, D., Easton, D., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. <i>Am. J. Hum. Genet.</i> 62, 676&#x2013;689.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+heterogeneity+and+penetrance+analysis+of+the+BRCA1+and+BRCA2+genes+in+breast+cancer+families%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Ford+D.&#x0026;author=Easton+D.&#x0026;author=Stratton+M.&#x0026;author=Narod+S.&#x0026;author=Goldgar+D.&#x0026;author=Devilee+P.&#x0026;publication_year=1998&#x0026;volume=62&#x0026;pages=676&#x2013;689" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B28" id="B28"></a>Fourati, A., Louchez, M.-M., Fournier, J., Gamoudi, A., Rahal, K., El May, M.-V., et al. (2014). Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. <i>Bull. Cancer</i> 101, E36&#x2013;E40.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Screening+for+common+mutations+in+BRCA1+and+BRCA2+genes%3A+interest+in+genetic+testing+of+Tunisian+families+with+breast+and%2For+ovarian+cancer%2E&#x0026;journal=Bull%2E+Cancer&#x0026;author=Fourati+A.&#x0026;author=Louchez+M.-M.&#x0026;author=Fournier+J.&#x0026;author=Gamoudi+A.&#x0026;author=Rahal+K.&#x0026;author=El+May+M.-V.&#x0026;publication_year=2014&#x0026;volume=101&#x0026;pages=E36&#x2013;E40" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B29" id="B29"></a>Gao, Y., Xuan, C., Jin, M., An, Q., Zhuo, B., Chen, X., et al. (2019). Ubiquitin ligase RNF5 serves an important role in the development of human glioma. <i>Oncol. Lett.</i> 18, 4659&#x2013;4666.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Ubiquitin+ligase+RNF5+serves+an+important+role+in+the+development+of+human+glioma%2E&#x0026;journal=Oncol%2E+Lett%2E&#x0026;author=Gao+Y.&#x0026;author=Xuan+C.&#x0026;author=Jin+M.&#x0026;author=An+Q.&#x0026;author=Zhuo+B.&#x0026;author=Chen+X.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=4659&#x2013;4666" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B30" id="B30"></a>Geoffroy, V., Herenger, Y., Kress, A., Stoetzel, C., Piton, A., Dollfus, H., et al. (2018). AnnotSV: an integrated tool for structural variations annotation. <i>Bioinformatics</i> 34, 3572&#x2013;3574. doi: 10.1093/bioinformatics/bty304</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29669011" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/bty304" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=AnnotSV%3A+an+integrated+tool+for+structural+variations+annotation%2E&#x0026;journal=Bioinformatics&#x0026;author=Geoffroy+V.&#x0026;author=Herenger+Y.&#x0026;author=Kress+A.&#x0026;author=Stoetzel+C.&#x0026;author=Piton+A.&#x0026;author=Dollfus+H.&#x0026;publication_year=2018&#x0026;volume=34&#x0026;pages=3572&#x2013;3574" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B31" id="B31"></a>Golmard, L., Delnatte, C., Laug&#x00E9;, A., Moncoutier, V., Lefol, C., Abidallah, K., et al. (2016). Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. <i>Oncogene</i> 35:1324.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+and+ovarian+cancer+predisposition+due+to+de+novo+BRCA1+and+BRCA2+mutations%2E&#x0026;journal=Oncogene&#x0026;author=Golmard+L.&#x0026;author=Delnatte+C.&#x0026;author=Laug&#x00E9;+A.&#x0026;author=Moncoutier+V.&#x0026;author=Lefol+C.&#x0026;author=Abidallah+K.&#x0026;publication_year=2016&#x0026;volume=35&#x0026;issue=1324" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B32" id="B32"></a>Gromowski, T., Masoj&#x00E6;, B., Scott, R. J., Cybulski, C., G&#x00F3;rski, B., Klu&#x017A;niak, W., et al. (2014). Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study. <i>Cancer Genet.</i> 207, 128&#x2013;132. doi: 10.1016/j.cancergen.2014.03.003</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24767713" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cancergen.2014.03.003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Prevalence+of+the+E318K+and+V320I+MITF+germline+mutations+in+Polish+cancer+patients+and+multiorgan+cancer+risk-a+population-based+study%2E&#x0026;journal=Cancer+Genet%2E&#x0026;author=Gromowski+T.&#x0026;author=Masoj&#x00E6;+B.&#x0026;author=Scott+R.+J.&#x0026;author=Cybulski+C.&#x0026;author=G&#x00F3;rski+B.&#x0026;author=Klu&#x017A;niak+W.&#x0026;publication_year=2014&#x0026;volume=207&#x0026;pages=128&#x2013;132" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B33" id="B33"></a>Han, M.-R., Long, J., Choi, J.-Y., Low, S.-K., Kweon, S.-S., Zheng, Y., et al. (2016). Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. <i>Hum. Mol. Genet.</i> 25, 3361&#x2013;3371.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Genome-wide+association+study+in+East+Asians+identifies+two+novel+breast+cancer+susceptibility+loci%2E&#x0026;journal=Hum%2E+Mol%2E+Genet%2E&#x0026;author=Han+M.-R.&#x0026;author=Long+J.&#x0026;author=Choi+J.-Y.&#x0026;author=Low+S.-K.&#x0026;author=Kweon+S.-S.&#x0026;author=Zheng+Y.&#x0026;publication_year=2016&#x0026;volume=25&#x0026;pages=3361&#x2013;3371" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B34" id="B34"></a>Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P., et al. (1999). Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. <i>N. Engl. J. Med.</i> 340, 77&#x2013;84.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Efficacy+of+bilateral+prophylactic+mastectomy+in+women+with+a+family+history+of+breast+cancer%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Hartmann+L.+C.&#x0026;author=Schaid+D.+J.&#x0026;author=Woods+J.+E.&#x0026;author=Crotty+T.+P.&#x0026;author=Myers+J.+L.&#x0026;author=Arnold+P.&#x0026;publication_year=1999&#x0026;volume=340&#x0026;pages=77&#x2013;84" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B35" id="B35"></a>Heikkinen, K., Karppinen, S., Soini, Y., M&#x00E4;kinen, M., and Winqvist, R. (2003). Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. <i>J. Med. Genet.</i> 40:e131.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Mutation+screening+of+Mre11+complex+genes%3A+indication+of+RAD50+involvement+in+breast+and+ovarian+cancer+susceptibility%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Heikkinen+K.&#x0026;author=Karppinen+S.&#x0026;author=Soini+Y.&#x0026;author=M&#x00E4;kinen+M.&#x0026;author=Winqvist+R.&#x0026;publication_year=2003&#x0026;volume=40&#x0026;issue=e131" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B36" id="B36"></a>Heikkinen, K., Rapakko, K., Karppinen, S.-M., Erkko, H., Knuutila, S., Lund&#x00E1;n, T., et al. (2006). RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. <i>Carcinogenesis</i> 27, 1593&#x2013;1599. doi: 10.1093/carcin/bgi360</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16474176" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/carcin/bgi360" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=RAD50+and+NBS1+are+breast+cancer+susceptibility+genes+associated+with+genomic+instability%2E&#x0026;journal=Carcinogenesis&#x0026;author=Heikkinen+K.&#x0026;author=Rapakko+K.&#x0026;author=Karppinen+S.-M.&#x0026;author=Erkko+H.&#x0026;author=Knuutila+S.&#x0026;author=Lund&#x00E1;n+T.&#x0026;publication_year=2006&#x0026;volume=27&#x0026;pages=1593&#x2013;1599" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B37" id="B37"></a>Higginbotham, K. S., Breyer, J. P., McReynolds, K. M., Bradley, K. M., Schuyler, P. A., Plummer, W. D., et al. (2012). A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. <i>Cancer Epidemiol. Prevention Biomarkers</i> 21, 1565&#x2013;1573. doi: 10.1158/1055-9965.epi-12-0386</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22806168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.epi-12-0386" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+multistage+genetic+association+study+identifies+breast+cancer+risk+loci+at+10q25+and+16q24%2E&#x0026;journal=Cancer+Epidemiol%2E+Prevention+Biomarkers&#x0026;author=Higginbotham+K.+S.&#x0026;author=Breyer+J.+P.&#x0026;author=McReynolds+K.+M.&#x0026;author=Bradley+K.+M.&#x0026;author=Schuyler+P.+A.&#x0026;author=Plummer+W.+D.&#x0026;publication_year=2012&#x0026;volume=21&#x0026;pages=1565&#x2013;1573" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B38" id="B38"></a>Hsu, H.-M., Wang, H.-C., Chen, S.-T., Hsu, G.-C., Shen, C.-Y., and Yu, J.-C. (2007). Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. <i>Cancer Epidemiol. Prevention Biomarkers</i> 16, 2024&#x2013;2032. doi: 10.1158/1055-9965.epi-07-0116</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17932350" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.epi-07-0116" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+cancer+risk+is+associated+with+the+genes+encoding+the+DNA+double-strand+break+repair+Mre11%2FRad50%2FNbs1+complex%2E&#x0026;journal=Cancer+Epidemiol%2E+Prevention+Biomarkers&#x0026;author=Hsu+H.-M.&#x0026;author=Wang+H.-C.&#x0026;author=Chen+S.-T.&#x0026;author=Hsu+G.-C.&#x0026;author=Shen+C.-Y.&#x0026;author=Yu+J.-C.&#x0026;publication_year=2007&#x0026;volume=16&#x0026;pages=2024&#x2013;2032" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B39" id="B39"></a>Jamroz, M., Kolinski, A., and Kmiecik, S. (2014). CABS-flex predictions of protein flexibility compared with NMR ensembles. <i>Bioinformatics</i> 30, 2150&#x2013;2154. doi: 10.1093/bioinformatics/btu184</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24735558" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btu184" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=CABS-flex+predictions+of+protein+flexibility+compared+with+NMR+ensembles%2E&#x0026;journal=Bioinformatics&#x0026;author=Jamroz+M.&#x0026;author=Kolinski+A.&#x0026;author=Kmiecik+S.&#x0026;publication_year=2014&#x0026;volume=30&#x0026;pages=2150&#x2013;2154" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B40" id="B40"></a>Janavi&#x010D;ius, R. (2010). Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. <i>EPMA J.</i> 1, 397&#x2013;412. doi: 10.1007/s13167-010-0037-y</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23199084" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s13167-010-0037-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Founder+BRCA1%2F2+mutations+in+the+Europe%3A+implications+for+hereditary+breast-ovarian+cancer+prevention+and+control%2E&#x0026;journal=EPMA+J%2E&#x0026;author=Janavi&#x010D;ius+R.&#x0026;publication_year=2010&#x0026;volume=1&#x0026;pages=397&#x2013;412" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B41" id="B41"></a>Jin, Y., Cui, D., Ren, J., Wang, K., Zeng, T., and Gao, L. (2017). CACNA2D3 is downregulated in gliomas and functions as a tumor suppressor. <i>Mol. Carcinogenesis</i> 56, 945&#x2013;959. doi: 10.1002/mc.22548</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27583705" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/mc.22548" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=CACNA2D3+is+downregulated+in+gliomas+and+functions+as+a+tumor+suppressor%2E&#x0026;journal=Mol%2E+Carcinogenesis&#x0026;author=Jin+Y.&#x0026;author=Cui+D.&#x0026;author=Ren+J.&#x0026;author=Wang+K.&#x0026;author=Zeng+T.&#x0026;author=Gao+L.&#x0026;publication_year=2017&#x0026;volume=56&#x0026;pages=945&#x2013;959" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B42" id="B42"></a>Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. <i>Nucleic Acids Res.</i> 28, 27&#x2013;30.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=KEGG%3A+kyoto+encyclopedia+of+genes+and+genomes%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Kanehisa+M.&#x0026;author=Goto+S.&#x0026;publication_year=2000&#x0026;volume=28&#x0026;pages=27&#x2013;30" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B43" id="B43"></a>Kim, H., Cho, D.-Y., Choi, D. H., Oh, M., Shin, I., Park, W., et al. (2017). Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. <i>Breast Cancer Res. Treat.</i> 161, 95&#x2013;102. doi: 10.1007/s10549-016-4034-2</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27783279" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-016-4034-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Frequency+of+pathogenic+germline+mutation+in+CHEK2%2C+PALB2%2C+MRE11%2C+and+RAD50+in+patients+at+high+risk+for+hereditary+breast+cancer%2E&#x0026;journal=Breast+Cancer+Res%2E+Treat%2E&#x0026;author=Kim+H.&#x0026;author=Cho+D.-Y.&#x0026;author=Choi+D.+H.&#x0026;author=Oh+M.&#x0026;author=Shin+I.&#x0026;author=Park+W.&#x0026;publication_year=2017&#x0026;volume=161&#x0026;pages=95&#x2013;102" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B44" id="B44"></a>Kleibl, Z., and Kristensen, V. N. (2016). Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. <i>Breast</i> 28, 136&#x2013;144. doi: 10.1016/j.breast.2016.05.006</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27318168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.breast.2016.05.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Women+at+high+risk+of+breast+cancer%3A+molecular+characteristics%2C+clinical+presentation+and+management%2E&#x0026;journal=Breast&#x0026;author=Kleibl+Z.&#x0026;author=Kristensen+V.+N.&#x0026;publication_year=2016&#x0026;volume=28&#x0026;pages=136&#x2013;144" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B45" id="B45"></a>Kong, X., Li, M., Shao, K., Yang, Y., Wang, Q., and Cai, M. (2020). Progesterone induces cell apoptosis via the CACNA2D3/Ca2+/p38 MAPK pathway in endometrial cancer. <i>Oncol. Reports</i> 43, 121&#x2013;132.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Progesterone+induces+cell+apoptosis+via+the+CACNA2D3%2FCa2%2B%2Fp38+MAPK+pathway+in+endometrial+cancer%2E&#x0026;journal=Oncol%2E+Reports&#x0026;author=Kong+X.&#x0026;author=Li+M.&#x0026;author=Shao+K.&#x0026;author=Yang+Y.&#x0026;author=Wang+Q.&#x0026;author=Cai+M.&#x0026;publication_year=2020&#x0026;volume=43&#x0026;pages=121&#x2013;132" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B46" id="B46"></a>Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., et al. (2020). Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. <i>J. Clin. Oncol.</i> 16, e835&#x2013;e838.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Germline+and+somatic+tumor+testing+in+epithelial+ovarian+cancer%3A+ASCO+guideline%2E&#x0026;journal=J%2E+Clin%2E+Oncol%2E&#x0026;author=Konstantinopoulos+P.+A.&#x0026;author=Norquist+B.&#x0026;author=Lacchetti+C.&#x0026;author=Armstrong+D.&#x0026;author=Grisham+R.+N.&#x0026;author=Goodfellow+P.+J.&#x0026;publication_year=2020&#x0026;volume=16&#x0026;pages=e835&#x2013;e838" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B47" id="B47"></a>Laarabi, F.-Z., Ratbi, I., Elalaoui, S. C., Mezzouar, L., Doubaj, Y., Bouguenouch, L., et al. (2017). High frequency of the recurrent c. 1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast&#x2013;ovarian cancer prevention and control. <i>BMC Res. Notes</i> 10:188.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=High+frequency+of+the+recurrent+c%2E+1310%5F1313delAAGA+BRCA2+mutation+in+the+North-East+of+Morocco+and+implication+for+hereditary+breast&#x2013;ovarian+cancer+prevention+and+control%2E&#x0026;journal=BMC+Res%2E+Notes&#x0026;author=Laarabi+F.-Z.&#x0026;author=Ratbi+I.&#x0026;author=Elalaoui+S.+C.&#x0026;author=Mezzouar+L.&#x0026;author=Doubaj+Y.&#x0026;author=Bouguenouch+L.&#x0026;publication_year=2017&#x0026;volume=10&#x0026;issue=188" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B48" id="B48"></a>Laraqui, A., Uhrhammer, N., El Rhaffouli, H., Sekhsokh, Y., Lahlou-Amine, I., Bajjou, T., et al. (2015). BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c. 798_799delTT) in North African. <i>Disease Markers</i> 2015:194293.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+genetic+screening+in+Middle+Eastern+and+North+African%3A+mutational+spectrum+and+founder+BRCA1+mutation+%28c%2E+798%5F799delTT%29+in+North+African%2E&#x0026;journal=Disease+Markers&#x0026;author=Laraqui+A.&#x0026;author=Uhrhammer+N.&#x0026;author=El+Rhaffouli+H.&#x0026;author=Sekhsokh+Y.&#x0026;author=Lahlou-Amine+I.&#x0026;author=Bajjou+T.&#x0026;publication_year=2015&#x0026;volume=2015&#x0026;issue=194293" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B49" id="B49"></a>Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. <i>Bioinformatics</i> 25, 1754&#x2013;1760. doi: 10.1093/bioinformatics/btp324</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19451168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btp324" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Fast+and+accurate+short+read+alignment+with+Burrows&#x2013;Wheeler+transform%2E&#x0026;journal=Bioinformatics&#x0026;author=Li+H.&#x0026;author=Durbin+R.&#x0026;publication_year=2009&#x0026;volume=25&#x0026;pages=1754&#x2013;1760" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B50" id="B50"></a>Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The sequence alignment/map format and SAMtools. <i>Bioinformatics</i> 25, 2078&#x2013;2079. doi: 10.1093/bioinformatics/btp352</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19505943" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btp352" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+sequence+alignment%2Fmap+format+and+SAMtools%2E&#x0026;journal=Bioinformatics&#x0026;author=Li+H.&#x0026;author=Handsaker+B.&#x0026;author=Wysoker+A.&#x0026;author=Fennell+T.&#x0026;author=Ruan+J.&#x0026;author=Homer+N.&#x0026;publication_year=2009&#x0026;volume=25&#x0026;pages=2078&#x2013;2079" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B51" id="B51"></a>Li, Y., Zhu, C.-L., Nie, C.-J., Li, J.-C., Zeng, T.-T., Zhou, J., et al. (2013). Investigation of tumor suppressing function of CACNA2D3 in esophageal squamous cell carcinoma. <i>PLoS One</i> 8:e60027. doi: 10.1371/journal.pone.0060027</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23560067" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0060027" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Investigation+of+tumor+suppressing+function+of+CACNA2D3+in+esophageal+squamous+cell+carcinoma%2E&#x0026;journal=PLoS+One&#x0026;author=Li+Y.&#x0026;author=Zhu+C.-L.&#x0026;author=Nie+C.-J.&#x0026;author=Li+J.-C.&#x0026;author=Zeng+T.-T.&#x0026;author=Zhou+J.&#x0026;publication_year=2013&#x0026;volume=8&#x0026;issue=e60027" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B52" id="B52"></a>Lopez-Llano, J., Campos, L., and Sancho, J. (2006). &#x03B1;-helix stabilization by alanine relative to glycine: roles of polar and apolar solvent exposures and of backbone entropy. <i>Proteins Struct. Funct. Bioinformatics</i> 64, 769&#x2013;778. doi: 10.1002/prot.21041</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16755589" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/prot.21041" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=&#x03B1;-helix+stabilization+by+alanine+relative+to+glycine%3A+roles+of+polar+and+apolar+solvent+exposures+and+of+backbone+entropy%2E&#x0026;journal=Proteins+Struct%2E+Funct%2E+Bioinformatics&#x0026;author=Lopez-Llano+J.&#x0026;author=Campos+L.&#x0026;author=Sancho+J.&#x0026;publication_year=2006&#x0026;volume=64&#x0026;pages=769&#x2013;778" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B53" id="B53"></a>Lovell, S. C. I, Davis, W., Arendall, W. B. III, De Bakker, P. I., Word, J. M., Prisant, M. G., et al. (2003). Structure validation by C&#x03B1; geometry: ?, &#x03C8; and C&#x03B2; deviation. <i>Proteins Struct. Funct. Bioinformatics</i> 50, 437&#x2013;450. doi: 10.1002/prot.10286</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12557186" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/prot.10286" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Structure+validation+by+C&#x03B1;+geometry%3A+%B4%2C+&#x03C8;+and+C&#x03B2;+deviation%2E&#x0026;journal=Proteins+Struct%2E+Funct%2E+Bioinformatics&#x0026;author=Lovell+S.+C.+I+Davis+W.&#x0026;author=Arendall+W.+B.+III&#x0026;author=De+Bakker+P.+I.&#x0026;author=Word+J.+M.&#x0026;author=Prisant+M.+G.&#x0026;publication_year=2003&#x0026;volume=50&#x0026;pages=437&#x2013;450" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B54" id="B54"></a>L&#x00FC;thy, R., Bowie, J. U., and Eisenberg, D. (1992). Assessment of protein models with three-dimensional profiles. <i>Nature</i> 356, 83&#x2013;85. doi: 10.1038/356083a0</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1538787" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/356083a0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Assessment+of+protein+models+with+three-dimensional+profiles%2E&#x0026;journal=Nature&#x0026;author=L&#x00FC;thy+R.&#x0026;author=Bowie+J.+U.&#x0026;author=Eisenberg+D.&#x0026;publication_year=1992&#x0026;volume=356&#x0026;pages=83&#x2013;85" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B55" id="B55"></a>Lv, M., Shen, Y., Yang, J., Li, S., Wang, B., Chen, Z., et al. (2017). Angiomotin family members: oncogenes or tumor suppressors? <i>Int. J. Biol. Sci.</i> 13:772. doi: 10.7150/ijbs.19603</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28656002" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.7150/ijbs.19603" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Angiomotin+family+members%3A+oncogenes+or+tumor+suppressors%B4&#x0026;journal=Int%2E+J%2E+Biol%2E+Sci%2E&#x0026;author=Lv+M.&#x0026;author=Shen+Y.&#x0026;author=Yang+J.&#x0026;author=Li+S.&#x0026;author=Wang+B.&#x0026;author=Chen+Z.&#x0026;publication_year=2017&#x0026;volume=13&#x0026;issue=772" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B56" id="B56"></a>Mahfoudh, W., Bouaouina, N., Ahmed, S. B., Gabbouj, S., Shan, J., Mathew, R., et al. (2012). Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. <i>Mol. Biol. Reports</i> 39, 1037&#x2013;1046. doi: 10.1007/s11033-011-0829-8</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21603858" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s11033-011-0829-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Hereditary+breast+cancer+in+Middle+Eastern+and+North+African+%28MENA%29+populations%3A+identification+of+novel%2C+recurrent+and+founder+BRCA1+mutations+in+the+Tunisian+population%2E&#x0026;journal=Mol%2E+Biol%2E+Reports&#x0026;author=Mahfoudh+W.&#x0026;author=Bouaouina+N.&#x0026;author=Ahmed+S.+B.&#x0026;author=Gabbouj+S.&#x0026;author=Shan+J.&#x0026;author=Mathew+R.&#x0026;publication_year=2012&#x0026;volume=39&#x0026;pages=1037&#x2013;1046" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B57" id="B57"></a>Maldonado, V., and Melendez-Zajgla, J. (2011). Role of Bcl-3 in solid tumors. <i>Mol. Cancer</i> 10:152. doi: 10.1186/1476-4598-10-152</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22195643" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1476-4598-10-152" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Role+of+Bcl-3+in+solid+tumors%2E&#x0026;journal=Mol%2E+Cancer&#x0026;author=Maldonado+V.&#x0026;author=Melendez-Zajgla+J.&#x0026;publication_year=2011&#x0026;volume=10&#x0026;issue=152" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B58" id="B58"></a>Manrai, A. K., Funke, B. H., Rehm, H. L., Olesen, M. S., Maron, B. A., Szolovits, P., et al. (2016). Genetic misdiagnoses and the potential for health disparities. <i>N. Engl. J. Med.</i> 375, 655&#x2013;665. doi: 10.1056/nejmsa1507092</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27532831" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/nejmsa1507092" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+misdiagnoses+and+the+potential+for+health+disparities%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Manrai+A.+K.&#x0026;author=Funke+B.+H.&#x0026;author=Rehm+H.+L.&#x0026;author=Olesen+M.+S.&#x0026;author=Maron+B.+A.&#x0026;author=Szolovits+P.&#x0026;publication_year=2016&#x0026;volume=375&#x0026;pages=655&#x2013;665" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B59" id="B59"></a>Mateo, J., Lord, C., Serra, V., Tutt, A., Balma&#x00F1;a, J., Castroviejo-Bermejo, M., et al. (2019). A decade of clinical development of PARP inhibitors in perspective. <i>Ann. Oncol.</i> 30, 1437&#x2013;1447. doi: 10.1093/annonc/mdz192</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31218365" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdz192" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+decade+of+clinical+development+of+PARP+inhibitors+in+perspective%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Mateo+J.&#x0026;author=Lord+C.&#x0026;author=Serra+V.&#x0026;author=Tutt+A.&#x0026;author=Balma&#x00F1;a+J.&#x0026;author=Castroviejo-Bermejo+M.&#x0026;publication_year=2019&#x0026;volume=30&#x0026;pages=1437&#x2013;1447" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B60" id="B60"></a>McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., et al. (2010). The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. <i>Genome Res.</i> 20, 1297&#x2013;1303. doi: 10.1101/gr.107524.110</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20644199" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/gr.107524.110" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+genome+analysis+toolkit%3A+a+MapReduce+framework+for+analyzing+next-generation+DNA+sequencing+data%2E&#x0026;journal=Genome+Res%2E&#x0026;author=McKenna+A.&#x0026;author=Hanna+M.&#x0026;author=Banks+E.&#x0026;author=Sivachenko+A.&#x0026;author=Cibulskis+K.&#x0026;author=Kernytsky+A.&#x0026;publication_year=2010&#x0026;volume=20&#x0026;pages=1297&#x2013;1303" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B61" id="B61"></a>Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>J. Clin. Oncol.</i> 22, 2328&#x2013;2335.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Contralateral+breast+cancer+in+BRCA1+and+BRCA2+mutation+carriers%2E&#x0026;journal=J%2E+Clin%2E+Oncol%2E&#x0026;author=Metcalfe+K.&#x0026;author=Lynch+H.+T.&#x0026;author=Ghadirian+P.&#x0026;author=Tung+N.&#x0026;author=Olivotto+I.&#x0026;author=Warner+E.&#x0026;publication_year=2004&#x0026;volume=22&#x0026;pages=2328&#x2013;2335" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B62" id="B62"></a>Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N. I, Olivotto, A., Foulkes, W. D., et al. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. <i>Gynecol. Oncol.</i> 96, 222&#x2013;226.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+risk+of+ovarian+cancer+after+breast+cancer+in+BRCA1+and+BRCA2+carriers%2E&#x0026;journal=Gynecol%2E+Oncol%2E&#x0026;author=Metcalfe+K.+A.&#x0026;author=Lynch+H.+T.&#x0026;author=Ghadirian+P.&#x0026;author=Tung+N.+I&#x0026;author=Olivotto+A.&#x0026;author=Foulkes+W.+D.&#x0026;publication_year=2005&#x0026;volume=96&#x0026;pages=222&#x2013;226" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B63" id="B63"></a>Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> 266, 66&#x2013;71. doi: 10.1126/science.7545954</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7545954" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.7545954" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+strong+candidate+for+the+breast+and+ovarian+cancer+susceptibility+gene+BRCA1%2E&#x0026;journal=Science&#x0026;author=Miki+Y.&#x0026;author=Swensen+J.&#x0026;author=Shattuck-Eidens+D.&#x0026;author=Futreal+P.+A.&#x0026;author=Harshman+K.&#x0026;author=Tavtigian+S.&#x0026;publication_year=1994&#x0026;volume=266&#x0026;pages=66&#x2013;71" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B64" id="B64"></a>Msolly, A., and Kassab, A. (2015). BRCA1 and BRCA2 mutations are they related to breast cancer in a sample of tunisian population? <i>Cancer Ther. Oncol. Int. J.</i> 1, 1&#x2013;5.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+mutations+are+they+related+to+breast+cancer+in+a+sample+of+tunisian+population%B4&#x0026;journal=Cancer+Ther%2E+Oncol%2E+Int%2E+J%2E&#x0026;author=Msolly+A.&#x0026;author=Kassab+A.&#x0026;publication_year=2015&#x0026;volume=1&#x0026;pages=1&#x2013;5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B65" id="B65"></a>Nath, A., and Chan, C. (2016). Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. <i>Sci. Rep.</i> 6:18669.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+alterations+in+fatty+acid+transport+and+metabolism+genes+are+associated+with+metastatic+progression+and+poor+prognosis+of+human+cancers%2E&#x0026;journal=Sci%2E+Rep%2E&#x0026;author=Nath+A.&#x0026;author=Chan+C.&#x0026;publication_year=2016&#x0026;volume=6&#x0026;issue=18669" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B66" id="B66"></a>Orr, K. S., and Savage, K. I. (2015). <i>Advances in DNA Repair</i>, Intech. 217&#x2013;253.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;author=Orr+K.+S.&#x0026;author=Savage+K.+I.&#x0026;publication_year=2015" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B67" id="B67"></a>Plagnol, V., Curtis, J., Epstein, M., Mok, K. Y., Stebbings, E., Grigoriadou, S., et al. (2012). A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. <i>Bioinformatics</i> 28, 2747&#x2013;2754. doi: 10.1093/bioinformatics/bts526</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22942019" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/bts526" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+robust+model+for+read+count+data+in+exome+sequencing+experiments+and+implications+for+copy+number+variant+calling%2E&#x0026;journal=Bioinformatics&#x0026;author=Plagnol+V.&#x0026;author=Curtis+J.&#x0026;author=Epstein+M.&#x0026;author=Mok+K.+Y.&#x0026;author=Stebbings+E.&#x0026;author=Grigoriadou+S.&#x0026;publication_year=2012&#x0026;volume=28&#x0026;pages=2747&#x2013;2754" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B68" id="B68"></a>Posey, J. E. (2019). Genome sequencing and implications for rare disorders. <i>Orphanet J. Rare Dis.</i> 14:153.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Genome+sequencing+and+implications+for+rare+disorders%2E&#x0026;journal=Orphanet+J%2E+Rare+Dis%2E&#x0026;author=Posey+J.+E.&#x0026;publication_year=2019&#x0026;volume=14&#x0026;issue=153" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B69" id="B69"></a>Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van&#x2019;t Veer, L., Garber, J. E., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. <i>N. Engl. J. Med.</i> 346, 1616&#x2013;1622.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Prophylactic+oophorectomy+in+carriers+of+BRCA1+or+BRCA2+mutations%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Rebbeck+T.+R.&#x0026;author=Lynch+H.+T.&#x0026;author=Neuhausen+S.+L.&#x0026;author=Narod+S.+A.&#x0026;author=Van&#x2019;t+Veer+L.&#x0026;author=Garber+J.+E.&#x0026;publication_year=2002&#x0026;volume=346&#x0026;pages=1616&#x2013;1622" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B70" id="B70"></a>Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., et al. (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA</i> 313, 1347&#x2013;1361.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Association+of+type+and+location+of+BRCA1+and+BRCA2+mutations+with+risk+of+breast+and+ovarian+cancer%2E&#x0026;journal=JAMA&#x0026;author=Rebbeck+T.+R.&#x0026;author=Mitra+N.&#x0026;author=Wan+F.&#x0026;author=Sinilnikova+O.+M.&#x0026;author=Healey+S.&#x0026;author=McGuffog+L.&#x0026;publication_year=2015&#x0026;volume=313&#x0026;pages=1347&#x2013;1361" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B71" id="B71"></a>Reeve, J. P., and Rannala, B. (2002). DMLE+: Bayesian linkage disequilibrium gene mapping. <i>Bioinformatics</i> 18, 894&#x2013;895. doi: 10.1093/bioinformatics/18.6.894</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12075030" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/18.6.894" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=DMLE%2B%3A+Bayesian+linkage+disequilibrium+gene+mapping%2E&#x0026;journal=Bioinformatics&#x0026;author=Reeve+J.+P.&#x0026;author=Rannala+B.&#x0026;publication_year=2002&#x0026;volume=18&#x0026;pages=894&#x2013;895" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B72" id="B72"></a>Repana, D., Nulsen, J., Dressler, L., Bortolomeazzi, M., Venkata, S. K., Tourna, A., et al. (2019). The network of cancer genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens. <i>Genome Biol.</i> 20:1.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+network+of+cancer+genes+%28NCG%29%3A+a+comprehensive+catalogue+of+known+and+candidate+cancer+genes+from+cancer+sequencing+screens%2E&#x0026;journal=Genome+Biol%2E&#x0026;author=Repana+D.&#x0026;author=Nulsen+J.&#x0026;author=Dressler+L.&#x0026;author=Bortolomeazzi+M.&#x0026;author=Venkata+S.+K.&#x0026;author=Tourna+A.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=1" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B73" id="B73"></a>Riahi, A., Kharrat, M., Ghourabi, M., Khomsi, F., Gamoudi, A., Lariani, I., et al. (2015). Mutation spectrum and prevalence of BRCA 1 and BRCA 2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia. <i>Clin. Genet.</i> 87, 155&#x2013;160. doi: 10.1111/cge.12337</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24372583" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12337" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Mutation+spectrum+and+prevalence+of+BRCA+1+and+BRCA+2+genes+in+patients+with+familial+and+early-onset+breast%2Fovarian+cancer+from+Tunisia%2E&#x0026;journal=Clin%2E+Genet%2E&#x0026;author=Riahi+A.&#x0026;author=Kharrat+M.&#x0026;author=Ghourabi+M.&#x0026;author=Khomsi+F.&#x0026;author=Gamoudi+A.&#x0026;author=Lariani+I.&#x0026;publication_year=2015&#x0026;volume=87&#x0026;pages=155&#x2013;160" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B74" id="B74"></a>Rice, P., Longden, I., and Bleasby, A. (2000). EMBOSS: the European molecular biology open software suite. <i>Trends Genet.</i> 16, 276&#x2013;277. doi: 10.1016/s0168-9525(00)02024-2</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/s0168-9525(00)02024-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=EMBOSS%3A+the+European+molecular+biology+open+software+suite%2E&#x0026;journal=Trends+Genet%2E&#x0026;author=Rice+P.&#x0026;author=Longden+I.&#x0026;author=Bleasby+A.&#x0026;publication_year=2000&#x0026;volume=16&#x0026;pages=276&#x2013;277" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B75" id="B75"></a>Riku, M., Inaguma, S., Ito, H., Tsunoda, T., Ikeda, H., and Kasai, K. (2016). Down-regulation of the zinc-finger homeobox protein TSHZ2 releases GLI1 from the nuclear repressor complex to restore its transcriptional activity during mammary tumorigenesis. <i>Oncotarget</i> 7:5690. doi: 10.18632/oncotarget.6788</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26744317" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/oncotarget.6788" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Down-regulation+of+the+zinc-finger+homeobox+protein+TSHZ2+releases+GLI1+from+the+nuclear+repressor+complex+to+restore+its+transcriptional+activity+during+mammary+tumorigenesis%2E&#x0026;journal=Oncotarget&#x0026;author=Riku+M.&#x0026;author=Inaguma+S.&#x0026;author=Ito+H.&#x0026;author=Tsunoda+T.&#x0026;author=Ikeda+H.&#x0026;author=Kasai+K.&#x0026;publication_year=2016&#x0026;volume=7&#x0026;issue=5690" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B76" id="B76"></a>Rines, A. K., Burke, M. A., Fernandez, R. P., Volpert, O. V., and Ardehali, H. (2012). Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of &#x03B2;-catenin. <i>FASEB J.</i> 26, 4685&#x2013;4695. doi: 10.1096/fj.12-212282</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22874833" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1096/fj.12-212282" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Snf1-related+kinase+inhibits+colon+cancer+cell+proliferation+through+calcyclin-binding+protein-dependent+reduction+of+&#x03B2;-catenin%2E&#x0026;journal=FASEB+J%2E&#x0026;author=Rines+A.+K.&#x0026;author=Burke+M.+A.&#x0026;author=Fernandez+R.+P.&#x0026;author=Volpert+O.+V.&#x0026;author=Ardehali+H.&#x0026;publication_year=2012&#x0026;volume=26&#x0026;pages=4685&#x2013;4695" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B77" id="B77"></a>Rodrigues, C. H., Pires, D. E., and Ascher, D. B. (2018). DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. <i>Nucleic Acids Res.</i> 46, W350&#x2013;W355.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=DynaMut%3A+predicting+the+impact+of+mutations+on+protein+conformation%2C+flexibility+and+stability%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Rodrigues+C.+H.&#x0026;author=Pires+D.+E.&#x0026;author=Ascher+D.+B.&#x0026;publication_year=2018&#x0026;volume=46&#x0026;pages=W350&#x2013;W355" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B78" id="B78"></a>Romdhane, L., Kefi, R., Azaiez, H., Halim, N. B., Dellagi, K., and Abdelhak, S. (2012). Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East. <i>Orphanet J. Rare Dis.</i> 7:52. doi: 10.1186/1750-1172-7-52</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22908982" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1750-1172-7-52" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Founder+mutations+in+Tunisia%3A+implications+for+diagnosis+in+North+Africa+and+Middle+East%2E&#x0026;journal=Orphanet+J%2E+Rare+Dis%2E&#x0026;author=Romdhane+L.&#x0026;author=Kefi+R.&#x0026;author=Azaiez+H.&#x0026;author=Halim+N.+B.&#x0026;author=Dellagi+K.&#x0026;author=Abdelhak+S.&#x0026;publication_year=2012&#x0026;volume=7&#x0026;issue=52" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B79" id="B79"></a>&#x0160;ali, A., and Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. <i>J. Mol. Biol.</i> 234, 779&#x2013;815. doi: 10.1006/jmbi.1993.1626</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8254673" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1006/jmbi.1993.1626" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+protein+modelling+by+satisfaction+of+spatial+restraints%2E&#x0026;journal=J%2E+Mol%2E+Biol%2E&#x0026;author=&#x0160;ali+A.&#x0026;author=Blundell+T.+L.&#x0026;publication_year=1993&#x0026;volume=234&#x0026;pages=779&#x2013;815" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B80" id="B80"></a>Seifert, F. U., Lammens, K., Stoehr, G., Kessler, B., and Hopfner, K. P. (2016). Structural mechanism of ATP-dependent DNA binding and DNA end bridging by eukaryotic Rad50. <i>EMBO J.</i> 35, 759&#x2013;772. doi: 10.15252/embj.201592934</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26896444" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.15252/embj.201592934" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Structural+mechanism+of+ATP-dependent+DNA+binding+and+DNA+end+bridging+by+eukaryotic+Rad50%2E&#x0026;journal=EMBO+J%2E&#x0026;author=Seifert+F.+U.&#x0026;author=Lammens+K.&#x0026;author=Stoehr+G.&#x0026;author=Kessler+B.&#x0026;author=Hopfner+K.+P.&#x0026;publication_year=2016&#x0026;volume=35&#x0026;pages=759&#x2013;772" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B81" id="B81"></a>Seklani, M. (1974). <i>La Population de la Tunisie. Presses de la Soci&#x00E9;t&#x00E9; Tunisienne des Arts Graphiques.</i></p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;author=Seklani+M.&#x0026;publication_year=1974" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B82" id="B82"></a>Serrano, L., Neira, J.-L., Sancho, J., and Fersht, A. R. (1992). Effect of alanine versus glycine in &#x03B1;-helices on protein stability. <i>Nature</i> 356, 453&#x2013;455. doi: 10.1038/356453a0</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/1557131" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/356453a0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Effect+of+alanine+versus+glycine+in+&#x03B1;-helices+on+protein+stability%2E&#x0026;journal=Nature&#x0026;author=Serrano+L.&#x0026;author=Neira+J.-L.&#x0026;author=Sancho+J.&#x0026;author=Fersht+A.+R.&#x0026;publication_year=1992&#x0026;volume=356&#x0026;pages=453&#x2013;455" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B83" id="B83"></a>Shahi, R. B., De Brakeleer, S., Caljon, B., Pauwels, I., Bonduelle, M., Joris, S., et al. (2019). Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. <i>BMC Cancer</i> 19:313.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+candidate+cancer+predisposing+variants+by+performing+whole-exome+sequencing+on+index+patients+from+BRCA1+and+BRCA2-negative+breast+cancer+families%2E&#x0026;journal=BMC+Cancer&#x0026;author=Shahi+R.+B.&#x0026;author=De+Brakeleer+S.&#x0026;author=Caljon+B.&#x0026;author=Pauwels+I.&#x0026;author=Bonduelle+M.&#x0026;author=Joris+S.&#x0026;publication_year=2019&#x0026;volume=19&#x0026;issue=313" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B84" id="B84"></a>Shen, M. Y., and Sali, A. (2006). Statistical potential for assessment and prediction of protein structures. <i>Protein Sci.</i> 15, 2507&#x2013;2524. doi: 10.1110/ps.062416606</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17075131" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1110/ps.062416606" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Statistical+potential+for+assessment+and+prediction+of+protein+structures%2E&#x0026;journal=Protein+Sci%2E&#x0026;author=Shen+M.+Y.&#x0026;author=Sali+A.&#x0026;publication_year=2006&#x0026;volume=15&#x0026;pages=2507&#x2013;2524" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B85" id="B85"></a>Situ, Y., Chung, L., Lee, C. S., and Ho, V. (2019). MRN (MRE11-RAD50-NBS1) complex in human cancer and prognostic implications in colorectal cancer. <i>Int. J. Mol. Sci.</i> 20:816. doi: 10.3390/ijms20040816</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30769804" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/ijms20040816" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=MRN+%28MRE11-RAD50-NBS1%29+complex+in+human+cancer+and+prognostic+implications+in+colorectal+cancer%2E&#x0026;journal=Int%2E+J%2E+Mol%2E+Sci%2E&#x0026;author=Situ+Y.&#x0026;author=Chung+L.&#x0026;author=Lee+C.+S.&#x0026;author=Ho+V.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=816" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B86" id="B86"></a>Slenter, D. N., Kutmon, M., Hanspers, K., Riutta, A., Windsor, J., Nunes, N., et al. (2017). WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. <i>Nucleic Acids Res.</i> 46, D661&#x2013;D667.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=WikiPathways%3A+a+multifaceted+pathway+database+bridging+metabolomics+to+other+omics+research%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Slenter+D.+N.&#x0026;author=Kutmon+M.&#x0026;author=Hanspers+K.&#x0026;author=Riutta+A.&#x0026;author=Windsor+J.&#x0026;author=Nunes+N.&#x0026;publication_year=2017&#x0026;volume=46&#x0026;pages=D661&#x2013;D667" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B87" id="B87"></a>Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. <i>Am. J. Hum. Genet.</i> 68, 978&#x2013;989. doi: 10.1086/319501</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11254454" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/319501" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+statistical+method+for+haplotype+reconstruction+from+population+data%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Stephens+M.&#x0026;author=Smith+N.+J.&#x0026;author=Donnelly+P.&#x0026;publication_year=2001&#x0026;volume=68&#x0026;pages=978&#x2013;989" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B88" id="B88"></a>Sturm, R. A., Fox, C., McClenahan, P., Jagirdar, K., Ibarrola-Villava, M., Banan, P., et al. (2014). Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. <i>J. Invest. Dermatol.</i> 134, 141&#x2013;149. doi: 10.1038/jid.2013.272</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23774529" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/jid.2013.272" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Phenotypic+characterization+of+nevus+and+tumor+patterns+in+MITF+E318K+mutation+carrier+melanoma+patients%2E&#x0026;journal=J%2E+Invest%2E+Dermatol%2E&#x0026;author=Sturm+R.+A.&#x0026;author=Fox+C.&#x0026;author=McClenahan+P.&#x0026;author=Jagirdar+K.&#x0026;author=Ibarrola-Villava+M.&#x0026;author=Banan+P.&#x0026;publication_year=2014&#x0026;volume=134&#x0026;pages=141&#x2013;149" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B89" id="B89"></a>Taskiran, E. Z., Korkmaz, E., Gucer, S., Kosukcu, C., Kaymaz, F., Koyunlar, C., et al. (2014). Mutations in ANKS6 cause a nephronophthisis-like phenotype with ESRD. <i>J. Am. Soc. Nephrol.</i> 25, 1653&#x2013;1661. doi: 10.1681/asn.2013060646</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24610927" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1681/asn.2013060646" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Mutations+in+ANKS6+cause+a+nephronophthisis-like+phenotype+with+ESRD%2E&#x0026;journal=J%2E+Am%2E+Soc%2E+Nephrol%2E&#x0026;author=Taskiran+E.+Z.&#x0026;author=Korkmaz+E.&#x0026;author=Gucer+S.&#x0026;author=Kosukcu+C.&#x0026;author=Kaymaz+F.&#x0026;author=Koyunlar+C.&#x0026;publication_year=2014&#x0026;volume=25&#x0026;pages=1653&#x2013;1661" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B90" id="B90"></a>Troudi, W., Uhrhammer, N., Romdhane, K. B., Sibille, C., Amor, M. B., Khil, E., et al. (2008). Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. <i>Cancer Biomarkers</i> 4, 11&#x2013;18. doi: 10.3233/cbm-2008-4102</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18334730" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3233/cbm-2008-4102" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Complete+mutation+screening+and+haplotype+characterization+of+BRCA1+gene+in+Tunisian+patients+with+familial+breast+cancer%2E&#x0026;journal=Cancer+Biomarkers&#x0026;author=Troudi+W.&#x0026;author=Uhrhammer+N.&#x0026;author=Romdhane+K.+B.&#x0026;author=Sibille+C.&#x0026;author=Amor+M.+B.&#x0026;author=Khil+E.&#x0026;publication_year=2008&#x0026;volume=4&#x0026;pages=11&#x2013;18" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B91" id="B91"></a>Troudi, W., Uhrhammer, N., Sibille, C., Dahan, C., Mahfoudh, W., Souissi, C. B., et al. (2007). Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. <i>J. Hum. Genet.</i> 52:915.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Contribution+of+the+BRCA1+and+BRCA2+mutations+to+breast+cancer+in+Tunisia%2E&#x0026;journal=J%2E+Hum%2E+Genet%2E&#x0026;author=Troudi+W.&#x0026;author=Uhrhammer+N.&#x0026;author=Sibille+C.&#x0026;author=Dahan+C.&#x0026;author=Mahfoudh+W.&#x0026;author=Souissi+C.+B.&#x0026;publication_year=2007&#x0026;volume=52&#x0026;issue=915" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B92" id="B92"></a>Turner, N. C., and Tutt, A. N. (2012). Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? <i>BioMed Central</i> 14:115.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Platinum+chemotherapy+for+BRCA1-related+breast+cancer%3A+do+we+need+more+evidence%B4&#x0026;journal=BioMed+Central&#x0026;author=Turner+N.+C.&#x0026;author=Tutt+A.+N.&#x0026;publication_year=2012&#x0026;volume=14&#x0026;issue=115" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B93" id="B93"></a>Uhrhammer, N., Abdelouahab, A., Lafarge, L., Feillel, V., Dib, A. B., and Bignon, Y.-J. (2008). BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. <i>Int. J. Med. Sci.</i> 5:197. doi: 10.7150/ijms.5.197</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18645608" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.7150/ijms.5.197" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+mutations+in+Algerian+breast+cancer+patients%3A+high+frequency+in+young%2C+sporadic+cases%2E&#x0026;journal=Int%2E+J%2E+Med%2E+Sci%2E&#x0026;author=Uhrhammer+N.&#x0026;author=Abdelouahab+A.&#x0026;author=Lafarge+L.&#x0026;author=Feillel+V.&#x0026;author=Dib+A.+B.&#x0026;author=Bignon+Y.-J.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;issue=197" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B94" id="B94"></a>Wong, A. M. G., Kong, K. L., Chen, L., Liu, M., Wong, A. M. G., Zhu, C., et al. (2013). Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. <i>Int. J. Cancer</i> 133, 2284&#x2013;2295. doi: 10.1002/ijc.28252</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23649311" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.28252" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Characterization+of+CACNA2D3+as+a+putative+tumor+suppressor+gene+in+the+development+and+progression+of+nasopharyngeal+carcinoma%2E&#x0026;journal=Int%2E+J%2E+Cancer&#x0026;author=Wong+A.+M.+G.&#x0026;author=Kong+K.+L.&#x0026;author=Chen+L.&#x0026;author=Liu+M.&#x0026;author=Wong+A.+M.+G.&#x0026;author=Zhu+C.&#x0026;publication_year=2013&#x0026;volume=133&#x0026;pages=2284&#x2013;2295" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B95" id="B95"></a>Wong, C., Chen, F., Alirezaie, N., Wang, Y., Cuggia, A., Borgida, A., et al. (2019). A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. <i>PLoS Genet.</i> 15:e1008344. doi: 10.1371/journal.pgen.1008344</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31469826" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pgen.1008344" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+region-based+gene+association+study+combined+with+a+leave-one-out+sensitivity+analysis+identifies+SMG1+as+a+pancreatic+cancer+susceptibility+gene%2E&#x0026;journal=PLoS+Genet%2E&#x0026;author=Wong+C.&#x0026;author=Chen+F.&#x0026;author=Alirezaie+N.&#x0026;author=Wang+Y.&#x0026;author=Cuggia+A.&#x0026;author=Borgida+A.&#x0026;publication_year=2019&#x0026;volume=15&#x0026;issue=e1008344" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B96" id="B96"></a>Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sj&#x00F6;blom, T., Leary, R. J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. <i>Science</i> 318, 1108&#x2013;1113.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+genomic+landscapes+of+human+breast+and+colorectal+cancers%2E&#x0026;journal=Science&#x0026;author=Wood+L.+D.&#x0026;author=Parsons+D.+W.&#x0026;author=Jones+S.&#x0026;author=Lin+J.&#x0026;author=Sj&#x00F6;blom+T.&#x0026;author=Leary+R.+J.&#x0026;publication_year=2007&#x0026;volume=318&#x0026;pages=1108&#x2013;1113" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B97" id="B97"></a>Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> 378:789.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+the+breast+cancer+susceptibility+gene+BRCA2%2E&#x0026;journal=Nature&#x0026;author=Wooster+R.&#x0026;author=Bignell+G.&#x0026;author=Lancaster+J.&#x0026;author=Swift+S.&#x0026;author=Seal+S.&#x0026;author=Mangion+J.&#x0026;publication_year=1995&#x0026;volume=378&#x0026;issue=789" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B98" id="B98"></a>Zhu, Y., Wu, J., Zhang, C., Sun, S., Zhang, J., Liu, W., et al. (2016). BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. <i>Oncotarget</i> 7:70113. doi: 10.18632/oncotarget.12158</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27659521" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/oncotarget.12158" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+mutations+and+survival+in+breast+cancer%3A+an+updated+systematic+review+and+meta-analysis%2E&#x0026;journal=Oncotarget&#x0026;author=Zhu+Y.&#x0026;author=Wu+J.&#x0026;author=Zhang+C.&#x0026;author=Sun+S.&#x0026;author=Zhang+J.&#x0026;author=Liu+W.&#x0026;publication_year=2016&#x0026;volume=7&#x0026;issue=70113" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords</span>: breast cancer, genetic screening, <i>BRCA1</i>-founder mutation, next-generation sequencing, novel mutation, <i>RAD50</i></p>
<p><span>Citation:</span> Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, Mejri N, Labidi S, Ayari J, Jaidene O, Bouaziz H, Ben Rekaya M, M&#x2019;rad R, Haddaoui A, Rahal K, Boussen H, Boubaker S and Abdelhak S (2020) Identification of Novel <i>BRCA1</i> and <i>RAD50</i> Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. <i>Front. Genet.</i> 11:552971. doi: 10.3389/fgene.2020.552971</p>
<p id="timestamps">
<span>Received:</span> 17 April 2020; <span>Accepted:</span> 16 October 2020;<br><span>Published:</span> 06 November 2020.</p>
<div>
<p>Edited by:</p>
<a href="https://loop.frontiersin.org/people/621226/overview">Anna Murray</a>, University of Exeter, United Kingdom</div>
<div>
<p>Reviewed by:</p>
<a href="https://loop.frontiersin.org/people/66539/overview">Natasa Djordjevic</a>, University of Kragujevac, Serbia<br>
<a href="https://loop.frontiersin.org/people/705890/overview">Jaakko Tapio Leinonen</a>, University of Helsinki, Finland</div>
<p><span>Copyright</span> &#x00A9; 2020 Mighri, Hamdi, Boujemaa, Othman, Ben Nasr, El Benna, Mejri, Labidi, Ayari, Jaidene, Bouaziz, Ben Rekaya, M&#x2019;rad, Haddaoui, Rahal, Boussen, Boubaker and Abdelhak. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>*Correspondence:</span> Yosr Hamdi, <a id="encmail">eW9zci5oYW1kaUBwYXN0ZXVyLnRu</a></p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2020.552971" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">9,8K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2,7K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">16</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/552971#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fgene.2020.552971" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fgene.2020.552971" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/621226/overview" data-event="editorInfo-a-annaMurray" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">M</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Anna  Murray</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Exeter, United Kingdom</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/66539/overview" data-event="editorInfo-a-natasaDjordjevic" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">N</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Natasa  Djordjevic</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Kragujevac, Serbia</div></div></a><a href="https://loop.frontiersin.org/people/705890/overview" data-event="editorInfo-a-jaakkoTapioLeinonen" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">J</span><span class="notranslate">T</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Jaakko  Tapio Leinonen</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, Faculty of Agriculture and Forestry, University of Helsinki, Finland</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Conclusion</a></li>
<li><a href="#h7">Data Availability Statement</a></li>
<li><a href="#h8">Ethics Statement</a></li>
<li><a href="#h9">Author Contributions</a></li>
<li><a href="#fun1">Funding</a></li>
<li><a href="#conf1">Conflict of Interest</a></li>
<li><a href="#ack1">Acknowledgments</a></li>
<li><a href="#S11">Supplementary Material</a></li>
<li><a href="#abbr1">Abbreviations</a></li>
<li><a href="#FNT1">Footnotes</a></li>
<li><a href="#refer1">References</a></li>
</ul>
</div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2020.552971" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/genetics/articles/10.3389/fgene.2020.552971/full",["Reactive",16],{"main":17,"user":514,"article":515,"articleHub":938,"mainHeader":942},{"ibar":18,"footer":276,"newsletterComponent":-1,"snackbarItem":358,"toggleShowSnackbar":359,"contentfulJournal":360,"graphJournal":414,"settingsFeaturesSwitchers":418,"templateToggleBanner":419,"tenantConfig":479},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":207,"aboutJournal":208,"mainLinks":257,"journalLinks":264,"helpCenterLink":273},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=30&specialtyid=0&entitytype=2&entityid=240",{"id":115,"name":116,"slug":117,"sections":118},240,"Frontiers in Genetics","genetics",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203],{"id":120,"name":121,"slug":122},549,"Applied Genetic Epidemiology","applied-genetic-epidemiology",{"id":124,"name":125,"slug":126},536,"Behavioral and Psychiatric Genetics","behavioral-and-psychiatric-genetics",{"id":128,"name":129,"slug":130},2030,"Cancer Genetics and Oncogenomics","cancer-genetics-and-oncogenomics",{"id":132,"name":133,"slug":134},551,"Computational Genomics","computational-genomics",{"id":136,"name":137,"slug":138},2512,"Cytogenomics","cytogenomics",{"id":140,"name":141,"slug":142},650,"ELSI in Science and Genetics","elsi-in-science-and-genetics",{"id":144,"name":145,"slug":146},455,"Epigenomics and Epigenetics","epigenomics-and-epigenetics",{"id":148,"name":149,"slug":150},535,"Evolutionary and Population Genetics","evolutionary-and-population-genetics",{"id":152,"name":153,"slug":154},596,"Genetics of Aging","genetics-of-aging",{"id":156,"name":157,"slug":158},635,"Genetics of Common and Rare Diseases","genetics-of-common-and-rare-diseases",{"id":160,"name":161,"slug":162},557,"Genomic Assay Technology","genomic-assay-technology",{"id":164,"name":165,"slug":166},1520,"Genomics of Plants and the Phytoecosystem","genomics-of-plants-and-the-phytoecosystem",{"id":168,"name":169,"slug":170},1419,"Human and Medical Genomics","human-and-medical-genomics",{"id":172,"name":173,"slug":174},2237,"Immunogenetics","immunogenetics",{"id":176,"name":177,"slug":178},241,"Livestock Genomics","livestock-genomics",{"id":180,"name":181,"slug":182},19,"Neurogenomics","neurogenomics",{"id":184,"name":185,"slug":186},3423,"Nutritional Genomics","nutritional-genomics",{"id":188,"name":189,"slug":190},198,"Pharmacogenetics and Pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":192,"name":193,"slug":194},556,"Predictive Toxicology and Exposomics","predictive-toxicology-and-exposomics",{"id":196,"name":197,"slug":198},555,"RNA","rna",{"id":200,"name":201,"slug":202},454,"Statistical Genetics and Methodology","statistical-genetics-and-methodology",{"id":204,"name":205,"slug":206},685,"Stem Cell Research","stem-cell-research","Sections",[209,233],{"title":210,"links":211},"Scope",[212,215,218,221,224,227,230],{"text":213,"url":214,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/genetics/about#about-editors",{"text":216,"url":217,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/genetics/about#about-scope",{"text":219,"url":220,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/genetics/about#about-facts",{"text":222,"url":223,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/genetics/about#about-submission",{"text":225,"url":226,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/genetics/about#about-open",{"text":228,"url":229,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/genetics/about#copyright-statement",{"text":231,"url":232,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/genetics/about#about-quality",{"title":234,"links":235},"For authors",[236,239,242,245,248,251,254],{"text":237,"url":238,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/genetics/for-authors/why-submit",{"text":240,"url":241,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/genetics/for-authors/article-types",{"text":243,"url":244,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines",{"text":246,"url":247,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines",{"text":249,"url":250,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees",{"text":252,"url":253,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist",{"text":255,"url":256,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office",[258,261],{"text":259,"url":260,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":262,"url":263,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[265,268,270],{"text":266,"url":267,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":269,"target":27,"ariaLabel":28},"research-topics",{"text":271,"url":272,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":274,"url":275,"target":77,"ariaLabel":274},"Help center","https://helpcenter.frontiersin.org",{"blocks":277,"socialLinks":331,"copyright":355,"termsAndConditionsUrl":356,"privacyPolicyUrl":357},[278,292,302,316],{"title":279,"links":280},"Guidelines",[281,283,286,289,291],{"text":243,"url":282,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":284,"url":285,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":287,"url":288,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":246,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":293,"links":294},"Explore",[295,296,299,301],{"text":266,"url":263,"target":27,"ariaLabel":28},{"text":297,"url":298,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":300,"url":260,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":303,"links":304},"Outreach",[305,308,311,315],{"text":306,"url":92,"target":77,"ariaLabel":307},"Frontiers Forum ","Frontiers Forum website",{"text":309,"url":310,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":312,"url":313,"target":77,"ariaLabel":314},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":317,"links":318},"Connect",[319,320,324,327,330],{"text":274,"url":275,"target":77,"ariaLabel":274},{"text":321,"url":322,"target":77,"ariaLabel":323},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":325,"url":111,"target":27,"ariaLabel":326},"Contact us ","Subscribe to newsletter",{"text":328,"url":329,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[332,340,345,350],{"link":333,"type":336,"color":337,"icon":338,"size":339,"hiddenText":13},{"text":334,"url":335,"target":77,"ariaLabel":334},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":341,"type":336,"color":337,"icon":344,"size":339,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":346,"type":336,"color":337,"icon":349,"size":339,"hiddenText":13},{"text":347,"url":348,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":351,"type":336,"color":337,"icon":354,"size":339,"hiddenText":13},{"text":352,"url":353,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":361,"identifier":115,"name":116,"slug":117,"banner":362,"description":407,"mission":408,"palette":409,"impactFactor":410,"citeScore":411,"citations":412,"showTagline":28,"twitter":413},"Journal",[363],{"id":364,"src":365,"name":366,"type":367,"width":368,"height":369,"idHash":370,"archive":371,"brandId":372,"limited":371,"fileSize":373,"isPublic":374,"original":375,"copyright":19,"extension":376,"thumbnails":378,"dateCreated":386,"description":19,"orientation":387,"userCreated":388,"watermarked":371,"dateModified":386,"datePublished":389,"ecsArchiveFiles":390,"propertyOptions":391,"property_Channel":396,"property_Sub-Type":398,"property_Asset_Type":400,"activeOriginalFocusPoint":402,"property_Office_Department":405},"12AFEC62-10F2-4A9B-900C8422E4B53D54","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/webimage-A09D2065-D257-435D-987C43E79D7FBDFD.png","FGENE_Main Visual_Purple_Website","image",6016,4016,"3b54103c3aad636f",0,"22C10171-81B3-4DA6-99342F272A32E8BB",10275124,1,"https://brand.frontiersin.org/m/3b54103c3aad636f/original/FGENE_Main-Visual_Purple_Website.jpg",[377],"jpg",{"mini":379,"thul":380,"webimage":365,"Guidelines":381,"WebsiteJpg_XL":382,"WebsiteWebP_L":383,"WebsiteWebP_M":384,"WebsiteWebP_XL":385},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/mini-8741E412-02C1-4126-84DDA81B97389D5E.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/thul-D176A038-2FDA-438D-B9A7E98CF3926BBE.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/Guidelines-FGENE_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteJpg_XL-FGENE_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_L-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_M-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_XL-FGENE_Main Visual_Purple_Website.webp","2022-06-27T09:59:48Z","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[392,393,394,395],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[397],"frontiersin_org",[399],"Main_Visual",[401],"Photography",{"x":403,"y":404},3008,2008,[406],"Publishing","Explore research from the world's most cited genetics and heredity journal, advancing our understanding of genes from humans to plants and other model organisms.","\u003Cp>Frontiers in Genetics publishes research on genes and genomes relating to all the domains of life, from humans to livestock, and plants to other model organisms.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Enrico Domenici (Department of Cellular, Computational and Integrated Biology, University of Trento, Italy) Frontiers in Genetics is indexed in PubMed Central (PMC) and Scopus, among others, and explores the full spectrum of genetic and genomic research, encompassing fundamental studies and their clinical applications, while also embracing methodological advancements and exploring their applications and implications. Topics of interest include, but are not limited to:\u003C/p>\n\n\u003Cdiv> &bull; how genes or genomes relate to traits and humanpathophysiology\u003C/div>\n\u003Cdiv> &bull; advances in genomic data technology and analysis\u003C/div>\n\u003Cdiv> &bull; gene flow among species and populations\u003C/div>\n\u003Cdiv> &bull; livestock genome research Interactions between organisms, theirenvironment, and xenobiotics\u003C/div>\n\u003Cdiv> &bull; molecular and cellular genetics\u003C/div>\n\u003Cdiv> &bull; societal implicationsof genetic research.\u003C/div>\n\u003Cbr>\n\u003Cp>Submissions that emphasize advancement in the understanding of the function and variability of the genome, the use of genetic and genomic tools, and the analysis of the genetic underpinnings of biological processes are of particular interest to this journal.\u003Cp>\n\u003Cp>Furthermore, the journal actively welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being.\u003C/p>\n\u003Cp>Manuscripts that focus solely on clinical outcomes, patient management, or therapeutic interventions without a clear genetic or genomic component are not suitable for publication in this journal. Studies that are purely epidemiological or observational, without a foundation in genetic or genomic mechanisms, are also not within the scope of this journal. Manuscripts consisting solely of bioinformatics, computational analyses of public data which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo) or are not highly innovative are not suitable for publication in this journal. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\u003Cp>Frontiers in Genetics is committed to advancing developments in the field of genetics and genomics by allowing unrestricted access to articles, and communicating scientific knowledge to both researchers and the public, to enable the scientific breakthroughs of the future.\u003C/p>","purple","3.7","5.2","277710","@FrontGenetics",{"id":115,"name":116,"slug":117,"abbreviation":415,"isOnline":13,"isOpenForSubmissions":13,"citeScore":416,"impactFactor":417},"fgene",6.2,2.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":359},{"isPublic":13,"allowCompanyUsers":359,"whiteListEmails":420,"enableAllJournals":13,"whiteListJournals":442},[421,422,423,424,425,426,427,428,429,426,430,431,432,433,434,435,436,437,438,439,440,441],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[443,444,445,446,447,448,374,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":374,"name":374,"availableJournalPages":480,"announcement":484},[267,272,269,481,482,483],"volumes","about","community-reviewers",{"__typename":485,"sys":486,"preHeader":42,"title":488,"description":489,"image":490,"link":512},"Announcement",{"id":487},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[491],{"archive":371,"brandId":372,"copyright":28,"dateCreated":492,"dateModified":493,"datePublished":494,"description":28,"extension":495,"fileSize":497,"height":498,"id":499,"isPublic":371,"limited":371,"name":500,"orientation":387,"original":28,"thumbnails":501,"type":367,"watermarked":371,"width":508,"videoPreviewURLs":509,"tags":510,"textMetaproperties":511,"src":502},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[496],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":502,"thul":503,"mini":504,"WebsiteWebP_L":505,"WebsiteWebP_M":506,"Guidelines":507},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":513,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":516,"isPreviewPage":359,"hasSupplementalData":359,"showCrossmarkWidget":13,"articleTemplate":745,"currentArticlePageMetaInfo":746,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":517,"doi":518,"title":519,"acceptanceDate":520,"receptionDate":521,"publicationDate":522,"lastModifiedDate":523,"isPublished":13,"abstract":524,"researchTopic":28,"articleType":525,"stage":528,"keywords":530,"authors":537,"editors":666,"reviewers":676,"journal":696,"section":703,"impactMetrics":708,"volume":712,"articleVolume":713,"relatedArticles":714,"isPublishedV2":359,"contents":715,"files":719},552971,"10.3389/fgene.2020.552971","Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients",["Date","2020-10-16T16:06:42.000Z"],["Date","2020-04-17T12:17:29.000Z"],["Date","2020-11-06T00:00:00.000Z"],["Date","2025-11-25T04:48:14.531Z"],"Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutations not only helped in selecting high risk individuals that need appropriate prevention approaches but also led to the development of the PARP-inhibitors targeted therapy.\nThis study aims to assess the prevalence of the most frequent BRCA1 mutation in Tunisia, c.211dupA, and provide evidence of its common origin as well as its clinicopathological characteristics. We also aimed to identify additional actionable variants using classical and next generation sequencing technologies (NGS) which would allow to implement cost-effective genetic testing in limited resource countries.\nPatients and Methods Using sanger sequencing, 112 breast cancer families have been screened for c.211dupA. A set of patients that do not carry this mutation have been investigated using NGS. Haplotype analysis was performed to assess the founder effect and to estimate the age of this mutation. Correlations between genetic and clinical data have been also performed.\nResults The c.211dupA mutation has been identified in 8 carriers and a novel private BRCA1 mutation, c.2418dupA, has been identified in one carrier. Both mutations are likely specific to North-Eastern Tunisia. Haplotype analysis confirmed the founder effect of c.211dupA and showed its recent origin. Phenotype-genotype correlation showed that both BRCA1 mutations seem to be associated with a severe phenotype. Whole Exome Sequencing (WES) analysis of a BRCA negative family revealed a Variant of Unknown Significance, c.3647C&gt;G on RAD50. Molecular modeling showed that this variant could be classified as deleterious as it is responsible for destabilizing the RAD50 protein structure. Variant prioritization and pathway analysis of the WES data showed additional interesting candidate genes including MITF and ANKS6. \nConclusions We recommend the prioritization of BRCA1-c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia. We also highlighted the importance of NGS in detecting novel mutations, such as RAD50-c.3647C&gt;G. In addition, we strongly recommend using data from different ethnic groups to review the pathogenicity of this variant and reconsider its classification in ClinVar.",{"id":526,"name":527},24,"Original Research",{"id":529,"name":19},18,[531,532,533,534,535,536],"breast cancer","genetic screening","BRCA1-Founder mutation","Next-generation sequencing","Novel mutation","Rad50",[538,547,554,561,570,579,587,594,601,609,617,623,629,637,643,649,656,662],{"id":539,"firstName":540,"middleName":19,"lastName":541,"givenNames":542,"isCorresponding":359,"isProfilePublic":13,"userId":539,"email":-1,"affiliations":543},958051,"Najah","Mighri","Najah ",[544],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar","Tunisia",{"id":548,"firstName":549,"middleName":19,"lastName":550,"givenNames":551,"isCorresponding":359,"isProfilePublic":13,"userId":548,"email":-1,"affiliations":552},954975,"Yosr","Hamdi","Yosr ",[553],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":555,"firstName":556,"middleName":19,"lastName":557,"givenNames":558,"isCorresponding":359,"isProfilePublic":13,"userId":555,"email":-1,"affiliations":559},956852,"Maroua","Boujemaa","Maroua ",[560],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":562,"firstName":563,"middleName":19,"lastName":564,"givenNames":565,"isCorresponding":359,"isProfilePublic":13,"userId":562,"email":-1,"affiliations":566},1014413,"Houcemeddine","Othman","Houcemeddine ",[567],{"organizationName":568,"countryName":569,"cityName":19,"stateName":19,"zipCode":19},"Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand","South Africa",{"id":571,"firstName":572,"middleName":19,"lastName":573,"givenNames":574,"isCorresponding":359,"isProfilePublic":13,"userId":571,"email":-1,"affiliations":575},957319,"Sonia","Ben Nasr","Sonia ",[576,577],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":578,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"The Military Hospital of Tunis, Department of Medical Oncology",{"id":580,"firstName":581,"middleName":19,"lastName":582,"givenNames":583,"isCorresponding":359,"isProfilePublic":13,"userId":580,"email":-1,"affiliations":584},1126178,"Houda","El Benna","Houda ",[585],{"organizationName":586,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Oncology, Abderrahmane Mami Hospital",{"id":371,"firstName":588,"middleName":19,"lastName":589,"givenNames":590,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":591},"Nesrine","Mejri","Nesrine ",[592,593],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":586,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":595,"middleName":19,"lastName":596,"givenNames":597,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":598},"Soumaya","Labidi","Soumaya ",[599,600],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":586,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":602,"firstName":603,"middleName":19,"lastName":604,"givenNames":605,"isCorresponding":359,"isProfilePublic":13,"userId":602,"email":-1,"affiliations":606},1125634,"Jihen","Ayari","Jihen ",[607,608],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":578,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":610,"firstName":611,"middleName":19,"lastName":612,"givenNames":613,"isCorresponding":359,"isProfilePublic":13,"userId":610,"email":-1,"affiliations":614},957930,"Olfa","Jaidene","Olfa ",[615],{"organizationName":616,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Department of Carcinological Surgery, Salah Azaiez Institute",{"id":371,"firstName":618,"middleName":19,"lastName":619,"givenNames":620,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":621},"Hanen","Bouaziz","Hanen ",[622],{"organizationName":616,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":624,"middleName":19,"lastName":625,"givenNames":626,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":627},"Mariem","Ben Rekaya","Mariem ",[628],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":630,"firstName":631,"middleName":19,"lastName":632,"givenNames":633,"isCorresponding":359,"isProfilePublic":13,"userId":630,"email":-1,"affiliations":634},956101,"Ridha","Mrad","Ridha ",[635],{"organizationName":636,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Service des Maladies Congnitales et Hrditaires, Hpital Charles Nicolle",{"id":371,"firstName":638,"middleName":19,"lastName":639,"givenNames":640,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":641},"Abderrazek","Haddaoui","Abderrazek ",[642],{"organizationName":578,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":644,"middleName":19,"lastName":645,"givenNames":646,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":647},"Khaled","Rahal","Khaled ",[648],{"organizationName":616,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":650,"middleName":19,"lastName":651,"givenNames":652,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":653},"Hamouda","Boussen","Hamouda ",[654,655],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":586,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":657,"middleName":19,"lastName":658,"givenNames":659,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":660},"Samir","Boubaker","Samir ",[661],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":572,"middleName":19,"lastName":663,"givenNames":574,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":664},"Abdelhak",[665],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},[667],{"id":668,"firstName":669,"middleName":19,"lastName":670,"givenNames":671,"isCorresponding":359,"isProfilePublic":13,"userId":668,"email":-1,"affiliations":672},621226,"Anna","Murray","Anna ",[673],{"organizationName":674,"countryName":675,"cityName":19,"stateName":19,"zipCode":19},"University of Exeter","United Kingdom",[677,686],{"id":678,"firstName":679,"middleName":19,"lastName":680,"givenNames":681,"isCorresponding":359,"isProfilePublic":13,"userId":678,"email":-1,"affiliations":682},66539,"Natasa","Djordjevic","Natasa ",[683],{"organizationName":684,"countryName":685,"cityName":19,"stateName":19,"zipCode":19},"University of Kragujevac","Serbia",{"id":687,"firstName":688,"middleName":689,"lastName":690,"givenNames":691,"isCorresponding":359,"isProfilePublic":13,"userId":687,"email":-1,"affiliations":692},705890,"Jaakko","Tapio","Leinonen","Jaakko  Tapio",[693],{"organizationName":694,"countryName":695,"cityName":19,"stateName":19,"zipCode":19},"Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, Faculty of Agriculture and Forestry, University of Helsinki","Finland",{"id":115,"slug":117,"name":116,"shortName":697,"electronicISSN":698,"field":699,"specialtyId":28,"journalSectionPaths":701},"Front. Genet.","1664-8021",{"id":700,"domainId":374},30,[702],{"section":703},{"id":704,"name":705,"slug":706,"specialtyId":707},1454,"Genomic Medicine","genomic-medicine",1889,{"views":709,"downloads":710,"citations":711},9845,2658,16,11,"Volume 11 - 2020",[],{"titleHtml":716,"fullTextHtml":717,"menuHtml":718},"Identification of Novel \u003Ci>BRCA1\u003C/i> and \u003Ci>RAD50\u003C/i> Mutations Associated With Breast Cancer Predisposition in Tunisian Patients","\u003Cdiv class=\"JournalAbstract\">\r\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\r\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\r\n\u003Ca href=\"https://loop.frontiersin.org/people/958051\" class=\"user-id-958051\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/958051/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\r\nNajah Mighri\">Najah Mighri\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/954975\" class=\"user-id-954975\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/954975/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Yosr Hamdi*\">Yosr Hamdi\u003C/a>\u003Csup>1*\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/956852\" class=\"user-id-956852\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/956852/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Maroua Boujemaa\">Maroua Boujemaa\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1014413\" class=\"user-id-1014413\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1014413/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Houcemeddine Othman\">Houcemeddine Othman\u003C/a>\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957319\" class=\"user-id-957319\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957319/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Sonia Ben Nasr,\">Sonia Ben Nasr\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126178\" class=\"user-id-1126178\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126178/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Houda El Benna\">Houda El Benna\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Nesrine Mejri,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Nesrine Mejri\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Soumaya Labidi,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Soumaya Labidi\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1125634\" class=\"user-id-1125634\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1125634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Jihen Ayari,\">Jihen Ayari\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957930\" class=\"user-id-957930\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957930/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Olfa Jaidene\">Olfa Jaidene\u003C/a>\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Hanen Bouaziz\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Hanen Bouaziz\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Mariem Ben Rekaya\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Mariem Ben Rekaya\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/956101\" class=\"user-id-956101\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/956101/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ridha M&#x;rad\">Ridha M&#x2019;rad\u003C/a>\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Abderrazek Haddaoui\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Abderrazek Haddaoui\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Khaled Rahal\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Khaled Rahal\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Hamouda Boussen,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Hamouda Boussen\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Samir Boubaker\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Samir Boubaker\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sonia Abdelhak\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sonia Abdelhak\u003Csup>1\u003C/sup>\u003C/span>\u003C/div>\r\n\u003Cul class=\"notes\">\r\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, Johannesburg, South Africa\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>The Military Hospital of Tunis, Department of Medical Oncology, Tunis, Tunisia\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Department of Medical Oncology, Abderrahmane Mami Hospital, Ariana, Tunisia\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Department of Carcinological Surgery, Salah Azaiez Institute, Tunis, Tunisia\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Service des Maladies Cong&#x00E9;nitales et H&#x00E9;r&#x00E9;ditaires, H&#x00F4;pital Charles Nicolle, Tunis, Tunisia\u003C/li>\r\n\u003C/ul>\r\n\u003Cp class=\"mb0\">\u003Cb>Background:\u003C/b> Deleterious mutations on \u003Ci>BRCA1/2\u003C/i> genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutations not only helped in selecting high risk individuals that need appropriate prevention approaches but also led to the development of the PARP-inhibitors targeted therapy. This study aims to assess the prevalence of the most frequent \u003Ci>BRCA1\u003C/i> mutation in Tunisia, c.211dupA, and provide evidence of its common origin as well as its clinicopathological characteristics. We also aimed to identify additional actionable variants using classical and next generation sequencing technologies (NGS) which would allow to implement cost-effective genetic testing in limited resource countries.\u003C/p>\r\n\u003Cp class=\"mb0\">\u003Cb>Patients and Methods:\u003C/b> Using sanger sequencing, 112 breast cancer families were screened for c.211dupA. A set of patients that do not carry this mutation were investigated using NGS. Haplotype analysis was performed to assess the founder effect and to estimate the age of this mutation. Correlations between genetic and clinical data were also performed.\u003C/p>\r\n\u003Cp class=\"mb0\">\u003Cb>Results:\u003C/b> The c.211dupA mutation was identified in 8 carriers and a novel private \u003Ci>BRCA1\u003C/i> mutation, c.2418dupA, was identified in one carrier. Both mutations are likely specific to North-Eastern Tunisia. Haplotype analysis supported the founder effect of c.211dupA and showed its recent origin. Phenotype-genotype correlation showed that both \u003Ci>BRCA1\u003C/i> mutations seem to be associated with a severe phenotype. Whole Exome Sequencing (WES) analysis of a \u003Ci>BRCA\u003C/i> negative family revealed a Variant of Unknown Significance, c.3647C &#x003E; G on \u003Ci>RAD50\u003C/i>. Molecular modeling showed that this variant could be classified as deleterious as it is responsible for destabilizing the RAD50 protein structure. Variant prioritization and pathway analysis of the WES data showed additional interesting candidate genes including \u003Ci>MITF\u003C/i> and \u003Ci>ANKS6.\u003C/i>\u003C/p>\r\n\u003Cp class=\"mb0\">\u003Cb>Conclusion:\u003C/b> We recommend the prioritization of \u003Ci>BRCA1\u003C/i>-c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia. We also highlighted the importance of NGS in detecting novel mutations, such as \u003Ci>RAD50-\u003C/i>c.3647C &#x003E; G. In addition, we strongly recommend using data from different ethnic groups to review the pathogenicity of this variant and reconsider its classification in ClinVar.\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"JournalFullText\">\r\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\r\n\u003Cp class=\"mb15\">Breast cancer remains the most common cancer among women worldwide (\u003Ca href=\"#B11\">Bray et al., 2018\u003C/a>). Each year, 2000 new breast cancer cases are diagnosed in Tunisia (\u003Ca href=\"#B11\">Bray et al., 2018\u003C/a>) and the mean age at diagnosis is around 50 years old, a decade younger than Western countries (\u003Ca href=\"#B15\">Chalabi et al., 2008\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">\u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> are the most studied breast cancer susceptibility genes that explain a significant proportion of hereditary breast and ovarian cancers (\u003Ca href=\"#B63\">Miki et al., 1994\u003C/a>; \u003Ca href=\"#B97\">Wooster et al., 1995\u003C/a>; \u003Ca href=\"#B27\">Ford et al., 1998\u003C/a>). It has been reported that the average cumulative risks in \u003Ci>BRCA1\u003C/i>-mutation carriers by age of 70 were 65% and 39% for breast and ovarian cancers respectively and the corresponding estimates for \u003Ci>BRCA2\u003C/i> were 45% and 11% (\u003Ca href=\"#B3\">Antoniou et al., 2003\u003C/a>). The frequency of germline mutations identified on the \u003Ci>BRCA\u003C/i> genes varies depending on the geographic and the ethnic distributions. Indeed, while most variations are shared between human populations, some of the \u003Ci>BRCA1/2\u003C/i> mutations are ethnic specific (\u003Ca href=\"#B26\">Fackenthal and Olopade, 2007\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Since a good knowledge of population structure is essential for the development of efficient and individualized screening approaches, the identification of founder \u003Ci>BRCA\u003C/i> mutations is crucial to set up affordable and cost-effective breast cancer genetic testing. In North Africa, several \u003Ci>BRCA1/2\u003C/i> founder mutations were identified among which \u003Ci>BRCA1\u003C/i>-c.798_799delTT that was reported in 9.8% and 36.4% of familial and sporadic Algerian breast cancer cases, respectively (\u003Ca href=\"#B93\">Uhrhammer et al., 2008\u003C/a>). This same mutation was reported in Tunisian population with a frequency of 18% (\u003Ca href=\"#B56\">Mahfoudh et al., 2012\u003C/a>). Furthermore, \u003Ci>BRCA2-\u003C/i>c.1310_1313delAAGA is considered as a North African founder mutation since it has been identified in Algerian, Moroccan and Tunisian breast cancer cases (\u003Ca href=\"#B18\">Cherbal et al., 2010\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B47\">Laarabi et al., 2017\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">In Tunisia, founder mutations explain around 42% of hereditary disorders (\u003Ca href=\"#B78\">Romdhane et al., 2012\u003C/a>). This is mainly due to the high rates of consanguinity and endogamy. So far, few \u003Ci>BRCA1\u003C/i> deleterious mutations were identified in Tunisia and the most recurrent ones are c.211dupA and c.5266dupC (\u003Ca href=\"#B90\">Troudi et al., 2008\u003C/a>; \u003Ca href=\"#B56\">Mahfoudh et al., 2012\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>). \u003Ci>BRCA1\u003C/i>-c.5266dupC was originally described as an Ashkenazi founder mutation. Then, it has been reported in several other populations such as Russian, Italian, Slovenian, Greek and Tunisian (\u003Ca href=\"#B40\">Janavi&#x010D;ius, 2010\u003C/a>). However, the c.211dupA mutation seems to be specific to Tunisia since it has never been previously described in any other population (\u003Ca href=\"#B91\">Troudi et al., 2007\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Besides \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>, more than 100 loci are known to be associated with breast cancer risk (\u003Ca href=\"#B33\">Han et al., 2016\u003C/a>). For \u003Ci>BRCA\u003C/i> negative families, fine mapping of other high to moderate penetrant breast cancer genes is needed to explain the genetic predisposition to breast cancer. For this purpose, next generation sequencing technologies are widely used as a cost-effective approach for the detection of novel mutations (\u003Ca href=\"#B83\">Shahi et al., 2019\u003C/a>). Indeed, target gene sequencing (TGS), whole exome sequencing (WES), and whole genome sequencing (WGS) are the main protocols currently used to identify either new mutations or new candidate genes associated with hereditary disorders (\u003Ca href=\"#B17\">Chandler et al., 2016\u003C/a>; \u003Ca href=\"#B1\">Akter et al., 2019\u003C/a>; \u003Ca href=\"#B8\">Bewicke-Copley et al., 2019\u003C/a>; \u003Ca href=\"#B68\">Posey, 2019\u003C/a>; \u003Ca href=\"#B83\">Shahi et al., 2019\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">In the present study, we used classical as well as next generation sequencing technologies to investigate the genetic predisposition to breast cancer in 112 Tunisian families. Targeted mutation screening followed by target gene and whole exome sequencing were performed. We have also studied the founder effect and the relative age of the most frequent \u003Ci>BRCA1\u003C/i> mutation in Tunisia (c.211dupA). In addition, genotypic data were correlated to drug response, clinicopathological and phenotypic features of all mutation carriers.\u003C/p>\r\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and Methods\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Patients\u003C/h3>\r\n\u003Cp class=\"mb15\">A total of 122 individuals with strong familial history of breast cancer (111 patients and 11 healthy) were recruited from three principal medical oncology centers based in Tunis that provide care and services for Tunisian cancer patients from all over the country (Departments of Medical oncology of Abderrahmane Mami Hospital, of Military Hospital of Tunis and the surgical oncology Department of Institut Salah Azaiez). Prior to specimen collection, all participants signed written and informed consents and gave relevant information about their personal and familial cancer histories as well as their geographic origins. A patient was recruited if at least one of the following criteria is fulfilled: (1) Presence of at least two related first or second-degree breast cancer cases, (2) Breast cancer in young patients aged less than 36 years, (3) Presence of at least two cases of breast or ovarian cancer, regardless of age. The mean age at diagnosis of the whole studied cohort is 42.84 years. The geographic distribution of birth locations is as follows; the majority are originating from Northern Tunisia, however approximately 20% are from the Central region and 6% from the South region. Forty-three percent of patients have a strong family history of breast cancer where 2 or multiple family members were diagnosed with breast cancer. A family history of ovarian cancer was observed among approximately 10% of patients. Breast cancer patients selected for next generation sequencing are those with the strongest family history of breast cancer (having 2 or more cases) and/or with age at onset of less than 36 years.\u003C/p>\r\n\u003Cp class=\"mb0\">Clinico-pathological characteristics and follow-up data have been collected from medical records of patients.\u003C/p>\r\n\u003Ch3>Sanger Sequencing\u003C/h3>\r\n\u003Cp class=\"mb15\">Total genomic DNA was isolated from peripheral blood using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x2019;s instructions. DNA purity and concentration were measured using a NanoDrop\u003Csup>TM\u003C/sup> spectrophotometer.\u003C/p>\r\n\u003Cp class=\"mb15\">Polymerase chain reaction reactions were performed on genomic DNA, following standard protocols. Sanger sequencing was performed using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA, United States) and a cycle sequencing reaction kit (Bigdye Terminator v3.1 kit, Applied Biosystems). Data was analyzed using BioEdit software version 7.2.5.\u003C/p>\r\n\u003Cp class=\"mb0\">Sanger sequencing technique was first used to screen the c.211dupA mutation on exon 5 of \u003Ci>BRCA1\u003C/i> (NM_007294.3) among all 122 participants. It was also used to validate the identified variants resulting from the NGS assays. Non-carriers of c.211dupA mutation were tested for other recurrent \u003Ci>BRCA1/2\u003C/i> mutations in Tunisia namely \u003Ci>BRCA1-\u003C/i>c.798_799delTT, \u003Ci>BRCA1-\u003C/i>c.5266dupC, and \u003Ci>BRCA2-\u003C/i>c.1310_1313delAAGA (\u003Ca href=\"#B56\">Mahfoudh et al., 2012\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B64\">Msolly and Kassab, 2015\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>).\u003C/p>\r\n\u003Ch3>Targeted \u003Ci>BRCA1/2\u003C/i> Genes Sequencing\u003C/h3>\r\n\u003Cp class=\"mb0\">Targeted \u003Ci>BRCA1/2\u003C/i> genes sequencing was performed for 9 patients. A DNA quantity of 40 ng measured by Qubit (Thermo Fisher Scientific, MA, United States) was used as a template to generate libraries for sequencing. Libraries were prepared using the QIAGEN Library Kit v2.0 and the GeneRead QIAact \u003Ci>BRCA1/2\u003C/i> panel (QIAGEN, Hilden, Germany), which comprises 253 pooled primer pairs custom designed to cover all coding regions of the \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes, including 20 bp flanking regions in adjacent introns. All steps of library preparation were performed according to the manufacturer&#x2019;s protocol. The libraries were then quantified using a Qubit dsDNA HS Assay Kit (Life Technologies, MA, United States) and QIAxcel (QIAGEN, Hilden, Germany). Nine individual libraries were pooled prior to emulsion PCR and bead enrichment steps that were carried out using an automated protocol on the GeneRead QIAcube (QIAGEN, Hilden, Germany) using the GeneRead Clonal Amp Q Kit (QIAGEN, Hilden, Germany), according to the manufacturer&#x2019;s protocol. Following bead enrichment, the pooled libraries were sequenced using the GeneReader platform (QIAGEN, Hilden, Germany).\u003C/p>\r\n\u003Ch3>Whole Exome Sequencing (WES)\u003C/h3>\r\n\u003Cp class=\"mb0\">Whole exome sequencing was performed for 8 patients. Samples were prepared according to Agilent SureSelect Protocol Version 1.2 and enrichment was carried out according to Agilent SureSelect protocols. Sequencing was performed on Illumina HiSeq2000 platform using TruSeq v3 chemistry with paired-end (2 &#x00D7; 100 pb). Exome DNA sequences were mapped to their location based on the hg19/b37 human genome using the Burrows&#x2013;Wheeler Aligner (BWA) package (\u003Ca href=\"#B49\">Li and Durbin, 2009\u003C/a>). Duplicate reads were removed using Picard (\u003Ca href=\"#B25\">Ebbert et al., 2016\u003C/a>). The subsequent SAM files were converted to BAM files using Samtools (\u003Ca href=\"#B50\">Li et al., 2009\u003C/a>). GATK was then used to recalibrate the base quality scores as well as for SNP and short INDEL calling (\u003Ca href=\"#B60\">McKenna et al., 2010\u003C/a>).\u003C/p>\r\n\u003Ch3>Functional Annotation and Variants Prioritization\u003C/h3>\r\n\u003Cp class=\"mb15\">Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) 2.10 software (\u003Ca href=\"#B23\">Desvignes et al., 2018\u003C/a>). The annotated InDels and SNPs were filtered according to several criteria: (1) considering breast cancer as autosomal dominant disease, we removed variants that were found at homozygous state, (2) variants identified as intronic, intergenic and non-coding or synonymous were discarded, (3) assuming that causal variants are rare, we removed all variants with an allele frequency &#x003E; 1% either in 1000 Genomes or GnomAD_Exome databases, (4) benign or tolerated variants were discarded according to the following \u003Ci>in silico\u003C/i> prediction tools: Sorting Intolerant From Tolerant (SIFT), PolyPhen-2, Mutation Taster, LRT_pred and Combined Annotation Dependent Depletion CADD tool. We used SiPhy_log odds score calculated by ANNOVAR to keep deleterious variants with high scores and Gene Damage Index Prediction database (GDI) to exclude highly mutated genes.\u003C/p>\r\n\u003Cp class=\"mb0\">The Wikipathways (\u003Ca href=\"#B86\">Slenter et al., 2017\u003C/a>) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (\u003Ca href=\"#B42\">Kanehisa and Goto, 2000\u003C/a>) databases were used to assign genes to their pathways and the Network of Cancer Genes V 6.0 (\u003Ca href=\"#B72\">Repana et al., 2019\u003C/a>) was used to identify genes associated with cancers.\u003C/p>\r\n\u003Ch3>Molecular Modeling\u003C/h3>\r\n\u003Cp class=\"mb15\">We used the protein sequence of RAD50 annotated under the accession Q92878 in the Uniprot database (\u003Ca href=\"#B20\">The Uniport Consortium, 2019\u003C/a>) as a reference sequence. To predict the 3D structure of the wild type RAD50 we used a comparative modeling approach with the satisfaction of spatial restraints using MODELLER version 9.22 (\u003Ca href=\"#B79\">&#x0160;ali and Blundell, 1993\u003C/a>). Template identification consists of searching for homologous proteins to the RAD50 reference sequence in the Protein Data Bank (PDB) (\u003Ca href=\"#B7\">Berman et al., 2000\u003C/a>) using BLAST (identity sequence cutoff &#x003E; 30%) (\u003Ca href=\"#B2\">Altschul et al., 1990\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The search for a template identified the structure of &#x201C;DH domain-containing protein&#x201D; from \u003Ci>Chaetomium thermophilum\u003C/i> (PDB code 5DAC) (\u003Ca href=\"#B80\">Seifert et al., 2016\u003C/a>) that shows a significant e-value of 4.2 e\u003Csup>&#x2013;72\u003C/sup> and a sequence identity of 50% (locally aligned) compared to hRAD50. The alignment of hRAD50 with the template covers 32% of the reference sequence including the position of the mutation. We introduced a distance restraint of 10 &#x00C5; between the terminal residues of the coiled-coil segments belonging to the same monomer. Moreover, we built the model in the presence of ATP&#x03B3;S: Mg\u003Csup>2+\u003C/sup> heteroatoms.\u003C/p>\r\n\u003Cp class=\"mb0\">The template and target sequences were then aligned using &#x2018;needle&#x2019; from the EMBOSS package (\u003Ca href=\"#B74\">Rice et al., 2000\u003C/a>) and the alignment was then edited manually to correct for errors. We then built the model by generating 50 conformers with different seeds using a rapid refinement protocol. The final model was selected based on the calculation of the DOPE score (\u003Ca href=\"#B84\">Shen and Sali, 2006\u003C/a>) and the quality assessment was checked by establishing the Ramachandran plot (\u003Ca href=\"#B53\">Lovell et al., 2003\u003C/a>) and the local energy profile Verify3D (\u003Ca href=\"#B54\">L&#x00FC;thy et al., 1992\u003C/a>). The structure of the mutant p.Ala1216Gly was then built using the 3D model of the wild type based on MODELLER script that mutates and refines the protein structure.\u003C/p>\r\n\u003Ch3>Stability Analysis\u003C/h3>\r\n\u003Cp class=\"mb0\">We estimated the free energy of folding between the wild type and the mutant structure (&#x0394;&#x0394;G\u003Csub>Wt\u003C/sub>\u003Csub>&#x2013;\u003C/sub>\u003Csub>Mut\u003C/sub>) using DynaMut (\u003Ca href=\"#B77\">Rodrigues et al., 2018\u003C/a>). Moreover, we performed a simulation of protein flexibility with CABS-flex 2.0 (\u003Ca href=\"#B39\">Jamroz et al., 2014\u003C/a>) for both the wild type and the mutant structures at a temperature of 1.6 (dimensionless value related to the physical temperature). For each protein, we performed four simulations with four different predefined seeds. The same set is used for the wild type and the mutant 3D structures. We run the simulation with a fully flexible backbone (protein-flexibility = 0), a number of Monte Carlo cycles of 100 (\u003Ci>y\u003C/i> = 100) and the protein restraints were reduced by a factor of 0.8. Root Mean Square Fluctuation (RMSF) value was analyzed by calculating the per residue one-tailed Welch&#x2019;s \u003Ci>t\u003C/i>-test under the null hypothesis that the RMSF at a given position in the sequence does not differ between the mutant and the wild type and an alternative hypothesis being that the RMSF value at given position of the sequence is greater for the mutant than the wild type structure. The analysis was performed using an in-house python script that employs the Scipy library for scientific computing.\u003C/p>\r\n\u003Ch3>Copy Number Variations Analysis\u003C/h3>\r\n\u003Cp class=\"mb0\">Copy Number Variations (CNVs) calling was performed on WES data using the ExomeDepth R package (\u003Ca href=\"#B67\">Plagnol et al., 2012\u003C/a>). All CNVs were annotated using AnnotSV software (\u003Ca href=\"#B30\">Geoffroy et al., 2018\u003C/a>), a program designed for annotating and ranking Structural Variations (SV) from genomes. This tool compiles functionally, regulatory and clinically relevant information and aims to provide useful annotations to interpret SV potential pathogenicity. AnnotSV classifies CNVs into 5 classes (Class 1: benign, Class 2: likely benign, Class 3: VUS (Variant of Unknown Significance), Class 4: likely pathogenic, and Class 5: pathogenic). In order to identify the most relevant CNVs which may be associated with breast cancer risk, only CNVs classified as class 3, 4, and 5 were kept for further analysis. Biological pathways analysis has been performed using Wikipathways (\u003Ca href=\"#B86\">Slenter et al., 2017\u003C/a>) and KEGG (\u003Ca href=\"#B42\">Kanehisa and Goto, 2000\u003C/a>) datasets. Network of Cancer Genes V6.0 (\u003Ca href=\"#B72\">Repana et al., 2019\u003C/a>) was used to identify genes associated with cancers.\u003C/p>\r\n\u003Ch3>Genotyping and Haplotype Analysis of c.211dupA Mutation\u003C/h3>\r\n\u003Cp class=\"mb0\">Haplotype analysis was carried out for 39 individuals: six carriers of the c.211dupA mutation, 3 relatives, 15 breast cancer non-carriers, and 15 healthy age-matched Tunisian women from the general population. Four microsatellite markers (D17S800, D17S855 D17S902, and D17S806), spanning a 6.75 Mb region around the \u003Ci>BRCA1\u003C/i> gene were studied (\u003Ca href=\"#FS1\">Supplementary Figure 1\u003C/a>). Primers&#x2019; sequences were obtained from the Probe NCBI database and PCR conditions are available on request. PCR product size was evaluated by capillary electrophoresis on an ABI prism 3500 DNA Genetic Analyzer using the GeneMapper V.5.0 software (Applied Biosystems, Foster City, CA, United States). For the D17S806 marker, results were inconclusive, and it was excluded from further analysis. Haplotypes were then reconstructed using PHASE v.2.1 software (\u003Ca href=\"#B87\">Stephens et al., 2001\u003C/a>) that uses Bayesian methods to predict haplotype distribution.\u003C/p>\r\n\u003Ch3>Estimation of c.211dupA Mutation Age\u003C/h3>\r\n\u003Cp class=\"mb15\">The DMLE + 2.3 program (\u003Ca href=\"#B71\">Reeve and Rannala, 2002\u003C/a>) was used to estimate the age of the c.211dupA mutation. The DMLE input file included the full genotypes or haplotypes of probands and controls for the analyzed markers, chromosome map distances derived from the Marshfield sex-average genetic map, population growth rate per generation and an estimate of the proportion of disease chromosomes sampled. The other DMLE parameters were kept to their default values.\u003C/p>\r\n\u003Cp class=\"mb0\">For the population growth rate (r), we used data from the Tunisian Institute of Statistics (INS\u003Csup id=\"footnotesuper1\">\u003Ca id=\"footnote1a\">\u003C/a>\u003Ca class=\"footnoteanchor\" href=\"#footnote1\">1\u003C/a>\u003C/sup>). This key parameter was estimated to be 1.348 per generation using the following formula: p\u003Csub>1\u003C/sub> = p\u003Csub>0\u003C/sub> &#x00D7; r\u003Csup>g\u003C/sup>, where p\u003Csub>1\u003C/sub> represents the Tunisian population size in 2014 (10.982.754), p\u003Csub>0\u003C/sub> represents the Tunisian population in 1860 (1.1 million) (\u003Ca href=\"#B81\">Seklani, 1974\u003C/a>), and g is the number of generations between these two-time points.\u003C/p>\r\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Investigating the State of \u003Ci>BRCA1\u003C/i>-c.211dupA, Founder Effect and Age\u003C/h3>\r\n\u003Cp class=\"mb15\">In the current study, 122 individuals from 112 Tunisian families with strong familial history of breast cancer were investigated using sanger and next generation sequencing. First, we looked for c.211dupA which is the most recurrent \u003Ci>BRCA1\u003C/i> mutation in the Tunisian population.\u003C/p>\r\n\u003Cp class=\"mb15\">A total of 8 carriers of c.211dupA belonging to 5 unrelated families were identified. All carriers originated from the North-Eastern region of Tunisia. The relative frequency of this mutation is 12.2% (5 out of 41) and 4.46% (5 out of 112) in this region and in the whole cohort, respectively. \u003Ci>BRCA1\u003C/i>-c.211dupA seems to be the most frequent \u003Ci>BRCA\u003C/i> mutation in Tunisia, accounting for approximately 41% of all identified \u003Ci>BRCA1\u003C/i> mutations, if we consider this report and previous Tunisian studies (\u003Ca href=\"#B91\">Troudi et al., 2007\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>). In addition, we have not been able to identify any of the other recurrent mutations (\u003Ci>BRCA1\u003C/i>-c.798_799delTT, \u003Ci>BRCA1\u003C/i>-c.5266dupC, and \u003Ci>BRCA2\u003C/i>-c.1310_1313delAAGA) in the other non-carrier patients of the c.211dupA mutation.\u003C/p>\r\n\u003Cp class=\"mb15\">To investigate the founder effect of c.211dupA, haplotype analysis was performed for 39 individuals. Results showed that 5 out of the 6 genotyped carriers shared an identical haplotype (170-145-147), corresponding to D17S800, D17S855, and D17S902 respectively and all carriers shared a common semi-haplotype (170-145) spanning a region of 2.15 Mb (1.08cM) on \u003Ci>BRCA1\u003C/i>. This haplotype was absent in non-carriers and was not found in control chromosomes. These results support the founder effect of the c.211dupA mutation in the North-East of Tunisia.\u003C/p>\r\n\u003Cp class=\"mb0\">Given that the prevalence of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> carriers in the Tunisian general population is not well defined, for the mutation age estimation, three separate analyses were performed, each using a different estimate for the proportion of sampled population carrying the c.211dupA mutation: 0.005, 0.01, and 0.015. Thus, the age estimates for c.211dupA mutation were approximately 6.5 generations (95% CI [5.2&#x2013;8.8]), 6.3 generations (95% CI [4.7&#x2013;8.5]), and 6.00 generations (95% CI [4.4&#x2013;8.1]). Assuming a generation time of 20 years, the corresponding ages are 130 (95% CI [104&#x2013;176]), 126 (95% CI [94&#x2013;170]), and 120 (95% CI [88&#x2013;162]) years.\u003C/p>\r\n\u003Ch3>Clinico-Pathological Features and Follow-up of c.211dupA Mutation Carriers\u003C/h3>\r\n\u003Cp class=\"mb0\">We further extended our analysis to the 9 additional carriers of c.211dupA mutation reported in previous Tunisian studies (\u003Ca href=\"#B91\">Troudi et al., 2007\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>). For a total of 15 c.211dupA carriers, the mean age at diagnosis was 39.41 years, ranging from 28 to 58 years (\u003Ca href=\"#T1\">Table 1\u003C/a>). Family history of breast cancer was observed in 93.33% cases (14/15) among which 20% (3/15) presented a family history of ovarian cancer. Other malignancies such as leukemia, prostate, colon and cervical cancers were observed in family members. Infiltrating ductal carcinoma (IDC) was the predominant tumor subtype, high grade 3 and axillary node involvement were observed in about 50% of carriers. The mean tumor size was 30 mm and 50% of carriers displayed a triple negative breast cancer (TNBC) phenotype with two additional cases harboring negative hormone receptors with unknown human epidermal growth factor receptor 2 (HER2) status. Thus, this mutation is likely associated with a severe phenotype.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" name=\"table1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 1.\u003C/strong> Clinico-pathological features of \u003Ci>BRCA1\u003C/i> and \u003Ci>RAD50\u003C/i> carriers.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Assessment of disease evolution for c.211dupA carriers as well as their response to treatment were performed. Radical mastectomy was performed in 4 cases. Sequential adjuvant chemotherapy, 5-Fluorouracil-Epirubicin-Cyclophosphamide-Paclitaxel/Docetaxel (FEC-TXL/TXT) was administered to the majority of carriers and radiotherapy was performed in non-metastatic cases (\u003Ca href=\"#T1\">Table 1\u003C/a>). Two carriers (BC-TN-F204 and BC-TN-F009) have developed ovarian cancer 13 and 15 years after their breast cancer diagnosis respectively. Contralateral recurrence was observed in two cases (BC-TN-F009 and BC-TN-F0049-1). One patient diagnosed with triple negative metastatic breast cancer (BC-TN-F199) has a refractory disease treatment and died within 12 months by disease progression. However, the median survival of non-metastatic carriers was 12 years. We therefore concluded that except for the metastatic breast cancer case, chemotherapy treatments were well tolerated, and carriers had a good survival despite the severity of their clinico-pathological phenotype.\u003C/p>\r\n\u003Ch3>BRCA1 and BRCA2 Variants Identified by Next-Generation Sequencing\u003C/h3>\r\n\u003Cp class=\"mb0\">After studying the carriers of c.211dupA mutation in detail, we then selected 17 other breast cancer patients to be investigated by next generation sequencing. The selection was done on the basis of family history and disease onset. Targeted \u003Ci>BRCA1/2\u003C/i> sequencing and whole exome sequencing were performed on 9 and 8 breast cancer patients respectively. Familial pedigrees as well as phenotypic characteristics of all carriers are shown in \u003Ca href=\"#F1\">Figure 1\u003C/a> and \u003Ca href=\"#T1\">Table 1\u003C/a> respectively.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" name=\"figure1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 1.\u003C/strong> Familial Pedigrees of \u003Ci>BRCA1\u003C/i> and \u003Ci>RAD50\u003C/i> mutations carriers. Available age at diagnosis of breast cancer cases is indicated between brackets. For some cases, only age at death was available and is indicated in square brackets. BOC, Breast and ovarian cancers; CBC, Contralateral breast cancer; IBC, Inflammatory breast cancer; OC, ovarian cancer. Black boxes mean breast cancer and half black boxes mean other cancer types.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">The distribution of the identified \u003Ci>BRCA1/2\u003C/i> variations is illustrated in \u003Ca href=\"#F2\">Figure 2\u003C/a>. Exonic coding variants represented 27 out of 67 variants and based on ClinVar database, the majority of the identified \u003Ci>BRCA1/2\u003C/i> variants were classified as benign (58), 4 were classified as likely benign and 4 variants were not reported in ClinVar.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" name=\"figure2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 2.\u003C/strong> Distribution of \u003Ci>BRCA1/2\u003C/i> variations identified in patients investigated by target gene and whole exome sequencing. \u003Cb>(A)\u003C/b> SNVs/InDels distribution, \u003Cb>(B)\u003C/b> Distribution of coding variations, \u003Cb>(C)\u003C/b> ClinVar classification of detected variations.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Additionally, our results identified a novel \u003Ci>BRCA1\u003C/i> pathogenic mutation on exon 11 (c.2418dupA and rs886040036) in one patient. This mutation has not been reported in previous studies neither in Tunisia nor in other populations. Nevertheless, it is already listed and classified as pathogenic in ClinVar and predicted to result in the substitution of Alanine to Serine (p.Ala807Serfs) followed by a premature truncation of BRCA1 protein at amino acid position 809.\u003C/p>\r\n\u003Cp class=\"mb15\">Patient (BC-TN-F0093) harboring the c.2418dupA mutation is also originating from the North Eastern region of Tunisia. She was diagnosed with triple negative inflammatory breast cancer at 34 years old. Pathological examination of the tumor revealed invasive ductal carcinoma, Scarff-Bloom and Richardson (SBR) grade 2 with Ki-67 of 30%. No additional carriers of this mutation were found in the studied cohort.\u003C/p>\r\n\u003Cp class=\"mb0\">The remaining 16 patients did not carry any pathogenic mutation on the \u003Ci>BRCA\u003C/i> genes.\u003C/p>\r\n\u003Ch3>Whole Exome Sequencing Data Analysis\u003C/h3>\r\n\u003Ch4 class=\"pt0\">Analysis of Known Breast Cancer Susceptibility Genes\u003C/h4>\r\n\u003Cp class=\"mb15\">In our current study, in addition to the sanger sequencing analysis, and after screening for pathogenic \u003Ci>BRCA1/2\u003C/i> mutations among 17 breast cancer patients by NGS. We then selected a unique patient investigated by WES, originating from the North-East of Tunisia for detailed analysis, in order to shed light on the genetic architecture of breast cancer in this specific region. First, we looked for variations on 29 genes known to be associated with breast cancer. At this step we have identified a VUS on \u003Ci>RAD50\u003C/i>. Therefore, for this same patient, we extended our analysis in order to select other relevant variants on candidate genes that could be associated with malignancies based on \u003Ci>in silico\u003C/i> analysis and several genomic and biological pathways databases. The proband (BC-TN-F0019) was diagnosed with a locally advanced breast cancer at age 49 with negative hormone receptors status and SBR grade 2. Using whole exome data, we first investigated a list of 29 genes known to be associated with hereditary breast and ovarian cancers. Coverage analysis for these 29 genes demonstrated that we reached a depth of &#x223C;50X and a percentage of coverage of 82% for the targeted regions (\u003Ca href=\"#S11\">Supplementary Table 1\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">A total of 31 exonic variants and one splicing SNP were identified on the 29 genes (\u003Ca href=\"#S11\">Supplementary Table 2\u003C/a>). None of these variants was classified as pathogenic in ClinVar. However, a VUS, c.3647C &#x003E; G, p.Ala1216Gly, was identified on \u003Ci>RAD50\u003C/i>. In the same patient, another variant, rs28908468, described by ClinVar as associated with &#x201C;Drug response&#x201D; (PARP inhibitors), was identified on \u003Ci>RAD51B.\u003C/i>\u003C/p>\r\n\u003Cp class=\"mb15\">We then made a detailed analysis of the mutation identified in the \u003Ci>RAD50\u003C/i> gene in order to investigate the possibility of revising its current classification in public databases such as ClinVar. Several \u003Ci>in silico\u003C/i> analysis, indeed, suggest the deleterious aspect of the RAD50 p.Ala1216Gly mutation.\u003C/p>\r\n\u003Cp class=\"mb0\">To assess the putative effect of this mutation on RAD50 function, we performed a protein modeling and simulation analysis. First, we verified the conservation of the residue \u003Ci>NP_005723.2: p.Ala1216\u003C/i> by establishing a multiple sequence alignment using homologous RAD50 proteins of model organisms (\u003Ca href=\"#F3\">Figure 3A\u003C/a>). We observed that \u003Ci>Ala1216\u003C/i> is located in a highly conserved segment found in all orthologous sequences belonging to organisms emerging at different evolution periods.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" name=\"figure3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 3.\u003C/strong> Molecular modeling and stability analysis of RAD50_p.Ala1216Gly variation. \u003Cb>(A)\u003C/b> Multiple sequence alignment of hRAD50 with homologous proteins from model organisms, \u003Ci>Gorilla\u003C/i> (XP_004042521.1), \u003Ci>Mus musculus\u003C/i> (NP_033038.2), \u003Ci>Gallus\u003C/i> (XP_414645.3), \u003Ci>Xenopus laevis\u003C/i> (NP_001154855.1), \u003Ci>Danio rerio\u003C/i> (XP_005167995.1), \u003Ci>Anolis carolinensis\u003C/i> (XP_003217435.1) and \u003Ci>Drosophila melanogaster\u003C/i> (NP_001246461.1). \u003Cb>(B)\u003C/b> Predicted 3D structure of hRAD50 predicted with comparative modeling showing the mutation site and the different domains of the protein. DNA docking was generated by transferring the coordinates of the nucleic acid after a structural superposition of the symmetric chains. \u003Cb>(C)\u003C/b> Position of the mutation A1216G on the ATP&#x03B3;S:Mg ++ stabilizing &#x03B1;-helix extended over residues 1203-1221. \u003Cb>(D)\u003C/b> Comparative RMSF analysis between the reference protein (A1216, solid lines) and the mutated protein (G1216, dashed lines). The values of RMSF for the reference protein were shifted to +3 &#x00C5;. For the sake of visibility. The green dots represent the position where p-values are significant at a confidence level &#x03B1; = 0.05.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Next, we constructed a homology model of RAD50. The predicted 3D model of hRAD50 consists of the assembly into a homodimer (\u003Ca href=\"#F3\">Figure 3B\u003C/a>). Each monomer covers segments 2-221 and 1098-1315 which include a relatively small coiled-coil region and the Walker A and Walker B globular domains. The assembly of the latter contains the Protein-DNA interface and the interaction surface with MRE11. The Stereochemical and the local energy quality were validated for the predicted model in comparison with the template structure (\u003Ca href=\"#FS2\">Supplementary Figure 2\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The mutation site is situated in the core of hRAD50 as part of an &#x03B1; helix extended over residues 1203-1221 (\u003Ca href=\"#F3\">Figures 3B,C\u003C/a>). Residue A1216 establishes a hydrophobic contact with I1146 situated on another &#x03B1;-helix with a C&#x03B1;-C&#x03B1; distance of 5.7 &#x00C5;. The mutation p.Ala1216Gly is able to preserve this hydrophobic contact. The N-terminal end of the &#x03B1;-helix stabilizes both the Mg\u003Csup>2+\u003C/sup> and the ATP&#x03B3;S particularly, the thiotriphosphate moiety of the substrate. The calculation of &#x0394;&#x0394;G\u003Csub>Wt\u003C/sub>\u003Csub>&#x2013;\u003C/sub>\u003Csub>Mut\u003C/sub> predicted a destabilizing effect for all five methods, DynaMut, ENCoM, mCSM, SDM and DUET with values of -0.037, -0.416, -1.4, -2.170, -1.643 kcal.mol\u003Csup>&#x2013;1\u003C/sup> respectively. Moreover, ENCoM predicted a vibrational entropy energy of 0.52 kcal.mol\u003Csup>&#x2013;1\u003C/sup>.K\u003Csup>&#x2013;1\u003C/sup> suggesting an increase of the molecular flexibility.\u003C/p>\r\n\u003Cp class=\"mb0\">Because a substitution to glycine may affect the flexibility of other regions in the protein, the extent of this mutation was evaluated by simulating hRAD50 using CABS-flex approach (\u003Ca href=\"#F3\">Figure 3D\u003C/a>). Our results suggest a significant increase in the RMSF values at a confidence level of 5% (Green dots of \u003Ca href=\"#F3\">Figure 3D\u003C/a>) for 71 positions located on both monomers. Of these, residues P165, L166, S1210, I1213 seems to be the most critical as they belong to the helix harboring the mutation (S1210, I1213) or are in the proximity of ATP&#x03B3;S: Mg\u003Csup>2+\u003C/sup> interaction site (P165, L166). Interestingly, the flexibility does also increase for several amino acids that belong to the surface patch involved in the interaction with MRE11 (\u003Ca href=\"#B80\">Seifert et al., 2016\u003C/a>). These residues are: F28, L31, V89, N90, G91, K112, T113, L114, E115, G116, I119 of Walker A and D1272, D1295, Q1296, C1297, S1298, K1301, C1302, S1303, V1304 of Walker B.\u003C/p>\r\n\u003Ch4>Identification of Novel Candidate Variants\u003C/h4>\r\n\u003Cp class=\"mb15\">In addition to the 29 genes known to be associated with breast cancer, we investigated all the other variants resulting from WES analysis. In order to identify the relevant variants that could be associated with malignancies, we used several \u003Ci>in silico\u003C/i> prediction tools, genomic databases, biological pathways databases and we performed a literature review. Eleven variants in 11 genes were identified of which 2 candidate variants have been submitted in the ClinVar database. The remaining variants were not reported in the ClinVar database and therefore, their pathogenicity is still not documented. For this, functional and association studies are needed to verify that.\u003C/p>\r\n\u003Cp class=\"mb0\">A total of 61,404 heterozygous variants were identified (\u003Ca href=\"#F4\">Figure 4\u003C/a>). Among them, 6773 relevant variants (exonic, splicing, non-synonymous, frameshift Indels, stopgain and stoploss) were identified. Variants with MAF &#x003E; 1% in 1000 Genomes and gnomAD_Exome databases were excluded. Therefore, 677 rare variations were selected for further investigations. In order to select the most relevant SNPs, several \u003Ci>in silico\u003C/i> prediction tools and databases were used as described in the methods section. A list of 33 non-synonymous variants belonging to 33 genes were retained.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 4\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" name=\"figure4\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g004.jpg\" alt=\"www.frontiersin.org\" id=\"F4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 4.\u003C/strong> Variants prioritization. Total variations: represents the total number of the identified heterozygous variants and CNVs. Rare relevant variants: we kept (exonic, splicing, non-synonymous, frameshift Indels, stop gain, stop loss) variants. We excluded variants with a frequency &#x003E; 1% in 1000 genomes and gnomAD_Exome databases and CNVs with a frequency &#x003E; 1% in DGV. Functional prediction: using several prediction tools: SIFT (Deleterious), PolyPhen2 (Probably damaging), Mutation Taster (disease-causing), LRT_pred (Deleterious), CADD (score &#x2265; 15), SiPhy_29way_logOdds (score &#x003E; 16), GDI database (excluding highly mutated genes). Using AnnotSV only CNVs (VUS, likely pathogenic or pathogenic) are kept. Biological pathways investigation and selection of candidate variants and CNVs disrupting cancer genes: Using wikipathways, KEGG databases, network of cancer genes 6.0 database and literature review.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">These 33 genes were further filtered based on their implication in cancer etiology using Network of Cancer Genes V6.0. The list of genes was compared to those listed in Wikipathways and KEGG datasets as belonging to pathways relevant in cancers. In addition, we performed a literature review to identify genes more likely to be involved in malignancies development.\u003C/p>\r\n\u003Cp class=\"mb0\">Based on these analyses, 11 genes were selected, namely \u003Ci>MITF, COL7A1, FOXM1, TSHZ2, AMOTL2, ANKS6, ACACB, LIPE, SNRK, CACNA2D3\u003C/i>, and \u003Ci>SMG1\u003C/i> (\u003Ca href=\"#T2\">Table 2\u003C/a>). Among all variants identified on these genes, two variants, namely \u003Ci>ANKS6\u003C/i>_rs199722684 and \u003Ci>MITF\u003C/i>_rs149617956 have been classified in ClinVar as a VUS and a variant with &#x201C;conflicting interpretations of pathogenicity,&#x201D; respectively.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" name=\"table2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 2.\u003C/strong> Candidate variations identified in whole exome sequenced breast cancer patient.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch4>Copy Number Variations Analysis\u003C/h4>\r\n\u003Cp class=\"mb15\">Copy number variations were also investigated in order to assess their possible contribution to disease susceptibility (\u003Ca href=\"#F4\">Figure 4\u003C/a>). Fifty-one CNVs including 30 deletions and 21 duplications were identified with an average size of 24.2 kb (ranging from 64 bp to 123918 bp). Only rare (&#x003C; 1%) and relevant CNVs (of unknown significance, likely pathogenic or pathogenic and ranked as class 3, class 4, and class 5 respectively based on AnnotSV) were kept (\u003Ca href=\"#F4\">Figure 4\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">A total of 7 CNVs affecting 11 genes were identified. Biological pathways analysis has been also performed to select genes linked to breast cancer etiology. In addition, we searched published literature regarding genes affected by CNVs and breast cancer risk (\u003Ca href=\"#T3\">Table 3\u003C/a>). Among the 11 genes, 5 had been previously identified as cancer genes or candidate cancer genes namely \u003Ci>TMTC3, BCL3, COL7A1, RNF5\u003C/i>, and \u003Ci>CEP290.\u003C/i>\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" name=\"table3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Table 3.\u003C/strong> Candidate rare Copy Number Variations likely associated with cancers.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\r\n\u003Cp class=\"mb15\">Since their discovery in 1994 and 1995, a wide range of mutational spectrum have been described for \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes (\u003Ca href=\"#B48\">Laraqui et al., 2015\u003C/a>). Several recurrent mutations have been reported in the Tunisian population. Some of these mutations are specific to Tunisians, others are shared with neighboring populations (\u003Ca href=\"#B90\">Troudi et al., 2008\u003C/a>; \u003Ca href=\"#B56\">Mahfoudh et al., 2012\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B64\">Msolly and Kassab, 2015\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>). So far, \u003Ci>BRCA1\u003C/i>-c.211dupA mutation has been reported only in Tunisian families with breast cancer (\u003Ca href=\"#B91\">Troudi et al., 2007\u003C/a>; \u003Ca href=\"#B28\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>). In the present report, 8 carriers of c.211dupA were identified, all originating from the North-East of Tunisia, suggesting that this mutation is specific to this region. This finding is in agreement with the results of Riahi and colleagues where all carriers of the c.211dupA mutation were all originating from the North-Eastern region of Tunisia (\u003Ca href=\"#B73\">Riahi et al., 2015\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">In order to unravel the genetic specificities of this mutation and to trace its origin, a haplotype analysis was conducted and results support the founder effect of c.211dupA mutation in the North-East of Tunisia. We have also estimated the \u003Ci>BRCA1-\u003C/i>c.211dupA approximative age. Indeed, it seems that this mutation appeared 130 years ago in Tunisia, during the second half of the 19th century and after the French occupation that took place in 1881. All migratory waves that occurred at the colonial period may be at the origin of new mutations and had therefore a considerable impact on the genetic diversity of the Tunisian population.\u003C/p>\r\n\u003Cp class=\"mb15\">The recent origin and the limited geographical distribution of this mutation may also suggest that it could be a \u003Ci>de novo\u003C/i> mutation that occurred in the 19th century in an individual from the North East of Tunisia. Despite the high rates of \u003Ci>de novo\u003C/i> mutation that have been observed in several other genes, only 15 carriers of \u003Ci>de novo BRCA1/2\u003C/i> mutations have been reported to date (\u003Ca href=\"#B31\">Golmard et al., 2016\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Furthermore, investigation of clinicopathological features of c.211dupA carriers showed that the majority exhibited high histological tumor grade and were diagnosed with TNBC. Our findings are in agreement with previous studies reporting that breast carcinomas in \u003Ci>BRCA1\u003C/i> mutation carriers are associated with aggressive tumor characteristics (\u003Ca href=\"#B4\">Armes et al., 1998\u003C/a>). Additionally, the TNBC phenotype is the most observed molecular subtype in patients with \u003Ci>BRCA1\u003C/i> mutation and it is well documented that breast cancer patients with \u003Ci>BRCA1\u003C/i> mutation are significantly associated with worse overall survival than patients with a non-mutated \u003Ci>BRCA1\u003C/i> allele (pooled HR = 1.69 (95% CI 1.35 to 2.12, \u003Ci>p\u003C/i> &#x003C; 0.001; \u003Ci>I\u003C/i>\u003Csup>2\u003C/sup> = 59.1%) (\u003Ca href=\"#B98\">Zhu et al., 2016\u003C/a>). Nevertheless, in the present study, median survival of non-metastatic carriers of c.211dupA mutation was 12 years.\u003C/p>\r\n\u003Cp class=\"mb15\">We have also investigated the treatment response and the clinical evolution of the disease among carriers. For c.211dupA mutation, two carriers have developed contralateral breast cancer. This observation is similar to those described in the literature where the risk of contralateral recurrence in women with \u003Ci>BRCA\u003C/i> mutation is approximately 40% at 10 years (\u003Ca href=\"#B61\">Metcalfe et al., 2004\u003C/a>). Besides, two other carriers have developed ovarian cancer 15 and 13 years after their breast cancer. This observation is also in accordance with what has been reported in the literature on the cumulative risk of developing ovarian carcinoma after breast cancer in \u003Ci>BRCA1\u003C/i> mutation carriers that was estimated to almost 12.7% at 10 years (\u003Ci>p\u003C/i> = 0.03) (\u003Ca href=\"#B62\">Metcalfe et al., 2005\u003C/a>). It is noteworthy that personal and/or familial ovarian cancer history was present in a high proportion of families (3/5) carrying the c.211dupA mutation.\u003C/p>\r\n\u003Cp class=\"mb15\">Based on the risk of contralateral recurrence and the risk of developing ovarian cancer several years after breast cancer, risk-reducing mastectomy (\u003Ca href=\"#B34\">Hartmann et al., 1999\u003C/a>) and salpingo-oophorectomy (\u003Ca href=\"#B69\">Rebbeck et al., 2002\u003C/a>) are recommended for \u003Ci>BRCA1\u003C/i>-c.211dupA carriers. Moreover, affected cases carrying this mutation could also benefit from personalized therapeutic options. Indeed, the identification of c.211dupA mutation in a metastatic breast cancer patient helped to reorient her therapeutic decision by using carboplatins, platinum-based agents, that are recommended for the treatment of metastatic \u003Ci>BRCA\u003C/i>-mutated breast cancer with an overall response rate of 80%, including 45% with complete response (\u003Ca href=\"#B13\">Byrski et al., 2012\u003C/a>; \u003Ca href=\"#B92\">Turner and Tutt, 2012\u003C/a>; \u003Ca href=\"#B19\">Coates et al., 2015\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Therefore, the severe phenotype associated with this mutation (young age of onset, contralateral recurrence, aggressive disease form and ovarian cancer presentation), could be managed if the disease is diagnosed at an early age and if adequate therapeutic and preventive measures are taken.\u003C/p>\r\n\u003Cp class=\"mb15\">In the current study, beyond the recurrent founder c.211dupA mutation, a novel private \u003Ci>BRCA1\u003C/i> mutation, c.2418dupA, was identified in a breast cancer patient from the North-East of Tunisia, using targeted gene sequencing. This mutation has never been reported in previous published studies neither in Tunisia nor in other populations. Furthermore, it is not described in the gnomAD database. However, it is listed and classified in ClinVar as pathogenic. This frameshift mutation is located in \u003Ci>BRCA1\u003C/i> exon 11 that binds important homologous recombination proteins including RAD50 and RAD51. Recent studies showed that \u003Ci>BRCA1\u003C/i>-exon 11 constitutes an Ovarian Cancer Clustering Region (OCCR) since mutations located in this region are more associated with ovarian cancer risk than breast cancer (\u003Ca href=\"#B66\">Orr and Savage, 2015\u003C/a>; \u003Ca href=\"#B70\">Rebbeck et al., 2015\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Using whole exome sequencing, we also identified a rare exonic VUS on \u003Ci>RAD50\u003C/i> (c.3647C &#x003E; G, rs1314725075, MAF = 4.061 &#x00D7; 10\u003Csup>&#x2013;06\u003C/sup>) in a breast cancer patient originating also from the North Eastern Tunisian region. Accumulating evidence indicates that \u003Ci>RAD50\u003C/i> is a breast cancer susceptibility gene associated with genomic instability (\u003Ca href=\"#B35\">Heikkinen et al., 2003\u003C/a>, \u003Ca href=\"#B36\">2006\u003C/a>; \u003Ca href=\"#B38\">Hsu et al., 2007\u003C/a>; \u003Ca href=\"#B22\">Damiola et al., 2014\u003C/a>; \u003Ca href=\"#B44\">Kleibl and Kristensen, 2016\u003C/a>; \u003Ca href=\"#B43\">Kim et al., 2017\u003C/a>; \u003Ca href=\"#B9\">Bian et al., 2019\u003C/a>). Indeed, RAD50 is part of the MRE11/RAD50/NBN (MRN) complex that plays a key role in detecting DNA double-strand breaks, recruiting and activating Ataxia-Telangiectasia Mutated protein (ATM) and in processing the DNA repair pathway (\u003Ca href=\"#B9\">Bian et al., 2019\u003C/a>; \u003Ca href=\"#B85\">Situ et al., 2019\u003C/a>). Mutations in one or more genes forming this complex may lead to hypersensitivity to genotoxic agents and predisposition to malignancy (\u003Ca href=\"#B9\">Bian et al., 2019\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">\u003Ci>In silico\u003C/i> analysis at the sequence and structure levels of hRAD50 protein suggest a deleterious impact of the substitution p.Ala1216Gly. The fact that the amino acid Ala is highly conserved in different distantly related orthologous sequences indicates a high positive selective pressure at that position suggesting, therefore, its functional importance for hRAD50. In addition, A1216 is located in the protein core as part of an &#x03B1;-helix segment that stabilizes the binding sites of ATP. Alanine residue, in particular, is the most stabilizing amino acid for helical secondary structures (\u003Ca href=\"#B82\">Serrano et al., 1992\u003C/a>; \u003Ca href=\"#B52\">Lopez-Llano et al., 2006\u003C/a>). A mutation to glycine, however, would be highly destabilizing for the entire &#x03B1;-helix and consequently for the ATP binding site. Non-capping &#x03B1;-helical Glycine may introduce a significant conformational degree of freedom due to its simple side chain and therefore introduce more flexibility to its local environment. Indeed, Alanine to Glycine mutations were found to have a significant increase in the stabilizing energy of an &#x03B1; helix of 0.4-2 kcal mol\u003Csup>&#x2013;1\u003C/sup> (\u003Ca href=\"#B82\">Serrano et al., 1992\u003C/a>) and in the increase in its local flexibility. Interestingly, the simulation revealed a putative outcome on the interaction of hRAD50 with MRE11 since several residues of the protein-protein interface showed an increase in the local flexibility that need to be investigated further.\u003C/p>\r\n\u003Cp class=\"mb15\">Moreover, RAD50 is involved in DNA double-stranded break (DSB) repair by homologous recombination (HR). Recent evidence showed that ovarian cancer patients with a homologous recombination deficiency phenotype (HRD) caused by germline and/or somatic mutations on HR genes exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors (\u003Ca href=\"#B59\">Mateo et al., 2019\u003C/a>). However, based on the latest guidelines released by the American Society of Clinical Oncology (ASCO), clinical decisions for ovarian cancer patients should not be based on VUSs identified on HRD genes (\u003Ca href=\"#B46\">Konstantinopoulos et al., 2020\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Therefore, re-evaluating the clinical relevance of VUS identified on HR genes such as the \u003Ci>RAD50\u003C/i> variant characterized in this current study (c.3647C &#x003E; G) is of keen interest to improve the clinical interpretation of this category of variants and their potential use in precision oncology practice. Indeed, Bope et al., investigated the \u003Ci>in silico\u003C/i> mutation prediction of variants in African genomes and propose recommendations for re-evaluating the pathogenicity of actionable variants used in research and clinical practice (\u003Ca href=\"#B10\">Bope et al., 2019\u003C/a>). In addition, Dorschener et al., analyzed actionable pathogenic variants in 500 European and 500 African descent using exome data (\u003Ca href=\"#B24\">Dorschner et al., 2013\u003C/a>). The results showed major disparities in Africans with an estimated frequency of around 3.4% for those with European origin and 1.2% for those with African descent. \u003Ca href=\"#B58\">Manrai et al. (2016)\u003C/a> reported a study on patients that were misdiagnosed with hypertrophic cardiomyopathy due to lack of access to non-European data. Indeed, patients from African or unspecified ancestry received positive reports with variants misclassified as pathogenic. Authors concluded that the inclusion of even a small number of African-Americans in control cohorts probably would have prevented this misclassification and misdiagnosis. Therefore, based on this evidence and on the results of our current study, we propose to update the classification of the \u003Ci>RAD50\u003C/i> c.3647C &#x003E; G mutation and maybe reclassifying it as &#x201C;likely pathogenic variant.&#x201D;\u003C/p>\r\n\u003Cp class=\"mb15\">For this same patient, a missense variant associated with PARP inhibitor response, rs28908468, has been identified on \u003Ci>RAD51B\u003C/i>, which is a paralog of \u003Ci>RAD51\u003C/i> that has an important role in DNA damage response. Indeed, it was demonstrated that RAD51 is a functional biomarker that enables the identification of PARP inhibitors-sensitive breast cancer cases (\u003Ca href=\"#B14\">Castroviejo-Bermejo et al., 2018\u003C/a>; \u003Ca href=\"#B21\">Cruz et al., 2018\u003C/a>). The \u003Ci>RAD51B\u003C/i> variant was clearly classified by an expert panel in ClinVar as a variant that affects only the drug response. However, for the \u003Ci>RAD50\u003C/i> variant, evidence of the pathogenicity was conflicting. Indeed, expert panel evaluation according to the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines for the interpretation of sequence variants, showed that this variant is of Uncertain Significance (VUS). Thus, we have made an extensive \u003Ci>in silico\u003C/i> analysis that suggested the need to revise its annotation status.\u003C/p>\r\n\u003Cp class=\"mb15\">After investigating known breast cancer genes, we extended our analysis to other genes not yet reported as associated with breast carcinoma. Eleven candidate genes were selected based on several filters, namely: \u003Ci>MITF, COL7A1, FOXM1, TSHZ2, AMOTL2, ANKS6, ACACB, LIPE, SNRK, CACNA2D3\u003C/i>, and \u003Ci>SMG1.\u003C/i> Only two variants identified on these genes were listed in ClinVar including one VUS found on \u003Ci>ANKS6\u003C/i> gene (rs199722684) and a variant of &#x201C;conflicting interpretations of pathogenicity&#x201D; identified on \u003Ci>MITF\u003C/i> gene (rs149617956).\u003C/p>\r\n\u003Cp class=\"mb15\">Mutations in \u003Ci>ANKS6\u003C/i> are known to cause a nephronophthisis-like phenotype (\u003Ca href=\"#B89\">Taskiran et al., 2014\u003C/a>). Based on Cancer Genetic Markers of Susceptibility breast cancer study (CGEMS), 3 SNPs located between \u003Ci>ANKS6\u003C/i> and \u003Ci>GALNT12\u003C/i> were identified as significantly associated with breast cancer (\u003Ca href=\"#B37\">Higginbotham et al., 2012\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">\u003Ci>MITF\u003C/i> is associated with development, differentiation, survival and cell cycle regulation. Recent studies showed that the same mutation (rs149617956, E318K) identified on \u003Ci>MITF\u003C/i>, has been reported as associated with a high risk of melanoma, renal cell carcinoma and pancreatic cancer (\u003Ca href=\"#B32\">Gromowski et al., 2014\u003C/a>; \u003Ca href=\"#B88\">Sturm et al., 2014\u003C/a>). The potential association between E318K and the risk of developing other malignancies such as breast carcinoma has been evaluated by Gromowski et al. Authors concluded that E318K is very rare in breast cancer patients (\u003Ca href=\"#B32\">Gromowski et al., 2014\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">Here we also identified 4 candidate CNVs disrupting 5 genes associated with several carcinomas and involved in interesting biological pathways namely \u003Ci>BCL3, COL7A1, RNF5, CEP290\u003C/i> and \u003Ci>TMTC3.\u003C/i> The screening of these CNVs could be considered particularly in breast cancer patients&#x2019; non-carriers of pathogenic point mutations.\u003C/p>\r\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Conclusion\u003C/h2>\r\n\u003Cp class=\"mb0\">The identification of founder and novel private mutations on \u003Ci>BRCA1/2\u003C/i> as well as functional variants on genes involved in the homologous recombination pathway has significant impact on genetic screening and clinical management of breast and ovarian cancer patients. Our findings also highlight the importance of the use of NGS technologies in detecting novel mutations involved in breast cancer susceptibility in under-investigated populations. \u003Ci>In silico\u003C/i> analyses that were performed in this study on \u003Ci>RAD50\u003C/i>-c.3647C &#x003E; G variant classified as VUS in ClinVar suggests a re-evaluation of the current classifications of several variants in public databases. Such a reconsideration would improve criteria of pathogenicity assessment by studying African populations, in particular, North Africans that are still poorly investigated.\u003C/p>\r\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\r\n\u003Cp class=\"mb0\">The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.\u003C/p>\r\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Ethics Statement\u003C/h2>\r\n\u003Cp class=\"mb0\">The study was conducted according to the declaration of Helsinki and with the approval of the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#x00F4;pital A-M). Written informed consent was obtained from the participants in this study for the publication of any potentially identifiable images or data included in this article.\u003C/p>\r\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\r\n\u003Cp class=\"mb0\">NaM did the experiments, analysis, and data interpretation, and drafted the manuscript. YH and MB did analysis and data interpretation, and reviewed the manuscript. MBR contributed in data analysis. SBN, HE, NeM, SL, JA, OJ, HanB, RM, AH, and KR contributed to clinical investigation of patients. HO performed the \u003Ci>in silico\u003C/i> analyses and reviewed the manuscript. YH and SA contributed to study concept and design. YH, HamB, SB, and SA critically revised the manuscript. YH and SA supervised the study. All authors read and approved the final manuscript.\u003C/p>\r\n\u003Ca id=\"fun1\" name=\"fun1\">\u003C/a>\u003Ch2>Funding\u003C/h2>\r\n\u003Cp class=\"mb0\">This work was supported by the Tunisian Ministry of Higher Education and Scientific Research (LR16IPT05) and the Tunisian Ministry of Public Health (PEC-4-TUN). MB and MBR are recipient of a MOBIDOC fellowship funded by the EU through the EMORI and PASRI programs managed by the ANPR.\u003C/p>\r\n\u003Ca id=\"conf1\" name=\"conf1\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\r\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\r\n\u003Ca id=\"ack1\" name=\"ack1\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\r\n\u003Cp class=\"mb0\">We are grateful to all participants and their family members for their participation in the study.\u003C/p>\r\n\u003Ca id=\"S11\" name=\"S11\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\r\n\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fgene.2020.552971/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fgene.2020.552971/full#supplementary-material\u003C/a>\u003C/p>\r\n\u003Cp class=\"mb15\" id=\"FS1\">\u003Cb>Supplementary Figure 1 &#x007C;\u003C/b> Diagram of the Short Tandem Repeats used for the haplotype analysis. This map is based on the information provided by UniSTS, UCSC. The location and order of the loci used in the present study, as well as their physical and genetic positions are shown. These data are extracted from the Marshfield genetic map (Marshfield Center for Medical Genetics).\u003C/p>\r\n\u003Cp class=\"mb0\" id=\"FS2\">\u003Cb>Supplementary Figure 2 &#x007C;\u003C/b> Assessment of the stereochemical \u003Cb>(A)\u003C/b> and local \u003Cb>(B)\u003C/b> qualities of hRAD50 homology model in comparison with the template structure by establishing the Ramachandran Plot and the Verif3D profile respectively.\u003C/p>\r\n\u003Ca id=\"abbr1\" name=\"abbr1\">\u003C/a>\u003Ch2>Abbreviations\u003C/h2>\r\n\u003Cp class=\"mb0\">ACMG, American College of Medical Genetics and Genomics; ATM, ataxia-telangiectasia mutated protein; CNVs, copy number variations; DNA, deoxyribonucleic acid; DSB, double-stranded break; HER2, human epidermal growth factor receptor 2; HR, homologous recombination; HRD, homologous recombination deficiency phenotype; IDC, intraductal carcinoma; InDels, insertions and deletions; INS, Institute of Statistics; KEGG, kyoto encyclopedia of genes and genomes; MAF, minor allele frequency; MRN, MRE11/RAD50/NBN; NCG, network of cancer genes; NGS, next generation sequencing; OCCR, ovarian cancer clustering region; PARP, poly (ADP-ribose) polymerase; PCR, polymerase chain reaction; PDB, protein data bank; RMSF, root mean square fluctuation; SBR, Scarff-Bloom and Richardson; SNP, single nucleotide polymorphism; SV, structural variations; TGS, target gene sequencing; TNBC, triple negative breast cancer; VarAFT, variant annotation and filtering tool; VUS, variant of unknown significance; WES, whole exome sequencing.\u003C/p>\r\n\u003Ca id=\"FNT1\" name=\"FNT1\">\u003C/a>\u003Ch2>Footnotes\u003C/h2>\r\n\u003Col>\r\n\u003Cli id=\"footnote1\">\u003Cstrong>\u003Ca style=\"color:gray;\" class=\"footnotetextanchor\" href=\"#footnote1a\" title=\"\">^\u003C/a>\u003C/strong> \u003Ca style=\"color:gray;\" href=\"http://www.ins.nat.tn\">www.ins.nat.tn\u003C/a>\u003C/li>\r\n\u003C/ol>\r\n\u003Ca id=\"refer1\" name=\"refer1\">\u003C/a>\u003Ch2>References\u003C/h2>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a>Akter, H., Sultana, N., Martuza, N., Siddiqua, A., Dity, N. J., Rahaman, M. A., et al. (2019). Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. \u003Ci>BMC Med. Genet.\u003C/i> 20:150.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Novel+mutations+in+actionable+breast+cancer+genes+by+targeted+sequencing+in+an+ethnically+homogenous+cohort%2E&#x0026;journal=BMC+Med%2E+Genet%2E&#x0026;author=Akter+H.&#x0026;author=Sultana+N.&#x0026;author=Martuza+N.&#x0026;author=Siddiqua+A.&#x0026;author=Dity+N.+J.&#x0026;author=Rahaman+M.+A.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=150\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a>Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. \u003Ci>J. Mol. Biol.\u003C/i> 215, 403&#x2013;410.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Basic+local+alignment+search+tool%2E&#x0026;journal=J%2E+Mol%2E+Biol%2E&#x0026;author=Altschul+S.+F.&#x0026;author=Gish+W.&#x0026;author=Miller+W.&#x0026;author=Myers+E.+W.&#x0026;author=Lipman+D.+J.&#x0026;publication_year=1990&#x0026;volume=215&#x0026;pages=403&#x2013;410\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a>Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. \u003Ci>Am. J. Hum. Genet.\u003C/i> 72, 1117&#x2013; 1130.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Average+risks+of+breast+and+ovarian+cancer+associated+with+BRCA1+or+BRCA2+mutations+detected+in+case+series+unselected+for+family+history%3A+a+combined+analysis+of+22+studies%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Antoniou+A.&#x0026;author=Pharoah+P.+D.&#x0026;author=Narod+S.&#x0026;author=Risch+H.+A.&#x0026;author=Eyfjord+J.+E.&#x0026;author=Hopper+J.+L.&#x0026;publication_year=2003&#x0026;volume=72&#x0026;pages=1117&#x2013; 1130\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a>Armes, J. E., Egan, A. M., Southey, M. C., Dite, G. S., McCredie, M. R., Giles, G. G., et al. (1998). The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. \u003Ci>Cancer Interdiscip. Int. J. Am. Cancer Soc.\u003C/i> 83, 2335&#x2013;2345. doi: 10.1002/(sici)1097-0142(19981201)83:11&#x003C;2335::aid-cncr13&#x003E;3.0.co;2-n\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1002/(sici)1097-0142(19981201)83:11&#x003C;2335::aid-cncr13&#x003E;3.0.co;2-n\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+histologic+phenotypes+of+breast+carcinoma+occurring+before+age+40+years+in+women+with+and+without+BRCA1+or+BRCA2+germline+mutations%3A+a+population-based+study%2E&#x0026;journal=Cancer+Interdiscip%2E+Int%2E+J%2E+Am%2E+Cancer+Soc%2E&#x0026;author=Armes+J.+E.&#x0026;author=Egan+A.+M.&#x0026;author=Southey+M.+C.&#x0026;author=Dite+G.+S.&#x0026;author=McCredie+M.+R.&#x0026;author=Giles+G.+G.&#x0026;publication_year=1998&#x0026;volume=83&#x0026;pages=2335&#x2013;2345\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a>Bai, J., Zhang, X., Kang, X., Jin, L., Wang, P., and Wang, Z. (2019). Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets. \u003Ci>Oncol. Lett.\u003C/i> 18, 5821&#x2013;5830.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Screening+of+core+genes+and+pathways+in+breast+cancer+development+via+comprehensive+analysis+of+multi+gene+expression+datasets%2E&#x0026;journal=Oncol%2E+Lett%2E&#x0026;author=Bai+J.&#x0026;author=Zhang+X.&#x0026;author=Kang+X.&#x0026;author=Jin+L.&#x0026;author=Wang+P.&#x0026;author=Wang+Z.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=5821&#x2013;5830\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a>Bektas, N., Ten Haaf, A., Veeck, J., Wild, P. J., &#x00FC;scher-Firzlaff, J. L., Hartmann, A., et al. (2008). Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. \u003Ci>BMC Cancer\u003C/i> 8:42.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Tight+correlation+between+expression+of+the+Forkhead+transcription+factor+FOXM1+and+HER2+in+human+breast+cancer%2E&#x0026;journal=BMC+Cancer&#x0026;author=Bektas+N.&#x0026;author=Ten+Haaf+A.&#x0026;author=Veeck+J.&#x0026;author=Wild+P.+J.&#x0026;author=&#x00FC;scher-Firzlaff+J.+L.&#x0026;author=Hartmann+A.&#x0026;publication_year=2008&#x0026;volume=8&#x0026;issue=42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a>Berman, H., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T., Weissig, H., et al. (2000). RCSB protein data bank: structural biology views for basic and applied research. \u003Ci>Nucleic Acids Res.\u003C/i> 28, 235&#x2013;242.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=RCSB+protein+data+bank%3A+structural+biology+views+for+basic+and+applied+research%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Berman+H.&#x0026;author=Westbrook+J.&#x0026;author=Feng+Z.&#x0026;author=Gilliland+G.&#x0026;author=Bhat+T.&#x0026;author=Weissig+H.&#x0026;publication_year=2000&#x0026;volume=28&#x0026;pages=235&#x2013;242\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a>Bewicke-Copley, F., Kumar, E. A., Palladino, G., Korfi, K., and Wang, J. (2019). Applications and analysis of targeted genomic sequencing in cancer studies. \u003Ci>Comput. Struct. Biotechnol. J.\u003C/i> 17, 1348&#x2013;1359. doi: 10.1016/j.csbj.2019.10.004\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31762958\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.csbj.2019.10.004\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Applications+and+analysis+of+targeted+genomic+sequencing+in+cancer+studies%2E&#x0026;journal=Comput%2E+Struct%2E+Biotechnol%2E+J%2E&#x0026;author=Bewicke-Copley+F.&#x0026;author=Kumar+E.+A.&#x0026;author=Palladino+G.&#x0026;author=Korfi+K.&#x0026;author=Wang+J.&#x0026;publication_year=2019&#x0026;volume=17&#x0026;pages=1348&#x2013;1359\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a>Bian, L., Meng, Y., Zhang, M., and Li, D. (2019). MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. \u003Ci>Mol. Cancer\u003C/i> 18, 1&#x2013;14. doi: 10.1002/9783527678679.dg07931\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1002/9783527678679.dg07931\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=MRE11-RAD50-NBS1+complex+alterations+and+DNA+damage+response%3A+implications+for+cancer+treatment%2E&#x0026;journal=Mol%2E+Cancer&#x0026;author=Bian+L.&#x0026;author=Meng+Y.&#x0026;author=Zhang+M.&#x0026;author=Li+D.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=1&#x2013;14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a>Bope, C. D., Chimusa, E. R., Nembaware, V., Mazandu, G. K., de Vries, J., and Wonkam, A. (2019). Dissecting in silico mutation prediction of variants in african genomes: challenges and perspectives. \u003Ci>Front. Genet.\u003C/i> 10:601.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Dissecting+in+silico+mutation+prediction+of+variants+in+african+genomes%3A+challenges+and+perspectives%2E&#x0026;journal=Front%2E+Genet%2E&#x0026;author=Bope+C.+D.&#x0026;author=Chimusa+E.+R.&#x0026;author=Nembaware+V.&#x0026;author=Mazandu+G.+K.&#x0026;author=de+Vries+J.&#x0026;author=Wonkam+A.&#x0026;publication_year=2019&#x0026;volume=10&#x0026;issue=601\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a>Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. \u003Ci>CA Cancer J. Clin.\u003C/i> 68, 394&#x2013;424. doi: 10.3322/caac.21492\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30207593\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21492\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries%2E&#x0026;journal=CA+Cancer+J%2E+Clin%2E&#x0026;author=Bray+F.&#x0026;author=Ferlay+J.&#x0026;author=Soerjomataram+I.&#x0026;author=Siegel+R.+L.&#x0026;author=Torre+L.+A.&#x0026;author=Jemal+A.&#x0026;publication_year=2018&#x0026;volume=68&#x0026;pages=394&#x2013;424\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a>Bromberg, K. D., Kluger, H. M., Delaunay, A., Abbas, S., DiVito, K. A., Krajewski, S., et al. (2007). Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. \u003Ci>Cancer Res.\u003C/i> 67, 8172&#x2013;8179. doi: 10.1158/0008-5472.can-07-0045\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17804730\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/0008-5472.can-07-0045\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Increased+expression+of+the+E3+ubiquitin+ligase+RNF5+is+associated+with+decreased+survival+in+breast+cancer%2E&#x0026;journal=Cancer+Res%2E&#x0026;author=Bromberg+K.+D.&#x0026;author=Kluger+H.+M.&#x0026;author=Delaunay+A.&#x0026;author=Abbas+S.&#x0026;author=DiVito+K.+A.&#x0026;author=Krajewski+S.&#x0026;publication_year=2007&#x0026;volume=67&#x0026;pages=8172&#x2013;8179\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a>Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., et al. (2012). Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. \u003Ci>Breast Cancer Res.\u003C/i> 14:R110.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Results+of+a+phase+II+open-label%2C+non-randomized+trial+of+cisplatin+chemotherapy+in+patients+with+BRCA1-positive+metastatic+breast+cancer%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Byrski+T.&#x0026;author=Dent+R.&#x0026;author=Blecharz+P.&#x0026;author=Foszczynska-Kloda+M.&#x0026;author=Gronwald+J.&#x0026;author=Huzarski+T.&#x0026;publication_year=2012&#x0026;volume=14&#x0026;issue=R110\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a>Castroviejo-Bermejo, M., Cruz, C., Llop-Guevara, A., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Ducy, M., Ibrahim, Y. H., et al. (2018). A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. \u003Ci>EMBO Mol. Med.\u003C/i> 10:e9172.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+RAD+51+assay+feasible+in+routine+tumor+samples+calls+PARP+inhibitor+response+beyond+BRCA+mutation%2E&#x0026;journal=EMBO+Mol%2E+Med%2E&#x0026;author=Castroviejo-Bermejo+M.&#x0026;author=Cruz+C.&#x0026;author=Llop-Guevara+A.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Ducy+M.&#x0026;author=Ibrahim+Y.+H.&#x0026;publication_year=2018&#x0026;volume=10&#x0026;issue=e9172\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a>Chalabi, N., Bernard-Gallon, D., Bignon, Y.-J., agier, M., Vidal, V., Laplace-Chabaud, V., et al. (2008). Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. \u003Ci>Cancer Genomics Proteomics\u003C/i> 5, 253&#x2013;261.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+clinical+and+transcriptomal+profiles+of+breast+cancer+between+French+and+South+Mediterranean+patients+show+minor+but+significative+biological+differences%2E&#x0026;journal=Cancer+Genomics+Proteomics&#x0026;author=Chalabi+N.&#x0026;author=Bernard-Gallon+D.&#x0026;author=Bignon+Y.-J.&#x0026;author=agier+M.&#x0026;author=Vidal+V.&#x0026;author=Laplace-Chabaud+V.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;pages=253&#x2013;261\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a>Chan, T. A., Glockner, S., Yi, J. M., Chen, W., Van Neste, L., Cope, L., et al. (2008). Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. \u003Ci>PLoS Med.\u003C/i> 5:e114. doi: 10.1371/journal.pmed.0050114\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18507500\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pmed.0050114\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Convergence+of+mutation+and+epigenetic+alterations+identifies+common+genes+in+cancer+that+predict+for+poor+prognosis%2E&#x0026;journal=PLoS+Med%2E&#x0026;author=Chan+T.+A.&#x0026;author=Glockner+S.&#x0026;author=Yi+J.+M.&#x0026;author=Chen+W.&#x0026;author=Van+Neste+L.&#x0026;author=Cope+L.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;issue=e114\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a>Chandler, M. R., Bilgili, E. P., and Merner, N. D. (2016). A review of whole-exome sequencing efforts toward hereditary breast cancer susceptibility gene discovery. \u003Ci>Hum. Mutat.\u003C/i> 37, 835&#x2013;846. doi: 10.1002/humu.23017\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27226120\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23017\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+review+of+whole-exome+sequencing+efforts+toward+hereditary+breast+cancer+susceptibility+gene+discovery%2E&#x0026;journal=Hum%2E+Mutat%2E&#x0026;author=Chandler+M.+R.&#x0026;author=Bilgili+E.+P.&#x0026;author=Merner+N.+D.&#x0026;publication_year=2016&#x0026;volume=37&#x0026;pages=835&#x2013;846\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a>Cherbal, F., Bakour, R., Adane, S., Boualga, K., Benais-Pont, G., and Maillet, P. (2010). BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. \u003Ci>Dis. Mark.\u003C/i> 28, 377&#x2013;384.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+germline+mutations+screening+in+Algerian+breast%2Fovarian+cancer+families%2E&#x0026;journal=Dis%2E+Mark%2E&#x0026;author=Cherbal+F.&#x0026;author=Bakour+R.&#x0026;author=Adane+S.&#x0026;author=Boualga+K.&#x0026;author=Benais-Pont+G.&#x0026;author=Maillet+P.&#x0026;publication_year=2010&#x0026;volume=28&#x0026;pages=377&#x2013;384\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a>Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., et al. (2015). Tailoring therapies&#x2014;improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. \u003Ci>Ann. Oncol.\u003C/i> 26, 1533&#x2013;1546.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Tailoring+therapies&#x2014;improving+the+management+of+early+breast+cancer%3A+St+Gallen+international+expert+consensus+on+the+primary+therapy+of+early+breast+cancer+2015%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Coates+A.+S.&#x0026;author=Winer+E.+P.&#x0026;author=Goldhirsch+A.&#x0026;author=Gelber+R.+D.&#x0026;author=Gnant+M.&#x0026;author=Piccart-Gebhart+M.&#x0026;publication_year=2015&#x0026;volume=26&#x0026;pages=1533&#x2013;1546\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a>The Uniport Consortium (2019). UniProt: a worldwide hub of protein knowledge. \u003Ci>Nucleic Acids Res.\u003C/i> 47, D506&#x2013;D515.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=UniProt%3A+a+worldwide+hub+of+protein+knowledge%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;publication_year=2019&#x0026;volume=47&#x0026;pages=D506&#x2013;D515\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a>Cruz, C., Castroviejo-Bermejo, M., Guti&#x00E9;rrez-Enr&#x00ED;quez, S., Llop-Guevara, A., Ibrahim, Y., Gris-Oliver, A., et al. (2018). RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. \u003Ci>Ann. Oncol.\u003C/i> 29, 1203&#x2013;1210. doi: 10.1093/annonc/mdy099\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29635390\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdy099\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=RAD51+foci+as+a+functional+biomarker+of+homologous+recombination+repair+and+PARP+inhibitor+resistance+in+germline+BRCA-mutated+breast+cancer%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Cruz+C.&#x0026;author=Castroviejo-Bermejo+M.&#x0026;author=Guti&#x00E9;rrez-Enr&#x00ED;quez+S.&#x0026;author=Llop-Guevara+A.&#x0026;author=Ibrahim+Y.&#x0026;author=Gris-Oliver+A.&#x0026;publication_year=2018&#x0026;volume=29&#x0026;pages=1203&#x2013;1210\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a>Damiola, F., Pertesi, M., Oliver, J., Calvez-Kelm, F. Le, Voegele, C., Young, E. L., et al. (2014). Rare key functional domain missense substitutions in MRE11A, RAD50, and NBNcontribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. \u003Ci>Breast Cancer Res.\u003C/i> 16:R58.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Rare+key+functional+domain+missense+substitutions+in+MRE11A%2C+RAD50%2C+and+NBNcontribute+to+breast+cancer+susceptibility%3A+results+from+a+Breast+Cancer+Family+Registry+case-control+mutation-screening+study%2E&#x0026;journal=Breast+Cancer+Res%2E&#x0026;author=Damiola+F.&#x0026;author=Pertesi+M.&#x0026;author=Oliver+J.&#x0026;author=Calvez-Kelm+F.+Le+Voegele+C.&#x0026;author=Young+E.+L.&#x0026;publication_year=2014&#x0026;volume=16&#x0026;issue=R58\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a>Desvignes, J.-P., Bartoli, M., Delague, V., Krahn, M., Miltgen, M., B&#x00E9;roud, C., et al. (2018). VarAFT: a variant annotation and filtration system for human next generation sequencing data. \u003Ci>Nucleic Acids Res.\u003C/i> 46, W545&#x2013;W553.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=VarAFT%3A+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Desvignes+J.-P.&#x0026;author=Bartoli+M.&#x0026;author=Delague+V.&#x0026;author=Krahn+M.&#x0026;author=Miltgen+M.&#x0026;author=B&#x00E9;roud+C.&#x0026;publication_year=2018&#x0026;volume=46&#x0026;pages=W545&#x2013;W553\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a>Dorschner, M. O., Amendola, L. M., Turner, E. H., Robertson, P. D., Shirts, B. H., Gallego, C. J., et al. (2013). Actionable, pathogenic incidental findings in 1,000 participants&#x2019; exomes. \u003Ci>Am. J. Hum. Genet.\u003C/i> 93, 631&#x2013;640. doi: 10.1016/j.ajhg.2013.08.006\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24055113\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ajhg.2013.08.006\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Actionable%2C+pathogenic+incidental+findings+in+1%2C000+participants&#x2019;+exomes%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Dorschner+M.+O.&#x0026;author=Amendola+L.+M.&#x0026;author=Turner+E.+H.&#x0026;author=Robertson+P.+D.&#x0026;author=Shirts+B.+H.&#x0026;author=Gallego+C.+J.&#x0026;publication_year=2013&#x0026;volume=93&#x0026;pages=631&#x2013;640\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a>Ebbert, M. T., Wadsworth, M. E., Staley, L. A., Hoyt, K. L., Pickett, B., Miller, J., et al. (2016). Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches. \u003Ci>BMC Bioinformatics\u003C/i> 17:239.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Evaluating+the+necessity+of+PCR+duplicate+removal+from+next-generation+sequencing+data+and+a+comparison+of+approaches%2E&#x0026;journal=BMC+Bioinformatics&#x0026;author=Ebbert+M.+T.&#x0026;author=Wadsworth+M.+E.&#x0026;author=Staley+L.+A.&#x0026;author=Hoyt+K.+L.&#x0026;author=Pickett+B.&#x0026;author=Miller+J.&#x0026;publication_year=2016&#x0026;volume=17&#x0026;issue=239\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a>Fackenthal, J. D., and Olopade, O. I. (2007). Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. \u003Ci>Nat. Rev. Cancer\u003C/i> 7:937. doi: 10.1038/nrc2054\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18034184\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc2054\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+cancer+risk+associated+with+BRCA1+and+BRCA2+in+diverse+populations%2E&#x0026;journal=Nat%2E+Rev%2E+Cancer&#x0026;author=Fackenthal+J.+D.&#x0026;author=Olopade+O.+I.&#x0026;publication_year=2007&#x0026;volume=7&#x0026;issue=937\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a>Ford, D., Easton, D., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. \u003Ci>Am. J. Hum. Genet.\u003C/i> 62, 676&#x2013;689.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+heterogeneity+and+penetrance+analysis+of+the+BRCA1+and+BRCA2+genes+in+breast+cancer+families%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Ford+D.&#x0026;author=Easton+D.&#x0026;author=Stratton+M.&#x0026;author=Narod+S.&#x0026;author=Goldgar+D.&#x0026;author=Devilee+P.&#x0026;publication_year=1998&#x0026;volume=62&#x0026;pages=676&#x2013;689\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a>Fourati, A., Louchez, M.-M., Fournier, J., Gamoudi, A., Rahal, K., El May, M.-V., et al. (2014). Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. \u003Ci>Bull. Cancer\u003C/i> 101, E36&#x2013;E40.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Screening+for+common+mutations+in+BRCA1+and+BRCA2+genes%3A+interest+in+genetic+testing+of+Tunisian+families+with+breast+and%2For+ovarian+cancer%2E&#x0026;journal=Bull%2E+Cancer&#x0026;author=Fourati+A.&#x0026;author=Louchez+M.-M.&#x0026;author=Fournier+J.&#x0026;author=Gamoudi+A.&#x0026;author=Rahal+K.&#x0026;author=El+May+M.-V.&#x0026;publication_year=2014&#x0026;volume=101&#x0026;pages=E36&#x2013;E40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a>Gao, Y., Xuan, C., Jin, M., An, Q., Zhuo, B., Chen, X., et al. (2019). Ubiquitin ligase RNF5 serves an important role in the development of human glioma. \u003Ci>Oncol. Lett.\u003C/i> 18, 4659&#x2013;4666.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Ubiquitin+ligase+RNF5+serves+an+important+role+in+the+development+of+human+glioma%2E&#x0026;journal=Oncol%2E+Lett%2E&#x0026;author=Gao+Y.&#x0026;author=Xuan+C.&#x0026;author=Jin+M.&#x0026;author=An+Q.&#x0026;author=Zhuo+B.&#x0026;author=Chen+X.&#x0026;publication_year=2019&#x0026;volume=18&#x0026;pages=4659&#x2013;4666\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a>Geoffroy, V., Herenger, Y., Kress, A., Stoetzel, C., Piton, A., Dollfus, H., et al. (2018). AnnotSV: an integrated tool for structural variations annotation. \u003Ci>Bioinformatics\u003C/i> 34, 3572&#x2013;3574. doi: 10.1093/bioinformatics/bty304\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29669011\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/bty304\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=AnnotSV%3A+an+integrated+tool+for+structural+variations+annotation%2E&#x0026;journal=Bioinformatics&#x0026;author=Geoffroy+V.&#x0026;author=Herenger+Y.&#x0026;author=Kress+A.&#x0026;author=Stoetzel+C.&#x0026;author=Piton+A.&#x0026;author=Dollfus+H.&#x0026;publication_year=2018&#x0026;volume=34&#x0026;pages=3572&#x2013;3574\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a>Golmard, L., Delnatte, C., Laug&#x00E9;, A., Moncoutier, V., Lefol, C., Abidallah, K., et al. (2016). Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. \u003Ci>Oncogene\u003C/i> 35:1324.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+and+ovarian+cancer+predisposition+due+to+de+novo+BRCA1+and+BRCA2+mutations%2E&#x0026;journal=Oncogene&#x0026;author=Golmard+L.&#x0026;author=Delnatte+C.&#x0026;author=Laug&#x00E9;+A.&#x0026;author=Moncoutier+V.&#x0026;author=Lefol+C.&#x0026;author=Abidallah+K.&#x0026;publication_year=2016&#x0026;volume=35&#x0026;issue=1324\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a>Gromowski, T., Masoj&#x00E6;, B., Scott, R. J., Cybulski, C., G&#x00F3;rski, B., Klu&#x017A;niak, W., et al. (2014). Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study. \u003Ci>Cancer Genet.\u003C/i> 207, 128&#x2013;132. doi: 10.1016/j.cancergen.2014.03.003\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24767713\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cancergen.2014.03.003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Prevalence+of+the+E318K+and+V320I+MITF+germline+mutations+in+Polish+cancer+patients+and+multiorgan+cancer+risk-a+population-based+study%2E&#x0026;journal=Cancer+Genet%2E&#x0026;author=Gromowski+T.&#x0026;author=Masoj&#x00E6;+B.&#x0026;author=Scott+R.+J.&#x0026;author=Cybulski+C.&#x0026;author=G&#x00F3;rski+B.&#x0026;author=Klu&#x017A;niak+W.&#x0026;publication_year=2014&#x0026;volume=207&#x0026;pages=128&#x2013;132\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a>Han, M.-R., Long, J., Choi, J.-Y., Low, S.-K., Kweon, S.-S., Zheng, Y., et al. (2016). Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci. \u003Ci>Hum. Mol. Genet.\u003C/i> 25, 3361&#x2013;3371.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Genome-wide+association+study+in+East+Asians+identifies+two+novel+breast+cancer+susceptibility+loci%2E&#x0026;journal=Hum%2E+Mol%2E+Genet%2E&#x0026;author=Han+M.-R.&#x0026;author=Long+J.&#x0026;author=Choi+J.-Y.&#x0026;author=Low+S.-K.&#x0026;author=Kweon+S.-S.&#x0026;author=Zheng+Y.&#x0026;publication_year=2016&#x0026;volume=25&#x0026;pages=3361&#x2013;3371\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a>Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P., et al. (1999). Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. \u003Ci>N. Engl. J. Med.\u003C/i> 340, 77&#x2013;84.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Efficacy+of+bilateral+prophylactic+mastectomy+in+women+with+a+family+history+of+breast+cancer%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Hartmann+L.+C.&#x0026;author=Schaid+D.+J.&#x0026;author=Woods+J.+E.&#x0026;author=Crotty+T.+P.&#x0026;author=Myers+J.+L.&#x0026;author=Arnold+P.&#x0026;publication_year=1999&#x0026;volume=340&#x0026;pages=77&#x2013;84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a>Heikkinen, K., Karppinen, S., Soini, Y., M&#x00E4;kinen, M., and Winqvist, R. (2003). Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. \u003Ci>J. Med. Genet.\u003C/i> 40:e131.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Mutation+screening+of+Mre11+complex+genes%3A+indication+of+RAD50+involvement+in+breast+and+ovarian+cancer+susceptibility%2E&#x0026;journal=J%2E+Med%2E+Genet%2E&#x0026;author=Heikkinen+K.&#x0026;author=Karppinen+S.&#x0026;author=Soini+Y.&#x0026;author=M&#x00E4;kinen+M.&#x0026;author=Winqvist+R.&#x0026;publication_year=2003&#x0026;volume=40&#x0026;issue=e131\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a>Heikkinen, K., Rapakko, K., Karppinen, S.-M., Erkko, H., Knuutila, S., Lund&#x00E1;n, T., et al. (2006). RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. \u003Ci>Carcinogenesis\u003C/i> 27, 1593&#x2013;1599. doi: 10.1093/carcin/bgi360\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16474176\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/carcin/bgi360\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=RAD50+and+NBS1+are+breast+cancer+susceptibility+genes+associated+with+genomic+instability%2E&#x0026;journal=Carcinogenesis&#x0026;author=Heikkinen+K.&#x0026;author=Rapakko+K.&#x0026;author=Karppinen+S.-M.&#x0026;author=Erkko+H.&#x0026;author=Knuutila+S.&#x0026;author=Lund&#x00E1;n+T.&#x0026;publication_year=2006&#x0026;volume=27&#x0026;pages=1593&#x2013;1599\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a>Higginbotham, K. S., Breyer, J. P., McReynolds, K. M., Bradley, K. M., Schuyler, P. A., Plummer, W. D., et al. (2012). A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24. \u003Ci>Cancer Epidemiol. Prevention Biomarkers\u003C/i> 21, 1565&#x2013;1573. doi: 10.1158/1055-9965.epi-12-0386\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22806168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.epi-12-0386\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+multistage+genetic+association+study+identifies+breast+cancer+risk+loci+at+10q25+and+16q24%2E&#x0026;journal=Cancer+Epidemiol%2E+Prevention+Biomarkers&#x0026;author=Higginbotham+K.+S.&#x0026;author=Breyer+J.+P.&#x0026;author=McReynolds+K.+M.&#x0026;author=Bradley+K.+M.&#x0026;author=Schuyler+P.+A.&#x0026;author=Plummer+W.+D.&#x0026;publication_year=2012&#x0026;volume=21&#x0026;pages=1565&#x2013;1573\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a>Hsu, H.-M., Wang, H.-C., Chen, S.-T., Hsu, G.-C., Shen, C.-Y., and Yu, J.-C. (2007). Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. \u003Ci>Cancer Epidemiol. Prevention Biomarkers\u003C/i> 16, 2024&#x2013;2032. doi: 10.1158/1055-9965.epi-07-0116\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17932350\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.epi-07-0116\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Breast+cancer+risk+is+associated+with+the+genes+encoding+the+DNA+double-strand+break+repair+Mre11%2FRad50%2FNbs1+complex%2E&#x0026;journal=Cancer+Epidemiol%2E+Prevention+Biomarkers&#x0026;author=Hsu+H.-M.&#x0026;author=Wang+H.-C.&#x0026;author=Chen+S.-T.&#x0026;author=Hsu+G.-C.&#x0026;author=Shen+C.-Y.&#x0026;author=Yu+J.-C.&#x0026;publication_year=2007&#x0026;volume=16&#x0026;pages=2024&#x2013;2032\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a>Jamroz, M., Kolinski, A., and Kmiecik, S. (2014). CABS-flex predictions of protein flexibility compared with NMR ensembles. \u003Ci>Bioinformatics\u003C/i> 30, 2150&#x2013;2154. doi: 10.1093/bioinformatics/btu184\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24735558\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btu184\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=CABS-flex+predictions+of+protein+flexibility+compared+with+NMR+ensembles%2E&#x0026;journal=Bioinformatics&#x0026;author=Jamroz+M.&#x0026;author=Kolinski+A.&#x0026;author=Kmiecik+S.&#x0026;publication_year=2014&#x0026;volume=30&#x0026;pages=2150&#x2013;2154\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a>Janavi&#x010D;ius, R. (2010). Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. \u003Ci>EPMA J.\u003C/i> 1, 397&#x2013;412. doi: 10.1007/s13167-010-0037-y\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23199084\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s13167-010-0037-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Founder+BRCA1%2F2+mutations+in+the+Europe%3A+implications+for+hereditary+breast-ovarian+cancer+prevention+and+control%2E&#x0026;journal=EPMA+J%2E&#x0026;author=Janavi&#x010D;ius+R.&#x0026;publication_year=2010&#x0026;volume=1&#x0026;pages=397&#x2013;412\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a>Jin, Y., Cui, D., Ren, J., Wang, K., Zeng, T., and Gao, L. (2017). CACNA2D3 is downregulated in gliomas and functions as a tumor suppressor. \u003Ci>Mol. Carcinogenesis\u003C/i> 56, 945&#x2013;959. doi: 10.1002/mc.22548\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27583705\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/mc.22548\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=CACNA2D3+is+downregulated+in+gliomas+and+functions+as+a+tumor+suppressor%2E&#x0026;journal=Mol%2E+Carcinogenesis&#x0026;author=Jin+Y.&#x0026;author=Cui+D.&#x0026;author=Ren+J.&#x0026;author=Wang+K.&#x0026;author=Zeng+T.&#x0026;author=Gao+L.&#x0026;publication_year=2017&#x0026;volume=56&#x0026;pages=945&#x2013;959\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a>Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. \u003Ci>Nucleic Acids Res.\u003C/i> 28, 27&#x2013;30.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=KEGG%3A+kyoto+encyclopedia+of+genes+and+genomes%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Kanehisa+M.&#x0026;author=Goto+S.&#x0026;publication_year=2000&#x0026;volume=28&#x0026;pages=27&#x2013;30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a>Kim, H., Cho, D.-Y., Choi, D. H., Oh, M., Shin, I., Park, W., et al. (2017). Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. \u003Ci>Breast Cancer Res. Treat.\u003C/i> 161, 95&#x2013;102. doi: 10.1007/s10549-016-4034-2\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27783279\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-016-4034-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Frequency+of+pathogenic+germline+mutation+in+CHEK2%2C+PALB2%2C+MRE11%2C+and+RAD50+in+patients+at+high+risk+for+hereditary+breast+cancer%2E&#x0026;journal=Breast+Cancer+Res%2E+Treat%2E&#x0026;author=Kim+H.&#x0026;author=Cho+D.-Y.&#x0026;author=Choi+D.+H.&#x0026;author=Oh+M.&#x0026;author=Shin+I.&#x0026;author=Park+W.&#x0026;publication_year=2017&#x0026;volume=161&#x0026;pages=95&#x2013;102\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a>Kleibl, Z., and Kristensen, V. N. (2016). Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. \u003Ci>Breast\u003C/i> 28, 136&#x2013;144. doi: 10.1016/j.breast.2016.05.006\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27318168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.breast.2016.05.006\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Women+at+high+risk+of+breast+cancer%3A+molecular+characteristics%2C+clinical+presentation+and+management%2E&#x0026;journal=Breast&#x0026;author=Kleibl+Z.&#x0026;author=Kristensen+V.+N.&#x0026;publication_year=2016&#x0026;volume=28&#x0026;pages=136&#x2013;144\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a>Kong, X., Li, M., Shao, K., Yang, Y., Wang, Q., and Cai, M. (2020). Progesterone induces cell apoptosis via the CACNA2D3/Ca2+/p38 MAPK pathway in endometrial cancer. \u003Ci>Oncol. Reports\u003C/i> 43, 121&#x2013;132.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Progesterone+induces+cell+apoptosis+via+the+CACNA2D3%2FCa2%2B%2Fp38+MAPK+pathway+in+endometrial+cancer%2E&#x0026;journal=Oncol%2E+Reports&#x0026;author=Kong+X.&#x0026;author=Li+M.&#x0026;author=Shao+K.&#x0026;author=Yang+Y.&#x0026;author=Wang+Q.&#x0026;author=Cai+M.&#x0026;publication_year=2020&#x0026;volume=43&#x0026;pages=121&#x2013;132\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a>Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., et al. (2020). Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. \u003Ci>J. Clin. Oncol.\u003C/i> 16, e835&#x2013;e838.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Germline+and+somatic+tumor+testing+in+epithelial+ovarian+cancer%3A+ASCO+guideline%2E&#x0026;journal=J%2E+Clin%2E+Oncol%2E&#x0026;author=Konstantinopoulos+P.+A.&#x0026;author=Norquist+B.&#x0026;author=Lacchetti+C.&#x0026;author=Armstrong+D.&#x0026;author=Grisham+R.+N.&#x0026;author=Goodfellow+P.+J.&#x0026;publication_year=2020&#x0026;volume=16&#x0026;pages=e835&#x2013;e838\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a>Laarabi, F.-Z., Ratbi, I., Elalaoui, S. C., Mezzouar, L., Doubaj, Y., Bouguenouch, L., et al. (2017). High frequency of the recurrent c. 1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast&#x2013;ovarian cancer prevention and control. \u003Ci>BMC Res. Notes\u003C/i> 10:188.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=High+frequency+of+the+recurrent+c%2E+1310%5F1313delAAGA+BRCA2+mutation+in+the+North-East+of+Morocco+and+implication+for+hereditary+breast&#x2013;ovarian+cancer+prevention+and+control%2E&#x0026;journal=BMC+Res%2E+Notes&#x0026;author=Laarabi+F.-Z.&#x0026;author=Ratbi+I.&#x0026;author=Elalaoui+S.+C.&#x0026;author=Mezzouar+L.&#x0026;author=Doubaj+Y.&#x0026;author=Bouguenouch+L.&#x0026;publication_year=2017&#x0026;volume=10&#x0026;issue=188\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a>Laraqui, A., Uhrhammer, N., El Rhaffouli, H., Sekhsokh, Y., Lahlou-Amine, I., Bajjou, T., et al. (2015). BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c. 798_799delTT) in North African. \u003Ci>Disease Markers\u003C/i> 2015:194293.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+genetic+screening+in+Middle+Eastern+and+North+African%3A+mutational+spectrum+and+founder+BRCA1+mutation+%28c%2E+798%5F799delTT%29+in+North+African%2E&#x0026;journal=Disease+Markers&#x0026;author=Laraqui+A.&#x0026;author=Uhrhammer+N.&#x0026;author=El+Rhaffouli+H.&#x0026;author=Sekhsokh+Y.&#x0026;author=Lahlou-Amine+I.&#x0026;author=Bajjou+T.&#x0026;publication_year=2015&#x0026;volume=2015&#x0026;issue=194293\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a>Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. \u003Ci>Bioinformatics\u003C/i> 25, 1754&#x2013;1760. doi: 10.1093/bioinformatics/btp324\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19451168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btp324\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Fast+and+accurate+short+read+alignment+with+Burrows&#x2013;Wheeler+transform%2E&#x0026;journal=Bioinformatics&#x0026;author=Li+H.&#x0026;author=Durbin+R.&#x0026;publication_year=2009&#x0026;volume=25&#x0026;pages=1754&#x2013;1760\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a>Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The sequence alignment/map format and SAMtools. \u003Ci>Bioinformatics\u003C/i> 25, 2078&#x2013;2079. doi: 10.1093/bioinformatics/btp352\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19505943\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btp352\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+sequence+alignment%2Fmap+format+and+SAMtools%2E&#x0026;journal=Bioinformatics&#x0026;author=Li+H.&#x0026;author=Handsaker+B.&#x0026;author=Wysoker+A.&#x0026;author=Fennell+T.&#x0026;author=Ruan+J.&#x0026;author=Homer+N.&#x0026;publication_year=2009&#x0026;volume=25&#x0026;pages=2078&#x2013;2079\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a>Li, Y., Zhu, C.-L., Nie, C.-J., Li, J.-C., Zeng, T.-T., Zhou, J., et al. (2013). Investigation of tumor suppressing function of CACNA2D3 in esophageal squamous cell carcinoma. \u003Ci>PLoS One\u003C/i> 8:e60027. doi: 10.1371/journal.pone.0060027\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23560067\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0060027\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Investigation+of+tumor+suppressing+function+of+CACNA2D3+in+esophageal+squamous+cell+carcinoma%2E&#x0026;journal=PLoS+One&#x0026;author=Li+Y.&#x0026;author=Zhu+C.-L.&#x0026;author=Nie+C.-J.&#x0026;author=Li+J.-C.&#x0026;author=Zeng+T.-T.&#x0026;author=Zhou+J.&#x0026;publication_year=2013&#x0026;volume=8&#x0026;issue=e60027\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a>Lopez-Llano, J., Campos, L., and Sancho, J. (2006). &#x03B1;-helix stabilization by alanine relative to glycine: roles of polar and apolar solvent exposures and of backbone entropy. \u003Ci>Proteins Struct. Funct. Bioinformatics\u003C/i> 64, 769&#x2013;778. doi: 10.1002/prot.21041\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16755589\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/prot.21041\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=&#x03B1;-helix+stabilization+by+alanine+relative+to+glycine%3A+roles+of+polar+and+apolar+solvent+exposures+and+of+backbone+entropy%2E&#x0026;journal=Proteins+Struct%2E+Funct%2E+Bioinformatics&#x0026;author=Lopez-Llano+J.&#x0026;author=Campos+L.&#x0026;author=Sancho+J.&#x0026;publication_year=2006&#x0026;volume=64&#x0026;pages=769&#x2013;778\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a>Lovell, S. C. I, Davis, W., Arendall, W. B. III, De Bakker, P. I., Word, J. M., Prisant, M. G., et al. (2003). Structure validation by C&#x03B1; geometry: ?, &#x03C8; and C&#x03B2; deviation. \u003Ci>Proteins Struct. Funct. Bioinformatics\u003C/i> 50, 437&#x2013;450. doi: 10.1002/prot.10286\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12557186\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/prot.10286\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Structure+validation+by+C&#x03B1;+geometry%3A+%B4%2C+&#x03C8;+and+C&#x03B2;+deviation%2E&#x0026;journal=Proteins+Struct%2E+Funct%2E+Bioinformatics&#x0026;author=Lovell+S.+C.+I+Davis+W.&#x0026;author=Arendall+W.+B.+III&#x0026;author=De+Bakker+P.+I.&#x0026;author=Word+J.+M.&#x0026;author=Prisant+M.+G.&#x0026;publication_year=2003&#x0026;volume=50&#x0026;pages=437&#x2013;450\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a>L&#x00FC;thy, R., Bowie, J. U., and Eisenberg, D. (1992). Assessment of protein models with three-dimensional profiles. \u003Ci>Nature\u003C/i> 356, 83&#x2013;85. doi: 10.1038/356083a0\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1538787\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/356083a0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Assessment+of+protein+models+with+three-dimensional+profiles%2E&#x0026;journal=Nature&#x0026;author=L&#x00FC;thy+R.&#x0026;author=Bowie+J.+U.&#x0026;author=Eisenberg+D.&#x0026;publication_year=1992&#x0026;volume=356&#x0026;pages=83&#x2013;85\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a>Lv, M., Shen, Y., Yang, J., Li, S., Wang, B., Chen, Z., et al. (2017). Angiomotin family members: oncogenes or tumor suppressors? \u003Ci>Int. J. Biol. Sci.\u003C/i> 13:772. doi: 10.7150/ijbs.19603\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28656002\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.7150/ijbs.19603\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Angiomotin+family+members%3A+oncogenes+or+tumor+suppressors%B4&#x0026;journal=Int%2E+J%2E+Biol%2E+Sci%2E&#x0026;author=Lv+M.&#x0026;author=Shen+Y.&#x0026;author=Yang+J.&#x0026;author=Li+S.&#x0026;author=Wang+B.&#x0026;author=Chen+Z.&#x0026;publication_year=2017&#x0026;volume=13&#x0026;issue=772\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a>Mahfoudh, W., Bouaouina, N., Ahmed, S. B., Gabbouj, S., Shan, J., Mathew, R., et al. (2012). Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. \u003Ci>Mol. Biol. Reports\u003C/i> 39, 1037&#x2013;1046. doi: 10.1007/s11033-011-0829-8\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21603858\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s11033-011-0829-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Hereditary+breast+cancer+in+Middle+Eastern+and+North+African+%28MENA%29+populations%3A+identification+of+novel%2C+recurrent+and+founder+BRCA1+mutations+in+the+Tunisian+population%2E&#x0026;journal=Mol%2E+Biol%2E+Reports&#x0026;author=Mahfoudh+W.&#x0026;author=Bouaouina+N.&#x0026;author=Ahmed+S.+B.&#x0026;author=Gabbouj+S.&#x0026;author=Shan+J.&#x0026;author=Mathew+R.&#x0026;publication_year=2012&#x0026;volume=39&#x0026;pages=1037&#x2013;1046\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a>Maldonado, V., and Melendez-Zajgla, J. (2011). Role of Bcl-3 in solid tumors. \u003Ci>Mol. Cancer\u003C/i> 10:152. doi: 10.1186/1476-4598-10-152\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22195643\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1476-4598-10-152\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Role+of+Bcl-3+in+solid+tumors%2E&#x0026;journal=Mol%2E+Cancer&#x0026;author=Maldonado+V.&#x0026;author=Melendez-Zajgla+J.&#x0026;publication_year=2011&#x0026;volume=10&#x0026;issue=152\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a>Manrai, A. K., Funke, B. H., Rehm, H. L., Olesen, M. S., Maron, B. A., Szolovits, P., et al. (2016). Genetic misdiagnoses and the potential for health disparities. \u003Ci>N. Engl. J. Med.\u003C/i> 375, 655&#x2013;665. doi: 10.1056/nejmsa1507092\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27532831\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/nejmsa1507092\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+misdiagnoses+and+the+potential+for+health+disparities%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Manrai+A.+K.&#x0026;author=Funke+B.+H.&#x0026;author=Rehm+H.+L.&#x0026;author=Olesen+M.+S.&#x0026;author=Maron+B.+A.&#x0026;author=Szolovits+P.&#x0026;publication_year=2016&#x0026;volume=375&#x0026;pages=655&#x2013;665\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a>Mateo, J., Lord, C., Serra, V., Tutt, A., Balma&#x00F1;a, J., Castroviejo-Bermejo, M., et al. (2019). A decade of clinical development of PARP inhibitors in perspective. \u003Ci>Ann. Oncol.\u003C/i> 30, 1437&#x2013;1447. doi: 10.1093/annonc/mdz192\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31218365\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdz192\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+decade+of+clinical+development+of+PARP+inhibitors+in+perspective%2E&#x0026;journal=Ann%2E+Oncol%2E&#x0026;author=Mateo+J.&#x0026;author=Lord+C.&#x0026;author=Serra+V.&#x0026;author=Tutt+A.&#x0026;author=Balma&#x00F1;a+J.&#x0026;author=Castroviejo-Bermejo+M.&#x0026;publication_year=2019&#x0026;volume=30&#x0026;pages=1437&#x2013;1447\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a>McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., et al. (2010). The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. \u003Ci>Genome Res.\u003C/i> 20, 1297&#x2013;1303. doi: 10.1101/gr.107524.110\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20644199\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/gr.107524.110\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+genome+analysis+toolkit%3A+a+MapReduce+framework+for+analyzing+next-generation+DNA+sequencing+data%2E&#x0026;journal=Genome+Res%2E&#x0026;author=McKenna+A.&#x0026;author=Hanna+M.&#x0026;author=Banks+E.&#x0026;author=Sivachenko+A.&#x0026;author=Cibulskis+K.&#x0026;author=Kernytsky+A.&#x0026;publication_year=2010&#x0026;volume=20&#x0026;pages=1297&#x2013;1303\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a>Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. \u003Ci>J. Clin. Oncol.\u003C/i> 22, 2328&#x2013;2335.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Contralateral+breast+cancer+in+BRCA1+and+BRCA2+mutation+carriers%2E&#x0026;journal=J%2E+Clin%2E+Oncol%2E&#x0026;author=Metcalfe+K.&#x0026;author=Lynch+H.+T.&#x0026;author=Ghadirian+P.&#x0026;author=Tung+N.&#x0026;author=Olivotto+I.&#x0026;author=Warner+E.&#x0026;publication_year=2004&#x0026;volume=22&#x0026;pages=2328&#x2013;2335\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B62\" id=\"B62\">\u003C/a>Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N. I, Olivotto, A., Foulkes, W. D., et al. (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. \u003Ci>Gynecol. Oncol.\u003C/i> 96, 222&#x2013;226.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+risk+of+ovarian+cancer+after+breast+cancer+in+BRCA1+and+BRCA2+carriers%2E&#x0026;journal=Gynecol%2E+Oncol%2E&#x0026;author=Metcalfe+K.+A.&#x0026;author=Lynch+H.+T.&#x0026;author=Ghadirian+P.&#x0026;author=Tung+N.+I&#x0026;author=Olivotto+A.&#x0026;author=Foulkes+W.+D.&#x0026;publication_year=2005&#x0026;volume=96&#x0026;pages=222&#x2013;226\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B63\" id=\"B63\">\u003C/a>Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. \u003Ci>Science\u003C/i> 266, 66&#x2013;71. doi: 10.1126/science.7545954\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7545954\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.7545954\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+strong+candidate+for+the+breast+and+ovarian+cancer+susceptibility+gene+BRCA1%2E&#x0026;journal=Science&#x0026;author=Miki+Y.&#x0026;author=Swensen+J.&#x0026;author=Shattuck-Eidens+D.&#x0026;author=Futreal+P.+A.&#x0026;author=Harshman+K.&#x0026;author=Tavtigian+S.&#x0026;publication_year=1994&#x0026;volume=266&#x0026;pages=66&#x2013;71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B64\" id=\"B64\">\u003C/a>Msolly, A., and Kassab, A. (2015). BRCA1 and BRCA2 mutations are they related to breast cancer in a sample of tunisian population? \u003Ci>Cancer Ther. Oncol. Int. J.\u003C/i> 1, 1&#x2013;5.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+and+BRCA2+mutations+are+they+related+to+breast+cancer+in+a+sample+of+tunisian+population%B4&#x0026;journal=Cancer+Ther%2E+Oncol%2E+Int%2E+J%2E&#x0026;author=Msolly+A.&#x0026;author=Kassab+A.&#x0026;publication_year=2015&#x0026;volume=1&#x0026;pages=1&#x2013;5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B65\" id=\"B65\">\u003C/a>Nath, A., and Chan, C. (2016). Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. \u003Ci>Sci. Rep.\u003C/i> 6:18669.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Genetic+alterations+in+fatty+acid+transport+and+metabolism+genes+are+associated+with+metastatic+progression+and+poor+prognosis+of+human+cancers%2E&#x0026;journal=Sci%2E+Rep%2E&#x0026;author=Nath+A.&#x0026;author=Chan+C.&#x0026;publication_year=2016&#x0026;volume=6&#x0026;issue=18669\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B66\" id=\"B66\">\u003C/a>Orr, K. S., and Savage, K. I. (2015). \u003Ci>Advances in DNA Repair\u003C/i>, Intech. 217&#x2013;253.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;author=Orr+K.+S.&#x0026;author=Savage+K.+I.&#x0026;publication_year=2015\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B67\" id=\"B67\">\u003C/a>Plagnol, V., Curtis, J., Epstein, M., Mok, K. Y., Stebbings, E., Grigoriadou, S., et al. (2012). A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. \u003Ci>Bioinformatics\u003C/i> 28, 2747&#x2013;2754. doi: 10.1093/bioinformatics/bts526\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22942019\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/bts526\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+robust+model+for+read+count+data+in+exome+sequencing+experiments+and+implications+for+copy+number+variant+calling%2E&#x0026;journal=Bioinformatics&#x0026;author=Plagnol+V.&#x0026;author=Curtis+J.&#x0026;author=Epstein+M.&#x0026;author=Mok+K.+Y.&#x0026;author=Stebbings+E.&#x0026;author=Grigoriadou+S.&#x0026;publication_year=2012&#x0026;volume=28&#x0026;pages=2747&#x2013;2754\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B68\" id=\"B68\">\u003C/a>Posey, J. E. (2019). Genome sequencing and implications for rare disorders. \u003Ci>Orphanet J. Rare Dis.\u003C/i> 14:153.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Genome+sequencing+and+implications+for+rare+disorders%2E&#x0026;journal=Orphanet+J%2E+Rare+Dis%2E&#x0026;author=Posey+J.+E.&#x0026;publication_year=2019&#x0026;volume=14&#x0026;issue=153\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B69\" id=\"B69\">\u003C/a>Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van&#x2019;t Veer, L., Garber, J. E., et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. \u003Ci>N. Engl. J. Med.\u003C/i> 346, 1616&#x2013;1622.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Prophylactic+oophorectomy+in+carriers+of+BRCA1+or+BRCA2+mutations%2E&#x0026;journal=N%2E+Engl%2E+J%2E+Med%2E&#x0026;author=Rebbeck+T.+R.&#x0026;author=Lynch+H.+T.&#x0026;author=Neuhausen+S.+L.&#x0026;author=Narod+S.+A.&#x0026;author=Van&#x2019;t+Veer+L.&#x0026;author=Garber+J.+E.&#x0026;publication_year=2002&#x0026;volume=346&#x0026;pages=1616&#x2013;1622\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B70\" id=\"B70\">\u003C/a>Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., et al. (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. \u003Ci>JAMA\u003C/i> 313, 1347&#x2013;1361.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Association+of+type+and+location+of+BRCA1+and+BRCA2+mutations+with+risk+of+breast+and+ovarian+cancer%2E&#x0026;journal=JAMA&#x0026;author=Rebbeck+T.+R.&#x0026;author=Mitra+N.&#x0026;author=Wan+F.&#x0026;author=Sinilnikova+O.+M.&#x0026;author=Healey+S.&#x0026;author=McGuffog+L.&#x0026;publication_year=2015&#x0026;volume=313&#x0026;pages=1347&#x2013;1361\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B71\" id=\"B71\">\u003C/a>Reeve, J. P., and Rannala, B. (2002). DMLE+: Bayesian linkage disequilibrium gene mapping. \u003Ci>Bioinformatics\u003C/i> 18, 894&#x2013;895. doi: 10.1093/bioinformatics/18.6.894\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12075030\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/18.6.894\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=DMLE%2B%3A+Bayesian+linkage+disequilibrium+gene+mapping%2E&#x0026;journal=Bioinformatics&#x0026;author=Reeve+J.+P.&#x0026;author=Rannala+B.&#x0026;publication_year=2002&#x0026;volume=18&#x0026;pages=894&#x2013;895\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B72\" id=\"B72\">\u003C/a>Repana, D., Nulsen, J., Dressler, L., Bortolomeazzi, M., Venkata, S. K., Tourna, A., et al. (2019). The network of cancer genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens. \u003Ci>Genome Biol.\u003C/i> 20:1.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+network+of+cancer+genes+%28NCG%29%3A+a+comprehensive+catalogue+of+known+and+candidate+cancer+genes+from+cancer+sequencing+screens%2E&#x0026;journal=Genome+Biol%2E&#x0026;author=Repana+D.&#x0026;author=Nulsen+J.&#x0026;author=Dressler+L.&#x0026;author=Bortolomeazzi+M.&#x0026;author=Venkata+S.+K.&#x0026;author=Tourna+A.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B73\" id=\"B73\">\u003C/a>Riahi, A., Kharrat, M., Ghourabi, M., Khomsi, F., Gamoudi, A., Lariani, I., et al. (2015). Mutation spectrum and prevalence of BRCA 1 and BRCA 2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia. \u003Ci>Clin. Genet.\u003C/i> 87, 155&#x2013;160. doi: 10.1111/cge.12337\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24372583\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12337\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Mutation+spectrum+and+prevalence+of+BRCA+1+and+BRCA+2+genes+in+patients+with+familial+and+early-onset+breast%2Fovarian+cancer+from+Tunisia%2E&#x0026;journal=Clin%2E+Genet%2E&#x0026;author=Riahi+A.&#x0026;author=Kharrat+M.&#x0026;author=Ghourabi+M.&#x0026;author=Khomsi+F.&#x0026;author=Gamoudi+A.&#x0026;author=Lariani+I.&#x0026;publication_year=2015&#x0026;volume=87&#x0026;pages=155&#x2013;160\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B74\" id=\"B74\">\u003C/a>Rice, P., Longden, I., and Bleasby, A. (2000). EMBOSS: the European molecular biology open software suite. \u003Ci>Trends Genet.\u003C/i> 16, 276&#x2013;277. doi: 10.1016/s0168-9525(00)02024-2\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/s0168-9525(00)02024-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=EMBOSS%3A+the+European+molecular+biology+open+software+suite%2E&#x0026;journal=Trends+Genet%2E&#x0026;author=Rice+P.&#x0026;author=Longden+I.&#x0026;author=Bleasby+A.&#x0026;publication_year=2000&#x0026;volume=16&#x0026;pages=276&#x2013;277\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B75\" id=\"B75\">\u003C/a>Riku, M., Inaguma, S., Ito, H., Tsunoda, T., Ikeda, H., and Kasai, K. (2016). Down-regulation of the zinc-finger homeobox protein TSHZ2 releases GLI1 from the nuclear repressor complex to restore its transcriptional activity during mammary tumorigenesis. \u003Ci>Oncotarget\u003C/i> 7:5690. doi: 10.18632/oncotarget.6788\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26744317\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/oncotarget.6788\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Down-regulation+of+the+zinc-finger+homeobox+protein+TSHZ2+releases+GLI1+from+the+nuclear+repressor+complex+to+restore+its+transcriptional+activity+during+mammary+tumorigenesis%2E&#x0026;journal=Oncotarget&#x0026;author=Riku+M.&#x0026;author=Inaguma+S.&#x0026;author=Ito+H.&#x0026;author=Tsunoda+T.&#x0026;author=Ikeda+H.&#x0026;author=Kasai+K.&#x0026;publication_year=2016&#x0026;volume=7&#x0026;issue=5690\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B76\" id=\"B76\">\u003C/a>Rines, A. K., Burke, M. A., Fernandez, R. P., Volpert, O. V., and Ardehali, H. (2012). Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of &#x03B2;-catenin. \u003Ci>FASEB J.\u003C/i> 26, 4685&#x2013;4695. doi: 10.1096/fj.12-212282\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22874833\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1096/fj.12-212282\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Snf1-related+kinase+inhibits+colon+cancer+cell+proliferation+through+calcyclin-binding+protein-dependent+reduction+of+&#x03B2;-catenin%2E&#x0026;journal=FASEB+J%2E&#x0026;author=Rines+A.+K.&#x0026;author=Burke+M.+A.&#x0026;author=Fernandez+R.+P.&#x0026;author=Volpert+O.+V.&#x0026;author=Ardehali+H.&#x0026;publication_year=2012&#x0026;volume=26&#x0026;pages=4685&#x2013;4695\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B77\" id=\"B77\">\u003C/a>Rodrigues, C. H., Pires, D. E., and Ascher, D. B. (2018). DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. \u003Ci>Nucleic Acids Res.\u003C/i> 46, W350&#x2013;W355.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=DynaMut%3A+predicting+the+impact+of+mutations+on+protein+conformation%2C+flexibility+and+stability%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Rodrigues+C.+H.&#x0026;author=Pires+D.+E.&#x0026;author=Ascher+D.+B.&#x0026;publication_year=2018&#x0026;volume=46&#x0026;pages=W350&#x2013;W355\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B78\" id=\"B78\">\u003C/a>Romdhane, L., Kefi, R., Azaiez, H., Halim, N. B., Dellagi, K., and Abdelhak, S. (2012). Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East. \u003Ci>Orphanet J. Rare Dis.\u003C/i> 7:52. doi: 10.1186/1750-1172-7-52\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22908982\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1750-1172-7-52\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Founder+mutations+in+Tunisia%3A+implications+for+diagnosis+in+North+Africa+and+Middle+East%2E&#x0026;journal=Orphanet+J%2E+Rare+Dis%2E&#x0026;author=Romdhane+L.&#x0026;author=Kefi+R.&#x0026;author=Azaiez+H.&#x0026;author=Halim+N.+B.&#x0026;author=Dellagi+K.&#x0026;author=Abdelhak+S.&#x0026;publication_year=2012&#x0026;volume=7&#x0026;issue=52\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B79\" id=\"B79\">\u003C/a>&#x0160;ali, A., and Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. \u003Ci>J. Mol. Biol.\u003C/i> 234, 779&#x2013;815. doi: 10.1006/jmbi.1993.1626\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8254673\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1006/jmbi.1993.1626\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Comparative+protein+modelling+by+satisfaction+of+spatial+restraints%2E&#x0026;journal=J%2E+Mol%2E+Biol%2E&#x0026;author=&#x0160;ali+A.&#x0026;author=Blundell+T.+L.&#x0026;publication_year=1993&#x0026;volume=234&#x0026;pages=779&#x2013;815\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B80\" id=\"B80\">\u003C/a>Seifert, F. U., Lammens, K., Stoehr, G., Kessler, B., and Hopfner, K. P. (2016). Structural mechanism of ATP-dependent DNA binding and DNA end bridging by eukaryotic Rad50. \u003Ci>EMBO J.\u003C/i> 35, 759&#x2013;772. doi: 10.15252/embj.201592934\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26896444\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.15252/embj.201592934\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Structural+mechanism+of+ATP-dependent+DNA+binding+and+DNA+end+bridging+by+eukaryotic+Rad50%2E&#x0026;journal=EMBO+J%2E&#x0026;author=Seifert+F.+U.&#x0026;author=Lammens+K.&#x0026;author=Stoehr+G.&#x0026;author=Kessler+B.&#x0026;author=Hopfner+K.+P.&#x0026;publication_year=2016&#x0026;volume=35&#x0026;pages=759&#x2013;772\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B81\" id=\"B81\">\u003C/a>Seklani, M. (1974). \u003Ci>La Population de la Tunisie. Presses de la Soci&#x00E9;t&#x00E9; Tunisienne des Arts Graphiques.\u003C/i>\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;author=Seklani+M.&#x0026;publication_year=1974\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B82\" id=\"B82\">\u003C/a>Serrano, L., Neira, J.-L., Sancho, J., and Fersht, A. R. (1992). Effect of alanine versus glycine in &#x03B1;-helices on protein stability. \u003Ci>Nature\u003C/i> 356, 453&#x2013;455. doi: 10.1038/356453a0\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/1557131\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/356453a0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Effect+of+alanine+versus+glycine+in+&#x03B1;-helices+on+protein+stability%2E&#x0026;journal=Nature&#x0026;author=Serrano+L.&#x0026;author=Neira+J.-L.&#x0026;author=Sancho+J.&#x0026;author=Fersht+A.+R.&#x0026;publication_year=1992&#x0026;volume=356&#x0026;pages=453&#x2013;455\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B83\" id=\"B83\">\u003C/a>Shahi, R. B., De Brakeleer, S., Caljon, B., Pauwels, I., Bonduelle, M., Joris, S., et al. (2019). Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. \u003Ci>BMC Cancer\u003C/i> 19:313.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+candidate+cancer+predisposing+variants+by+performing+whole-exome+sequencing+on+index+patients+from+BRCA1+and+BRCA2-negative+breast+cancer+families%2E&#x0026;journal=BMC+Cancer&#x0026;author=Shahi+R.+B.&#x0026;author=De+Brakeleer+S.&#x0026;author=Caljon+B.&#x0026;author=Pauwels+I.&#x0026;author=Bonduelle+M.&#x0026;author=Joris+S.&#x0026;publication_year=2019&#x0026;volume=19&#x0026;issue=313\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B84\" id=\"B84\">\u003C/a>Shen, M. Y., and Sali, A. (2006). Statistical potential for assessment and prediction of protein structures. \u003Ci>Protein Sci.\u003C/i> 15, 2507&#x2013;2524. doi: 10.1110/ps.062416606\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17075131\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1110/ps.062416606\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Statistical+potential+for+assessment+and+prediction+of+protein+structures%2E&#x0026;journal=Protein+Sci%2E&#x0026;author=Shen+M.+Y.&#x0026;author=Sali+A.&#x0026;publication_year=2006&#x0026;volume=15&#x0026;pages=2507&#x2013;2524\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B85\" id=\"B85\">\u003C/a>Situ, Y., Chung, L., Lee, C. S., and Ho, V. (2019). MRN (MRE11-RAD50-NBS1) complex in human cancer and prognostic implications in colorectal cancer. \u003Ci>Int. J. Mol. Sci.\u003C/i> 20:816. doi: 10.3390/ijms20040816\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30769804\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/ijms20040816\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=MRN+%28MRE11-RAD50-NBS1%29+complex+in+human+cancer+and+prognostic+implications+in+colorectal+cancer%2E&#x0026;journal=Int%2E+J%2E+Mol%2E+Sci%2E&#x0026;author=Situ+Y.&#x0026;author=Chung+L.&#x0026;author=Lee+C.+S.&#x0026;author=Ho+V.&#x0026;publication_year=2019&#x0026;volume=20&#x0026;issue=816\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B86\" id=\"B86\">\u003C/a>Slenter, D. N., Kutmon, M., Hanspers, K., Riutta, A., Windsor, J., Nunes, N., et al. (2017). WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. \u003Ci>Nucleic Acids Res.\u003C/i> 46, D661&#x2013;D667.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=WikiPathways%3A+a+multifaceted+pathway+database+bridging+metabolomics+to+other+omics+research%2E&#x0026;journal=Nucleic+Acids+Res%2E&#x0026;author=Slenter+D.+N.&#x0026;author=Kutmon+M.&#x0026;author=Hanspers+K.&#x0026;author=Riutta+A.&#x0026;author=Windsor+J.&#x0026;author=Nunes+N.&#x0026;publication_year=2017&#x0026;volume=46&#x0026;pages=D661&#x2013;D667\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B87\" id=\"B87\">\u003C/a>Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. \u003Ci>Am. J. Hum. Genet.\u003C/i> 68, 978&#x2013;989. doi: 10.1086/319501\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11254454\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/319501\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+statistical+method+for+haplotype+reconstruction+from+population+data%2E&#x0026;journal=Am%2E+J%2E+Hum%2E+Genet%2E&#x0026;author=Stephens+M.&#x0026;author=Smith+N.+J.&#x0026;author=Donnelly+P.&#x0026;publication_year=2001&#x0026;volume=68&#x0026;pages=978&#x2013;989\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B88\" id=\"B88\">\u003C/a>Sturm, R. A., Fox, C., McClenahan, P., Jagirdar, K., Ibarrola-Villava, M., Banan, P., et al. (2014). Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. \u003Ci>J. Invest. Dermatol.\u003C/i> 134, 141&#x2013;149. doi: 10.1038/jid.2013.272\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23774529\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/jid.2013.272\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Phenotypic+characterization+of+nevus+and+tumor+patterns+in+MITF+E318K+mutation+carrier+melanoma+patients%2E&#x0026;journal=J%2E+Invest%2E+Dermatol%2E&#x0026;author=Sturm+R.+A.&#x0026;author=Fox+C.&#x0026;author=McClenahan+P.&#x0026;author=Jagirdar+K.&#x0026;author=Ibarrola-Villava+M.&#x0026;author=Banan+P.&#x0026;publication_year=2014&#x0026;volume=134&#x0026;pages=141&#x2013;149\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B89\" id=\"B89\">\u003C/a>Taskiran, E. Z., Korkmaz, E., Gucer, S., Kosukcu, C., Kaymaz, F., Koyunlar, C., et al. (2014). Mutations in ANKS6 cause a nephronophthisis-like phenotype with ESRD. \u003Ci>J. Am. Soc. Nephrol.\u003C/i> 25, 1653&#x2013;1661. doi: 10.1681/asn.2013060646\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24610927\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1681/asn.2013060646\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Mutations+in+ANKS6+cause+a+nephronophthisis-like+phenotype+with+ESRD%2E&#x0026;journal=J%2E+Am%2E+Soc%2E+Nephrol%2E&#x0026;author=Taskiran+E.+Z.&#x0026;author=Korkmaz+E.&#x0026;author=Gucer+S.&#x0026;author=Kosukcu+C.&#x0026;author=Kaymaz+F.&#x0026;author=Koyunlar+C.&#x0026;publication_year=2014&#x0026;volume=25&#x0026;pages=1653&#x2013;1661\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B90\" id=\"B90\">\u003C/a>Troudi, W., Uhrhammer, N., Romdhane, K. B., Sibille, C., Amor, M. B., Khil, E., et al. (2008). Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. \u003Ci>Cancer Biomarkers\u003C/i> 4, 11&#x2013;18. doi: 10.3233/cbm-2008-4102\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18334730\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3233/cbm-2008-4102\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Complete+mutation+screening+and+haplotype+characterization+of+BRCA1+gene+in+Tunisian+patients+with+familial+breast+cancer%2E&#x0026;journal=Cancer+Biomarkers&#x0026;author=Troudi+W.&#x0026;author=Uhrhammer+N.&#x0026;author=Romdhane+K.+B.&#x0026;author=Sibille+C.&#x0026;author=Amor+M.+B.&#x0026;author=Khil+E.&#x0026;publication_year=2008&#x0026;volume=4&#x0026;pages=11&#x2013;18\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B91\" id=\"B91\">\u003C/a>Troudi, W., Uhrhammer, N., Sibille, C., Dahan, C., Mahfoudh, W., Souissi, C. B., et al. (2007). Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. \u003Ci>J. Hum. Genet.\u003C/i> 52:915.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Contribution+of+the+BRCA1+and+BRCA2+mutations+to+breast+cancer+in+Tunisia%2E&#x0026;journal=J%2E+Hum%2E+Genet%2E&#x0026;author=Troudi+W.&#x0026;author=Uhrhammer+N.&#x0026;author=Sibille+C.&#x0026;author=Dahan+C.&#x0026;author=Mahfoudh+W.&#x0026;author=Souissi+C.+B.&#x0026;publication_year=2007&#x0026;volume=52&#x0026;issue=915\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B92\" id=\"B92\">\u003C/a>Turner, N. C., and Tutt, A. N. (2012). Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? \u003Ci>BioMed Central\u003C/i> 14:115.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Platinum+chemotherapy+for+BRCA1-related+breast+cancer%3A+do+we+need+more+evidence%B4&#x0026;journal=BioMed+Central&#x0026;author=Turner+N.+C.&#x0026;author=Tutt+A.+N.&#x0026;publication_year=2012&#x0026;volume=14&#x0026;issue=115\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B93\" id=\"B93\">\u003C/a>Uhrhammer, N., Abdelouahab, A., Lafarge, L., Feillel, V., Dib, A. B., and Bignon, Y.-J. (2008). BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. \u003Ci>Int. J. Med. Sci.\u003C/i> 5:197. doi: 10.7150/ijms.5.197\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18645608\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.7150/ijms.5.197\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA1+mutations+in+Algerian+breast+cancer+patients%3A+high+frequency+in+young%2C+sporadic+cases%2E&#x0026;journal=Int%2E+J%2E+Med%2E+Sci%2E&#x0026;author=Uhrhammer+N.&#x0026;author=Abdelouahab+A.&#x0026;author=Lafarge+L.&#x0026;author=Feillel+V.&#x0026;author=Dib+A.+B.&#x0026;author=Bignon+Y.-J.&#x0026;publication_year=2008&#x0026;volume=5&#x0026;issue=197\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B94\" id=\"B94\">\u003C/a>Wong, A. M. G., Kong, K. L., Chen, L., Liu, M., Wong, A. M. G., Zhu, C., et al. (2013). Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. \u003Ci>Int. J. Cancer\u003C/i> 133, 2284&#x2013;2295. doi: 10.1002/ijc.28252\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23649311\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.28252\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Characterization+of+CACNA2D3+as+a+putative+tumor+suppressor+gene+in+the+development+and+progression+of+nasopharyngeal+carcinoma%2E&#x0026;journal=Int%2E+J%2E+Cancer&#x0026;author=Wong+A.+M.+G.&#x0026;author=Kong+K.+L.&#x0026;author=Chen+L.&#x0026;author=Liu+M.&#x0026;author=Wong+A.+M.+G.&#x0026;author=Zhu+C.&#x0026;publication_year=2013&#x0026;volume=133&#x0026;pages=2284&#x2013;2295\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B95\" id=\"B95\">\u003C/a>Wong, C., Chen, F., Alirezaie, N., Wang, Y., Cuggia, A., Borgida, A., et al. (2019). A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. \u003Ci>PLoS Genet.\u003C/i> 15:e1008344. doi: 10.1371/journal.pgen.1008344\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31469826\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pgen.1008344\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+region-based+gene+association+study+combined+with+a+leave-one-out+sensitivity+analysis+identifies+SMG1+as+a+pancreatic+cancer+susceptibility+gene%2E&#x0026;journal=PLoS+Genet%2E&#x0026;author=Wong+C.&#x0026;author=Chen+F.&#x0026;author=Alirezaie+N.&#x0026;author=Wang+Y.&#x0026;author=Cuggia+A.&#x0026;author=Borgida+A.&#x0026;publication_year=2019&#x0026;volume=15&#x0026;issue=e1008344\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B96\" id=\"B96\">\u003C/a>Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sj&#x00F6;blom, T., Leary, R. J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. \u003Ci>Science\u003C/i> 318, 1108&#x2013;1113.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+genomic+landscapes+of+human+breast+and+colorectal+cancers%2E&#x0026;journal=Science&#x0026;author=Wood+L.+D.&#x0026;author=Parsons+D.+W.&#x0026;author=Jones+S.&#x0026;author=Lin+J.&#x0026;author=Sj&#x00F6;blom+T.&#x0026;author=Leary+R.+J.&#x0026;publication_year=2007&#x0026;volume=318&#x0026;pages=1108&#x2013;1113\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B97\" id=\"B97\">\u003C/a>Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. \u003Ci>Nature\u003C/i> 378:789.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Identification+of+the+breast+cancer+susceptibility+gene+BRCA2%2E&#x0026;journal=Nature&#x0026;author=Wooster+R.&#x0026;author=Bignell+G.&#x0026;author=Lancaster+J.&#x0026;author=Swift+S.&#x0026;author=Seal+S.&#x0026;author=Mangion+J.&#x0026;publication_year=1995&#x0026;volume=378&#x0026;issue=789\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B98\" id=\"B98\">\u003C/a>Zhu, Y., Wu, J., Zhang, C., Sun, S., Zhang, J., Liu, W., et al. (2016). BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. \u003Ci>Oncotarget\u003C/i> 7:70113. doi: 10.18632/oncotarget.12158\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27659521\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/oncotarget.12158\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=BRCA+mutations+and+survival+in+breast+cancer%3A+an+updated+systematic+review+and+meta-analysis%2E&#x0026;journal=Oncotarget&#x0026;author=Zhu+Y.&#x0026;author=Wu+J.&#x0026;author=Zhang+C.&#x0026;author=Sun+S.&#x0026;author=Zhang+J.&#x0026;author=Liu+W.&#x0026;publication_year=2016&#x0026;volume=7&#x0026;issue=70113\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\r\n\u003Cdiv class=\"AbstractSummary\">\r\n\u003Cp>\u003Cspan>Keywords\u003C/span>: breast cancer, genetic screening, \u003Ci>BRCA1\u003C/i>-founder mutation, next-generation sequencing, novel mutation, \u003Ci>RAD50\u003C/i>\u003C/p>\r\n\u003Cp>\u003Cspan>Citation:\u003C/span> Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, Mejri N, Labidi S, Ayari J, Jaidene O, Bouaziz H, Ben Rekaya M, M&#x2019;rad R, Haddaoui A, Rahal K, Boussen H, Boubaker S and Abdelhak S (2020) Identification of Novel \u003Ci>BRCA1\u003C/i> and \u003Ci>RAD50\u003C/i> Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. \u003Ci>Front. Genet.\u003C/i> 11:552971. doi: 10.3389/fgene.2020.552971\u003C/p>\r\n\u003Cp id=\"timestamps\">\r\n\u003Cspan>Received:\u003C/span> 17 April 2020; \u003Cspan>Accepted:\u003C/span> 16 October 2020;\u003Cbr>\u003Cspan>Published:\u003C/span> 06 November 2020.\u003C/p>\r\n\u003Cdiv>\r\n\u003Cp>Edited by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/621226/overview\">Anna Murray\u003C/a>, University of Exeter, United Kingdom\u003C/div>\r\n\u003Cdiv>\r\n\u003Cp>Reviewed by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/66539/overview\">Natasa Djordjevic\u003C/a>, University of Kragujevac, Serbia\u003Cbr>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/705890/overview\">Jaakko Tapio Leinonen\u003C/a>, University of Helsinki, Finland\u003C/div>\r\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x00A9; 2020 Mighri, Hamdi, Boujemaa, Othman, Ben Nasr, El Benna, Mejri, Labidi, Ayari, Jaidene, Bouaziz, Ben Rekaya, M&#x2019;rad, Haddaoui, Rahal, Boussen, Boubaker and Abdelhak. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\r\n\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Yosr Hamdi, \u003Ca id=\"encmail\">eW9zci5oYW1kaUBwYXN0ZXVyLnRu\u003C/a>\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Data Availability Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Ethics Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#fun1\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#conf1\">Conflict of Interest\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#ack1\">Acknowledgments\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#S11\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#abbr1\">Abbreviations\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#FNT1\">Footnotes\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#refer1\">References\u003C/a>\u003C/li>\r\n\u003C/ul>\r\n",[720,726,732,735,741],{"name":721,"fileServerPackageEntryId":19,"fileServerId":722,"fileServerVersionNumber":723,"type":724},"EPUB.epub","552971/epub",2,{"code":725,"name":725},"EPUB",{"name":727,"fileServerPackageEntryId":728,"fileServerId":729,"fileServerVersionNumber":723,"type":730},"fgene-11-552971.pdf","fgene-11-552971-r1/fgene-11-552971.pdf","552971/pubmed-zip",{"code":731,"name":731},"PDF",{"name":727,"fileServerPackageEntryId":19,"fileServerId":733,"fileServerVersionNumber":723,"type":734},"552971/publishers-proof/pdf",{"code":731,"name":731},{"name":736,"fileServerPackageEntryId":737,"fileServerId":729,"fileServerVersionNumber":723,"type":738},"fgene-11-552971.xml","fgene-11-552971-r1/fgene-11-552971.xml",{"code":739,"name":740},"NLM_XML","XML",{"name":742,"fileServerPackageEntryId":19,"fileServerId":743,"fileServerVersionNumber":374,"type":744},"Provisional PDF.pdf","552971/provisional-pdf",{"code":731,"name":731},"v3",{"title":747,"link":748,"meta":752,"script":926},"Frontiers | Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients",[749],{"rel":750,"href":751},"canonical","https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/full",[753,756,759,761,764,768,771,775,778,781,784,786,788,790,792,794,797,800,802,805,808,810,813,816,819,822,825,829,833,836,838,841,843,846,849,852,854,857,860,863,865,868,870,873,875,878,881,884,886,889,891,894,897,900,903,906,908,911,913,916,918,921,923],{"hid":754,"property":754,"name":754,"content":755},"description","Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutatio...",{"hid":757,"property":757,"name":758,"content":747},"og:title","title",{"hid":760,"property":760,"name":754,"content":755},"og:description",{"hid":762,"name":762,"content":763},"keywords","breast cancer,genetic screening,BRCA1-Founder mutation,Next-generation sequencing,Novel mutation,Rad50",{"hid":765,"property":765,"name":766,"content":767},"og:site_name","site_name","Frontiers",{"hid":769,"property":769,"name":367,"content":770},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/552971/fgene-11-552971-HTML-r1/image_m/fgene-11-552971-g001.jpg",{"hid":772,"property":772,"name":773,"content":774},"og:type","type","article",{"hid":776,"property":776,"name":777,"content":751},"og:url","url",{"hid":779,"name":779,"content":780},"twitter:card","summary_large_image",{"hid":782,"name":782,"content":783},"citation_volume","11",{"hid":785,"name":785,"content":116},"citation_journal_title",{"hid":787,"name":787,"content":767},"citation_publisher",{"hid":789,"name":789,"content":697},"citation_journal_abbrev",{"hid":791,"name":791,"content":698},"citation_issn",{"hid":793,"name":793,"content":518},"citation_doi",{"hid":795,"name":795,"content":796},"citation_firstpage","552971",{"hid":798,"name":798,"content":799},"citation_language","English",{"hid":801,"name":801,"content":519},"citation_title",{"hid":803,"name":803,"content":804},"citation_keywords","breast cancer; genetic screening; BRCA1-Founder mutation; Next-generation sequencing; Novel mutation; Rad50",{"hid":806,"name":806,"content":807},"citation_abstract","Background Deleterious mutations on BRCA1/2 genes are known to confer high risk of developing breast and ovarian cancers. The identification of these mutations not only helped in selecting high risk individuals that need appropriate prevention approaches but also led to the development of the PARP-inhibitors targeted therapy.This study aims to assess the prevalence of the most frequent BRCA1 mutation in Tunisia, c.211dupA, and provide evidence of its common origin as well as its clinicopathological characteristics. We also aimed to identify additional actionable variants using classical and next generation sequencing technologies (NGS) which would allow to implement cost-effective genetic testing in limited resource countries.Patients and Methods Using sanger sequencing, 112 breast cancer families have been screened for c.211dupA. A set of patients that do not carry this mutation have been investigated using NGS. Haplotype analysis was performed to assess the founder effect and to estimate the age of this mutation. Correlations between genetic and clinical data have been also performed.Results The c.211dupA mutation has been identified in 8 carriers and a novel private BRCA1 mutation, c.2418dupA, has been identified in one carrier. Both mutations are likely specific to North-Eastern Tunisia. Haplotype analysis confirmed the founder effect of c.211dupA and showed its recent origin. Phenotype-genotype correlation showed that both BRCA1 mutations seem to be associated with a severe phenotype. Whole Exome Sequencing (WES) analysis of a BRCA negative family revealed a Variant of Unknown Significance, c.3647C&gt;G on RAD50. Molecular modeling showed that this variant could be classified as deleterious as it is responsible for destabilizing the RAD50 protein structure. Variant prioritization and pathway analysis of the WES data showed additional interesting candidate genes including MITF and ANKS6. Conclusions We recommend the prioritization of BRCA1-c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia. We also highlighted the importance of NGS in detecting novel mutations, such as RAD50-c.3647C&gt;G. In addition, we strongly recommend using data from different ethnic groups to review the pathogenicity of this variant and reconsider its classification in ClinVar.",{"hid":809,"name":809,"content":527},"citation_article_type",{"hid":811,"name":811,"content":812},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/pdf",{"hid":814,"name":814,"content":815},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2020.552971/xml",{"hid":817,"name":817,"content":818},"citation_fulltext_world_readable","yes",{"hid":820,"name":820,"content":821},"citation_online_date","2020/10/16",{"hid":823,"name":823,"content":824},"citation_publication_date","2020/11/06",{"hid":826,"name":827,"content":828},"citation_author_0","citation_author","Mighri, Najah ",{"hid":830,"name":831,"content":832},"citation_author_institution_0","citation_author_institution","Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia",{"hid":834,"name":827,"content":835},"citation_author_1","Hamdi, Yosr ",{"hid":837,"name":831,"content":832},"citation_author_institution_1",{"hid":839,"name":827,"content":840},"citation_author_2","Boujemaa, Maroua ",{"hid":842,"name":831,"content":832},"citation_author_institution_2",{"hid":844,"name":827,"content":845},"citation_author_3","Othman, Houcemeddine ",{"hid":847,"name":831,"content":848},"citation_author_institution_3","Sydney Brenner Institute for Molecular Bioscience, University of the Witwatersrand, South Africa",{"hid":850,"name":827,"content":851},"citation_author_4","Ben Nasr, Sonia ",{"hid":853,"name":831,"content":832},"citation_author_institution_4",{"hid":855,"name":827,"content":856},"citation_author_5","El Benna, Houda ",{"hid":858,"name":831,"content":859},"citation_author_institution_5","Department of Medical Oncology, Abderrahmane Mami Hospital, Tunisia",{"hid":861,"name":827,"content":862},"citation_author_6","Mejri, Nesrine ",{"hid":864,"name":831,"content":832},"citation_author_institution_6",{"hid":866,"name":827,"content":867},"citation_author_7","Labidi, Soumaya ",{"hid":869,"name":831,"content":832},"citation_author_institution_7",{"hid":871,"name":827,"content":872},"citation_author_8","Ayari, Jihen ",{"hid":874,"name":831,"content":832},"citation_author_institution_8",{"hid":876,"name":827,"content":877},"citation_author_9","Jaidene, Olfa ",{"hid":879,"name":831,"content":880},"citation_author_institution_9","Department of Carcinological Surgery, Salah Azaiez Institute, Tunisia",{"hid":882,"name":827,"content":883},"citation_author_10","Bouaziz, Hanen ",{"hid":885,"name":831,"content":880},"citation_author_institution_10",{"hid":887,"name":827,"content":888},"citation_author_11","Ben Rekaya, Mariem ",{"hid":890,"name":831,"content":832},"citation_author_institution_11",{"hid":892,"name":827,"content":893},"citation_author_12","Mrad, Ridha ",{"hid":895,"name":831,"content":896},"citation_author_institution_12","Service des Maladies Congnitales et Hrditaires, Hpital Charles Nicolle, Tunisia",{"hid":898,"name":827,"content":899},"citation_author_13","Haddaoui, Abderrazek ",{"hid":901,"name":831,"content":902},"citation_author_institution_13","The Military Hospital of Tunis, Department of Medical Oncology, Tunisia",{"hid":904,"name":827,"content":905},"citation_author_14","Rahal, Khaled ",{"hid":907,"name":831,"content":880},"citation_author_institution_14",{"hid":909,"name":827,"content":910},"citation_author_15","Boussen, Hamouda ",{"hid":912,"name":831,"content":832},"citation_author_institution_15",{"hid":914,"name":827,"content":915},"citation_author_16","Boubaker, Samir ",{"hid":917,"name":831,"content":832},"citation_author_institution_16",{"hid":919,"name":827,"content":920},"citation_author_17","Abdelhak, Sonia ",{"hid":922,"name":831,"content":832},"citation_author_institution_17",{"hid":924,"name":924,"content":925},"dc.identifier","doi:10.3389/fgene.2020.552971",[927,930,932,934,936],{"src":928,"body":13,"type":929,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":931,"body":13,"type":929,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":933,"body":13,"type":929,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":935,"body":13,"type":929,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fgene.2020.552971?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":937,"body":13,"type":929,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":939,"articleHubArticlesList":940,"canJournalHasArticleHub":359,"articleDoiList":941},{},[],[],{"title":19,"image":-1,"breadcrumbs":943,"linksCollection":944,"metricsCollection":946},[],{"total":371,"items":945},[],{"total":371,"items":947},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fgene.2020.552971?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>